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Abstract 
Introduction: Anthracyclines (ANTC) are potent chemotherapy agents, but may cause chronic 
irreversible cardiac failure. Recent data suggest cardiac damage due to ANTC begins early and 
may be a continuum. Cardioprotective modalities effective against acute injury may therefore 
provide prolonged benefit. Hypoxic Preconditioning (HP), i.e., subjecting cardiomyocytes to 
sub-lethal hypoxia and reoxygenation before a prolonged lethal ischaemic insult, protects 
cardiomyocytes by activating the pro-survival Reperfusion Injury Salvage Kinase (RISK) pathway. 
We examined the hypothesis that HP can protect cardiomyocytes against toxicity of the ANTC 
compound Doxorubicin (Dox). 
Methods: A toxic concentration of Dox was identified in an in vitro model of cardiotoxicity 
established in isolated adult rat ventricular myocytes (ARVM), using Propidium iodide (PI) 
permeability and altered morphology including cell-membrane blebbing as markers of cell-
death. An in vitro hypoxic preconditioning (HP) protocol was characterised, and the effect of 
this HP-stimulus on cell-death with subsequent Dox-treatment was assessed. Induction of the 
RISK pathway by HP was investigated by pre-inhibiting the Phosphoinositide 3-kinase (PI3K)/Akt 
cascade and the Mitogen Activated Protein Kinase (MAPK) Extracellular signal-regulated Kinase 
(ERK) 1/2 pathway with 10µM LY294002 (LY) and 30µM PD98059 (PD) respectively. The role of 
oxidative stress in Dox-toxicity was probed using N-acetyl cysteine, a known Reactive Oxygen 
Species (ROS)-scavenger. Fluorescence of 30 nM Tetramethylrhodamine methyl ester (TMRM) 
was used to assess the mitochondrial transmembrane potential (ΔΨm). Laser-induced ROS 
generation with 3 µM TMRM was used to assess mitochondrial permeability transmembrane 
pore (mPTP) induction after Dox-treatment, with 1µM Ciclosporine A (CsA) as a positive-
protective control against mPTP induction. Dox-induced cell-death was also reassessed as an 
agent to protect against mPTP induction. 
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Results and Discussion: 7.5 μM Dox resulted in significant increase in cell-death (p<0.05) after 
18h (44.2 + 4.7% Dox vs 18.7 + 1.5 % Control). HP protected cardiomyocytes from Dox (35.4 ± 
1.7% Dox; 14.7 ± 1.5% Dox HP). LY, but not PD, abrogated this HP-induced protection (Dox HP: 
16.9 + 1.5%; Dox HP LY: 38.5 + 3.3%; Dox HP PD: 15.9 + 1.3%). ROS-scavenging failed to rescue 
cardiomyocytes from Dox-toxicity. Dox failed to alter ΔΨm or mPTP-induction. However, 
although the protective effect of presence of CsA on mPTP-induction was abrogated in cells 
pre-treated with Dox, concomitant treatment with dox and CsA could not protect ARVMs from 
dox-toxicity. 
Conclusions and future directions: HP protects cardiomyocytes against cell-death due to Dox. 
Cell-death data suggest this protection is mediated via the PI3K/Akt pathway. The role of MAPK 
ERK 1/2 against Dox-toxicity in vitro is unclear. Dox-toxicity appears to be independent of 
oxidative stress, variations in ΔΨm, or vulnerability of the mPTP-induction. Further work to 
delineate mechanisms of toxicity, and the downstream components of HP-induced protection 
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Chapter 1. Introduction. 
Anthracyclines (ANTC) are a group of anthracenedione antibiotics that form integral part of 
chemotherapeutic protocols against a multitude of cancers, including solid organ tumours (e.g. 
Breast Cancer, Renal Cancer); soft tissue malignancies (e.g. Sarcomas); childhood cancers e.g., 
Acute Myeloid Leukaemia (AML), Acute Lymphoid Leukaemia (ALL); as well as haematological 
malignancies, e.g., Non-Hodgkin’s Lymphoma (NHL), Multiple Myeloma (MM) (Minotti et al, 
2004). Unfortunately their use is significantly limited by cardiotoxicity, which includes acute as 
well as chronic toxic effects. Acute ANTC-cardiotoxicity may manifest as inflammatory heart 
diseases (such as myocarditis or pericarditis), conduction abnormalities, and altered myocardial 
repolarisation. However, dilated cardiomyopathy (DCM) and refractory congestive cardiac 
failure (CCF) remains the most common and poorly understood manifestation of the chronic 
cardiotoxic effects of ANTC treatment (Schwartz et al, 1987; Gianni et al, 2008). 
 
1.1. Anthracyclines.  
Initially developed as antibiotics in late 1960s, ANTCs share a tetracyclic aglycone structure (see 
Fig.1.1) of four cyclohexane chains with a Daunosamine sugar moiety at Carbon C7 of ring A; 
adjacent quinone-hydroquinone groups in rings C and B; a methoxy substituent carbon C4 in 
ring D; a carbonyl group at C13; and a short side chain in C9. Doxorubicin (Dox) and 
Daunorubicin (DNR) were the first isolated ANTC, differing in the short side chains in C9 of ring 
D. In Dox this is a primary alcohol, while in DNR this side chain is a methyl group. Epirubicin (Epi) 
is a stereoisomer of Dox derived through axial-to-equitorial epimerisation of a hydroxyl group 
in the Daunosamine moiety, which leads to an increased volume of distribution and  
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Fig.1.1. Molecular structure of Anthracyclines. The core tetracyclic aglycone structure of 
anthracyclines contain four cyclohexane chains with a sugar moiety at Carbon C7 of ring A; 
adjacent quinone-hydroquinone groups in rings C and B; and in ring D a methoxy substituent 
carbon C4 (DNR and Dox), a carbonyl group at C13 and a short side chain in C9 (Abbreviations: 
Dox-Doxorubicin, DNR- Daunorubicin, EPI-Epirubicin, IDA-Idarubicin). 
 
shorter half-life. Idarubicin (Ida) is a derivative of DNR obtained by removing the 4-methoxy 
group in ring D. It has greater lipophilicity, higher cellular uptake, and a broader spectrum of 
activity against AML, MM, NHL, Breast cancer as well as multi drug resistant tumours. Other 
ANTC that have reached clinical practice include Pirarubicin, Aclarubicin and Mitoxantrone and 
find clinical use in disease as diverse as Systemic Sclerosis and Multiple Sclerosis (Minotti et al, 
2004). The potential population vulnerable to cardiotoxicity of ANTCs is therefore not restricted 
to cancer-survivors only. 
1.1.1. Manifestations and diagnosis of ANTC-Cardiotoxicity.  
The cytotoxic potential of ANTC compounds rapidly found chemotherapeutic use in clinical 
setting, with DNR and Dox being used in chemotherapy regimen by early 1970s. The 
cardiotoxicity of ANTC, manifesting as heart failure, was soon apparent in clinical practice (von 
Hoff et al, 1979). Early observational data and retrospective study from symptomatic patient-
cohorts led to a distinction between early (or, acute) cardiac complaints that manifested within 
hours to days, and the late onset toxicity of ANTC that manifested several months (and in many 
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cases years) after anthracycline treatment had been completed.  Acute ANTC-associated injury 
that have been described include manifestations of myocarditis or pericarditis, transient 
arrhythmias, QT-prolongations, delayed ventricular repolarisation, and transient depression of 
Left ventricular (LV) ejection fraction (LVEF) (von Hoff et al, 1979; Gianni et al, 2008). These 
were considered reversible, and hence different in pathogenesis from the irreversible chronic 
heart-failure syndromes associated with ANTC-chemotherapy. In adults, the chief 
manifestations of chronic ANTC-cardiotoxicity, however, are in the forms of DCM and CCF. 
Irreversible cardiac-failure syndromes may manifest months to years following cessation of 
treatment (Zhai et al, 2010). For example, it has been noted that the risk of symptomatic CCF 
increases by 15-fold in childhood cancer survivors compared to age-matched controls (Lipshultz 
et al, 2013b), while the risk of cardiac-death in patients who have received ANTC-based 
chemotherapy is nearly 8-fold greater than in the background population (Khawaja et al, 2014). 
Despite these findings, and despite investigations into the pathogenesis of ANTC-cardiotoxicity 
for several years, the molecular mechanism and the underlying pathophysiology of this late 
manifestation of cardiac-injury remains poorly understood. 
In recent years, however, considerable insights have been made into the problem of ANTC-
cardiotoxicity, with the result that the understanding of this puzzling clinical problem is 
undergoing a paradigm shift. Increasing literature suggests that ANTC-mediated cardiotoxicity 
is a dynamic process. Acute-cardiotoxicity maybe the manifestation of a more progressive 
injury, with early changes remaining physiologically compensated, subclinical, asymptomatic, 
and only later manifesting as overt heart-failure (Ganz et al, 1993; Cardinale et al, 2015). For 
example, Cardinale et al (2015) followed a study-population of 2600 patients who received 
ANTC-based chemotherapy over a period of ten years. Echocardiographic monitoring in this 
study revealed a significant fall in LVEF, beginning as early as 3 months after ANTC 
chemotherapy in nearly 9% patients over the ten years of the study (Fig. 1.2). Similarly, Cove-
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Smith et al (2014) found that in animal-models, rats subjected to weekly doses of Dox showed 
decline in cardiac function on cardiac magnetic resonance imaging (cMRI), and also 
demonstrated histological signs of cardiac-tissue injury, along with elevation of serum 
biomarkers e.g. cardiac Troponins (cTn) before symptomatic cardiac failure was noted. These 
data suggest that the functional decline seen in animal models and the subclinical decline 
observed in humans reflect a progressive injury. The toxicity of anthracyclines on the 
myocardium may therefore begin early, and acute cardiotoxicity may be the consequence of 
early exhaustion of compensatory mechanisms in a subpopulation, while in others the clinical 
manifestation may only be delayed by more prolonged compensation. Continuous but 
physiologically compensated asymptomatic decline in LVEF, therefore, may be the mechanism 
of ANTC-cardiotoxicity. Indeed, a 2016 position paper from the European Society for Cardiology 
(ESC) reflects this emerging consensus that ANTC cardiotoxicity is a phenomenon of continuous 
progressive decline in LVEF, with many patients initially remaining  asymptomatic,  
  
Fig.1.2. Incidence of heart-failure following ANTC-based chemotherapy over ten years, as 
determined by echocardiography-measured fall in ejection fraction. The cumulative incidence 






Angshuman Maulik   Page | 13 
 
but later presenting with heart failure in the context of a secondary trigger which may 
precipitate exhaustion of compensatory mechanisms (Zamorano et al, 2016). This physiological 
compensatory capacity of the heart may, in fact, be a factor in the lack of clarity of ANTC-cardiac 
injury, since CCF itself is considered a clinical diagnosis of a syndrome of physiological 
decompensation, with overall absolute LVEF value being a part of interpretation of the clinical 
picture. Further, the most commonly used investigation to determine LV systolic function 
(LVSF)- echocardiography- holds considerable variability between user. Various different 
approaches have been taken therefore to classify and characterise ANTC-cardiotoxicity in 
efforts to better define and address this poorly understood clinical problem. However, despite 
emerging evidences of early changes to the myocardium, optimum modality of investigation, 
ideal time for investigating, and ideal window for intervention is debated in clinical practice. As 
early as the later part of 1970s, Bristow et al (1978) tried to classify ANTC-cardiotoxicity 
histologically. Schwartz et al (1987) subsequently attempted a classification based on LVEF, 
while Stoddard et al (1992) described decline in isovolumetric relaxation time measured by 
Doppler-ultrasound. Indeed, in association with subclinical LVEF decline, LV end systolic volume 
(LVESV) and pulse wave velocity show an increase within 6 months of ANTC-based 
chemotherapy, suggesting increase in ventricular strain (Drafts et al, 2013).  However, a 
uniform consensus diagnosis of ANTC-cardiotoxicity still remains elusive, owing to the varied 
morphological manifestations and the unpredictable temporal sequence associated with it. In 
general, a significant decrease in LVEF by 10-20% from baseline, or a decline in LVEF in 
association with signs and symptoms of CCF may be considered consistent with cardiotoxicity 
associated with ANTC treatment, even if absolute LVEF remains above what is considered 
normal (Khawaja et al, 2014). However, efforts to identify patients at risk, and to identify early 
ANTC-cardiotoxicity has so far failed to reach definitive consensus translating into clinical 
practice. Among other investigations, circulating serum cardiac biomarkers have been explored 
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in efforts to identify and predict patients at risk of ANTC-cardiotoxicity. Cardiac troponin T 
(cTnT) and cardiac troponin I (cTnI) levels correlate to a high degree of specificity with 
cardiomyocyte injury. cTns are therefore among the first-line cardiac investigations used to 
detect myocyte necrosis and risk stratify patients suspected of suffering from acute myocardial 
infarction. cTn is also useful in other cinical contexts, e.g., pulmonary embolism, sepsis, stroke 
etc (Agewall and Giannitsis, 2014) where information on cardiac strain offer guide clinical 
anagement. Indeed, with ANTC-treatment, early rise and persistent elevation in cTnI in the first 
month after chemotherapy have been reported to correlate with decline in LVEF confirmed by 
echocardiography in patients receiving chemotherapy with high dose anthracyclines (Cardinale 
et al, 2000). However, it ought to be recognised that the large-volume troponin release 
detected during, e.g., myocardial ischaemia arises from thin filament necrosis, reflecting 
irreversible myocyte death (Anaya and Moliterno, 2013). By comparison, smaller volumes of 
troponin may be detected by newer high sensitivity assays in a number of different clinical 
contexts including stroke, sepsis, and even vigorous exercise. The source of this troponin is 
believed to be the cytosolic compartment of cardiomyocytes, and not necessarily reflect 
cardiomyocyte necrosis. The clinical significance of such rise is therefore unclear (Agewall and 
Giannitsis, 2014). Indeed, studies investigating cTn rise in chemotherapy-induced cardiotoxicity 
have found a less clear role for these biomarkers in prediction and prognostication of 
cardiotoxicity, particularly in moderate and low dose ANTC chemotherapy-protocols where 
cumulative doses are less than 300mg/m2 (Ky et al, 2014; Tian et al, 2014). Further, studies 
exploring cTn levels after ANTC-chemotherapy have failed to detect significant circulating levels 
late after chemotherapy in order of months, highlighting the difficulty in identifying 
asymptomatic individuals at risk of cardiotoxicity (Feola et al, 2011; Armenian et al, 2014). 
Other serum markers of cardiomyocyte-stress have been investigated to detect ANTC-
cardiotoxicity, including the natriuretic peptide Brain-Natriuretic peptide (BNP) and its N-
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teminal propeptide NT-proBNP. Both BNP and NT-proBNP are used in clinical practice in 
investigation of cardiac failure. However, rise in NT-proBNP has been observed after ANTC-
chemotherapy with stable LVEF (Romano et al, 2011) and, as with cTn, their value in predicting 
ANTC-cardiotoxicity has been questioned in subsequent larger studies (Ky et al, 2014). More 
novel serum biomarkers to predict and identify ANTC-cardiotoxicity have been investigated, 
including Galectin-3, Myeloperoxidase, soluble suppression of tumorigenicity-2 (sST-2), Heart-
type fatty acid binding protein (HF-ABP). However, the data remain preliminary and none have 
translated into routine use in clinical practice (Moazeni et al, 2017). 
The effort to identify patients at risk of ANTC-induced cardiotoxicity, and to detect early 
cardiotoxicity arises from the observations suggesting that ANTC-associated cardiac 
dysfunction, if detected early, may be amenable to treatment. For example in the study by 
Cardinale et al (2015), a significant proportion of patient who were identified to have 
asymptomatic decline in LVEF showed recovery towards baseline values when they were 
treated in line with current medical practice guidelines, with Angiotensin convertase enzyme II 
(ACE)-inhibition or β-adrenergic blockade (β-blockade) after decline in ejection fraction was 
identified (Fig. 1.3). Similarly, treatment with high dose hydroxymethylglutaryl-Coenzyme A 
(HMG-CoA) reductase inhibitors (“statins”) to inhibit cholesterol biosynthesis may have a 
beneficial role in protecting the at-risk myocardium from ANTC-cardiotoxicity (Henninger and 
Fritz, 2017). Indeed, although large scale prospective trial remains awaited to evaluate the role 
of statins in ANTC-cardiotoxicity, a meta-analysis of fourteen studies conducted by Kalam et al 
(2013) found a significant association between the administration of statins, and reduction in 
occurrence of cardiovascular events in patients who had received ANTC and/or Trastuzumab.  
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Fig. 1.3. The influence of early intervention against anthracycline-induced cardiotoxicity. The left 
ventricular ejection fraction (LVEF) in 82% of patients with echocardiogram-defined heart-
failure improved when they were treated with optimum combinations of Angotensin II 
convertase enzyme (ACE)-inhibition and/or β-adrenergic blockade (Cardinale et al, 2015) 
(Abbreviations: CT=Chemotherapy, HF=Heart failure, LVEF=Left Ventricular Ejection Fraction). 
 
The protective effect was similar to those observed with β-blockade, ACE-inhibition, as well as 
administration of the iron chelating agent Dexrazoxane (DXZ). DXZ was previously investigated 
as a protective agent against ANTC-induced cardiotoxicity in children receiving ANTC-
chemotherapy (Lipshultz et al, 2012). Using NT-proBNP rise as a marker of cardiac injury, 
Lipshultz et al (2012) observed a significant decrease in cardiac strain in the group receiving 
DXZ. However, the clinical use of DXZ is limited given a small but significant concern regarding 
long-term potential for causing secondary malignancies (Lipshultz et al, 2012). Other measures 
explored against ANTC-cardiac injury include dietary supplementation of, e.g., Coenzyme Q10, 
α-tocopherol, etc, but analysis of experimental data fail to support definitive evidence of 
protection with these measures (van Dalen et al, 2011). Lifestyle factors, including smoking-
cessation and physical exercise are recognised as important aspects in primary interventions 
against ANTC-cardiotoxicity. Interestingly, data from small animal models supports the advice 
that life-style modification to include exercise may have beneficial effects in protecting the 
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in preventing ANTC-induced cardiac injury. Haywards group, for example, observed a beneficial 
effect against ANTC-cardiotoxicity in a rodent model of exercise-training three times per week, 
compared to sedentary rats (Chicco et al 2006a). The authors noted a protective effect against 
LV dysfunction when Dox (2.5mg/kg) was administered after exercise, as well as a protective 
effect against caspase-3 induction as a marker of apoptosis, compared to rats with sedentary 
regime subjected to Dox. Further, the authors noted reduced levels of lipid peroxidation and 
increased levels of glutathione peroxidase in rats subjected to regular exercise along with Dox 
treatment, compared to rats treated with Dox alone. Other groups have reported observation 
that preconditioning with short acute bouts of exercise before Dox administration protects 
against subsequent measured decline in cardiac function (Wonders et al, 2008, Hydock et al, 
2008). Indeed, this importance of lifestyle measures is reflected in the current 
recommendations in clinical practice, where the ESC supports primary preventative life-style 
measures including modifying risk factors such as smoking-cessation, addressing obesity, and 
adequate exercise, in addition to secondary measures including pharmacotherapy (Zamorano 
et al, 2016). 
1.1.2. Risk factors of ANTC-cardiotoxicity. 
Currently known clinical variables poorly predict the risk and onset of ANTC-cardiotoxicity 
(Khawaja et al, 2014). Risk of cardiac-failure due to ANTC has been postulated to depend 
primarily on the cumulative-dose of ANTC administered during the chemotherapy regimen. 
Doses up to 300 mg/m2 Dox (and equivalent-doses of other ANTCs) are considered relatively 
safe, with an incidence of CCF reaching up to 2%. By contrast, the mortality from symptomatic 
heart failure secondary to DCM approaches 60% within 2 years in patients who have received 
high dose ANTC of 450 to 600 mg/m2 Dox or equivalent (Suter et al, 2013). However, even lower 
doses of ANTC may trigger injury resulting in asymptomatic decline in cardiac function that does 
not manifest in overt, clinically decompensated cardiac failure. For example, the incidence of 
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cardiotoxicity in patients receiving the highest limits of safe recommended dose is 
approximately 5%. However in childhood cancer survivors, reduced fractional shortening and 
increased afterload (compared to age matched controls) has been demonstrated beginning 
from doses approximating 100 mg/m2, with a noticeable 4.5-fold increase noted at doses in 
excess of 270 mg/m2 (Hudson et al, 2007). In survivors of childhood lymphoma who received 
ANTC-based treatment (with or without mediastinal irradiation), echocardiographic 
measurements demonstrated a higher prevalence of diastolic dysfunction at median doses 
equivalent to 160 mg/m2 Dox, more than 10 years after completion of treatment (Christiansen 
et al, 2014). Further, in adult populations, asymptomatic deterioration in LVEF, LV end systolic 
diameter (LVESD) and increased LV strain has been demonstrated within 6 months of initiating 
ANTC-based chemotherapy (Drafts et al, 2013). Underlying cardiopulmonary disorders, 
metabolic disorders, and increasing age are recognised to increase the risk of ANTC-toxicity. 
For example for ANTC-induced heart failure, Pinder et al (2007) reported a hazard ratio (HR) of 
1.58 with a 95% confidence interval (CI) of 1.39 to 1.79 in patients with concomitant coronary 
artery disease (CAD), with diabetes a HR of 1.74 (95% CI 1.66 to 1.83), and with increasing age 
risk a HR of 1.79 per 10 years (95% CI 1.66 to 1.93). Some authors estimate an approximate 
doubling of risk of ANTC-cardiotoxicity with each additional 10 years increase in age (Harbeck 
et al, 2011). 
Amongst other risk factors associated with ANTC-cardiotoxicity, chromosomal factors and 
genetic determinants have been identified as influences (Lipshultz et al, 2013b). The female sex 
is associated with a higher incidence of cardiotoxicity, which may be related to higher 
percentage of body fat allowing greater cardiac-accumulation of the lipophobic ANTC-
compound. Genetic determinants associated with altered incidence of LV dysfunction after 
ANTC therapy include, e.g., the hereditary hemochromatosis associated gene allele HFE C282Y, 
which confers a 9-fold increase in risk of myocardial damage, and may reflect concomitant 
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toxicities of iron-loading and of ANTC-chemotherapy (Lipshultz et al, 2013a). The CBR3 G allele 
homozygosity for the carbonyl reductase 3 enzyme confers an increased risk of approximately 
5-fold compared to the GA/AA genotype (Lipshultz et al, 2013b). Similarly, gene-variants of 
proteins involved in cellular redox pathways, e.g., the NAD(P)H: quinone oxidoreductase 1 gene 
NQO1 (Blanco et al 2008) and the Glutathione GSTP1p.I105V variant (Dasgupta et al, 2003) have 
been identified to confer increased risk. This may be a reflection of oxidative-stress postulated 
to be induced by ANTC group of drugs. Gene alleles of the Dox efflux transporter ABCC2 have 
also been suggested to confer increased risk, possibly by influencing drug-efflux from sub-
cellular organelles (Armenian et al, 2013). Survivors with trisomy 21, even when the congenital 
cardiovascular abnormalities are excluded, have an increased risk of cardiotoxicity, while Afro-
Caribbean race is considered to confer increased risk (Grenier and Lipshultz, 1998).  Additionally, 
comorbid conditions such as cardiovascular disease, endocrinopathies, inflammatory 
conditions, obesity, as well as traditional life style factors including smoking and sedentary 
lifestyle are known to be associated with increase in incidence of cardiotoxicity following ANTC 
chemotherapy (Lipshultz et al, 2013a; Lipshultz et al 2013b Lipshultz et al, 2014). 
Therefore, the risk of ANTC-cardiotoxicity is very likely a composite of the insult on the 
myocardium due to the cumulative drug-dose; factors that affect the distribution; metabolism 
and transport of the drug; along with individual hereditary and acquired factors that increase 
the vulnerability of the myocardium to drug-induced injury. 
 
1.1.3. Pathology of ANTC-mediated cardiac injury. 
The exact mechanism of chronic cardiotoxicity of ANTC still remains debated, but an 
inflammatory response and compensatory adaptations have been noted in the ANTC-insulted 
myocardial tissue in humans (Bristow et al, 1978), as well as in animal models (Cove-Smith et  
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al, 2014). Human autopsy studies show that ANTC distributes widely within the body, 
accumulating in the liver, heart and the brain (Berthiaume e al, 2007). Histologically, animal 
models show that repeated administrations of Dox leads to delayed chronic active myocarditis, 
lymphocytic infiltration, cardiomyocyte degeneration, compensatory hypertrophy, oedema, 
fibroblast proliferation and, over a longer period of time, collagen deposition and fibrosis.  For 
example, in the animal model study by Cove-Smith et al (2014) cited above, chronic low-dose 
administration of Dox in a rat-model was reported to lead to myocardial necrosis, oedema, 
lymphocytic infiltration and loss of myofibrillar architecture (Fig.1.4). This suggests a chronic 




Fig. 1.4. Histological features of cardiotoxicity of Anthracyclines in an animal model. Multi-focal 
and well-demarcated intracellular vacuolation of cardiomyocytes (dashed arrows); 
lymphoplasmacytic inflammation (solid arrow); and a degenerate cardiomyocyte (bent arrow) 
in rat atria seven weeks after beginning a once-weekly Doxorubicin treatment protocol (Cove-
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1.1.4. Molecular pathology of ANTC-mediated cardiac damage. 
In bio-molecular aetiology, evidence supports a multi-factorial process in ANTC-induced cardiac 
dysfunction, which includes an immune-system mediated response against cardiomyocytes 
and extracellular matrix degradation. This may lead to altered signalling between the basement 
membrane and the cardiomyocyte, e.g., through alterations of laminin-integrin interactions 
and consequent attenuation of integrin-linked small G-protein coupled signalling (Ross and 
Ross, 2001). Further, degradations of structural components of the cardiomyocyte contractile 
apparatus and disruption of the cellular bioenergetic pathway may attenuate the pumping 
function and efficiency through the cardiac cycle, reducing cardiac output. Decreased viability 
of potential stem-cell pools may also mediate an altered and inefficient repair response (Zhang 
et al, 2009).  
Supporting a role for activation of cardiomyocyte death pathways, proteomic analysis of hearts 
from rabbits subjected to a chronic dosing regimen of DNR-induced cardiomyopathy 
demonstrated an increase in calpain protease, along with an increase in caspase-6 activity 
(Stěrba et al, 2011). The authors in this experiment further demonstrated a decrease in 
myoglobin and Heart-type fatty Acid Binding Protein (HFABP) abundance, suggesting 
alterations in myocardial energy storage and metabolism. Additionally, they identified a 
number of sarcomeric-structural changes including increased desmin expression, diminished 
localisation of desmin to the cardiomyocyte Z-disk, decreased expression of myosin light chain 
isoforms 1 and 2, and attenuated beta isoform of myosin heavy chain protein. Similarly, using 
transmission electron microscopy, Cove-Smith et al (2014) observed a temporal disruption of 
myofibrillar architecture and Z-line distortion. These observations may partly explain 
contractile dysfunction observed in ANTC-toxicity. Desmin is known to form a link between the 
Z-disk and basement membrane proteins, e.g., Laminin, and alterations have been noted to 
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lead to disrupted signalling in some forms of inherited cardiomyopathies (Mavroidis et al, 
2008).  
In addition to intracellular structural alterations, animal models of Dox-toxicity utilising both 
bolus dosing as well as interrupted chronic dosing regimen exhibit changes associated with 
extracellular remodelling. This includes increased matrix metalloproteinase (MMP)-2 and 
MMP-9 expression, decreased density of fibronectin distribution, and decreased contents of 
tubulin, fibronectin, kinase-related protein (or telokin), and smooth muscle/nonmuscle myosin 
light-chain kinase (Stěrba et al, 2011). Further, increased Collagen IV α-chain expression and an 
increase in vimentin (expressed from activated fibroblasts, endothelial cells and smooth muscle 
cells) has been reported in small animal models of ANTC-toxicity (Lenčová-Popelová et al, 
2014).  Importantly, Collagen IV is known to be elevated in the inflammatory peri-infarct zones 
post- myocardial infarction (MI) (Morishita et al, 1996). In other organ systems e.g. lung, kidney, 
and liver, collagen IV isoform expressions have been associated with fibrotic diseases (Sand et 
al, 2013). This suggests extracellular matrix remodelling and alteration of the basement 
membrane molecular structure is a component of the ANTC-injury to the heart.  
ANTC have also been demonstrated to deplete the human cardiac progenitor stem cell (CPC) 
pool through induction of premature senescence, inhibition of growth, and induction of cell-
death. In rat models of cardiotoxicity, Dox decreases the viability of clonogenic c-kit positive 
CPCs in vitro (De Angelis et al, 2010). Further, in mice, knock-out of the cardiac senescence 
marker protein SMP 30 leads to increased Dox-induced cardiomyocyte apoptosis compared to 
wild type controls (Miyata et al, 2013).  Transplantation of induced pluripotential stem cells 
(iPSCs) and embryonic cells post-MI in Dox stressed murine heart has been demonstrated to 
improve fractional shortening and ejection fraction in-vivo, along with lower levels of 
cardiomyocyte apoptosis in vitro (Merino et al, 2014). The improvement in cardiac function and 
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cardiomyocyte apoptosis was associated with reduced MMP-9 activity, along with attenuation 
of interstitial and vascular fibrosis compared to control animals which did not receive similar 
cell-transplants. This suggests depletion of CPC population and attenuation of progenitor cell 
function may have a role in induction and/or exacerbation of myocardial injury due to ANTC. 
These data highlight that anthracycline-induced cardiac injury is likely to be the result of a 
complex multifactorial process, which includes inflammation and extracellular matrix (ECM) 
degradation, alterations to structural and contractile proteins, as well as increased collagen 
deposition and impaired repair processes.   
 
1.2. Mechanism of ANTC-mediated cardiomyocyte death. 
Given that ANTC are chemotherapy agents, it is not surprising that they are cellular toxins and 
inhibit survival-related signalling cascades. In dividing cells, ANTC exert their cytotoxic effect 
through intercalation with DNA, forming a stable ternary complex with the DNA-Topoisomerase 
II structure during DNA replication. This leads to inhibition of DNA replication, arrest of cell 
cycle in G1 and G2, and induction of programmed cell-death (Zhang et al, 2012).  However, 
since cardiomyocytes are terminally differentiated cells, the mechanism of ANTC-mediated 
cardiomyocyte death is less well understood, but postulated to involve a number of different 
mechanisms, including inhibition of pro-survival signalling, induction of apoptosis, necrosis, 
protein misfolding, alterations of autophagic flux, as well as disruption of cellular and 
mitochondrial metabolomics and mitochondrial biogenesis pathways (Lenčová-Popelová et al, 
2014; Khiati et al, 2014). 
1.2.1. ANTCs modulate pro-survival signalling cascades. 
ANTC compounds have been shown experimentally to modulate a number of protein-signalling 
cascades in the myocardium, although the exact contributions of these changes on the 
observed cardiotoxicity of anthracyclines remains far from clear. Altered induction or 
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inhibitions of specific signalling cascades may, however, explain the pathological responses of 
the intact myocardium culminating in cardiomyocyte injury, cell-death, and altered myocardial 
structure and function. For example in cultured H9C2 cardiomyoblast-derived cell lines, Dox 
has been reported previously to induce phosphorylation of Akt/Protein Kinase B (PKB), a 
downstream mediator of Phosphoinositide3-Kinase (PI3K) (Merten et al, 2006). In this report, 
the authors noted a cellular-hypertrophic response as a consequence of Dox treatment, which 
was specific to the induction of the PI3K/Akt pathway, distinct from additional activation of 
calcineurin signalling. Further, the authors were able to demonstrate sustained Akt 
phosphorylation for upto 360 minutes following exposure to Dox. Interestingly, in ex vivo 
models, Deres et al (2005) had previously demonstrated phosphorylation of Akt when isolated 
rat hearts were perfused with a supraphysiological concentration (100 µM) of Dox for 60 
minutes in a Langendorff-apparatus. Further of interest, in in vivo models, Ichihara et al (2007) 
observed a phosphorylation response of Akt with high-dose bolus injection in a murine model 
of Dox-toxicity. Free oxide radical generation (discussed in section 1.3.1) may have a role in this 
PI3K/Akt phosphorylation induction, since reactive oxygen species (ROS)-species may 
accumulate in cardiomyocytes consequent to Dox-tretment, and secondarily lead to 
accumulation of reactive nitrative and nitrosative species.  Nitration of tyrosine residues of 
receptor tyrosine kinases secondary to this accumulation of reactive oxygen and nitrative 
species has been hyposthesised to activate PI3K/Akt pathways (Deres et al, 2005). Supporting 
their hypothesis, Deres et al noted that Akt phosphorylation could be abrogated by 
concomitant perfusion with the antioxidant compound dihydrolipoamide at 200 µM, while 
Ichihara et al (2007) could inhibit PI3K/Akt induction with concurrent administration of super 
oxide dismutase (SOD). Moreover, PI3K/Akt phosphorylation-induction may serve an adaptive 
stress response, since activation of this pathway has been observed to prevent induction of 
death pathways by modulating mitochondrial morphology in response to pathological stress, 
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e.g., ischaemia-reperfusion injury (Ong et al, 2015).  Gharanei et al (2013b), for example, noted 
an upregulation of Akt phosphorylation after perfusing rat hearts with Dox in an ex vivo 
Langendorff models, which the authors noted to increase further when the mitochondrial 
division inhibitor mdivi-1 was coperfused with Dox. In contrast to this, Dox has also been 
observed to promote the degradation of PI3K/Akt pathway by protein phosphatases (Fan et al, 
2008). This may secondarily allow activation of the pro-apoptotic proteins, e.g. BCL-2 
associated death promoter (BAD). Conversely, potentiaing the pathway of PI3K signalling has 
been reported to offer a protective effect against ANTC-toxicity. Kitamura et al (2014), for 
example, observed that deleting ARIA (apoptosis regulator through modulating IAP expression), 
a plasma-membrane recruiter for the PI3K-phosphatase Phosphatase and tensin homologue 
(pTEN) protein in rat models ameliorated Dox-induced Cardiomyopathy in vivo (Kitamura et al, 
2014). Moreover, a number of agents e.g. Erythropoietin (Epo) (Kim et al, 2008), Propranolol 
(Yano et al, 2008), Propofol (Sun et al, 2014) etc. that show a cytoprotective effect against 
ANTC-cardiotoxicity do so, at least in part, by potentiation of PI3K/Akt pathway (Jia et al, 2014).  
Induction, attenuation, and inhibition responses of other pro-survival kinases have further been 
noted in experimental models of ANTC-cardiotoxicity. For example, using Terminal 
Deoxynucleotidyl Transferase-Mediated dUTP Nick End-Labeling (TUNEL) assays to measure 
apoptosis, Zhu et al (1999) observed an increase in cardiomyocyte apoptosis in cultured 
neonatal rat cardiomyocytes upon treatment with the anthracycline Daunomycin (DNM). In 
their report, the authors demonstrated activation of the Mitogen activated protein kinases 
(MAPK) p38 MAPK, Jun N-terminal Kinase (JNK) and Extracellular signalling regulated kinase 
(ERK) 1 and ERK 2 (collectively, ERK 1/2) in response to DNM treatment. Interestingly however, 
selective inhibition of ERK 1/2 with 50 µM of the inhibitor PD98059 was noted to exacerbate 
DNM toxicity, while inhibition of p38 MAPK with 10 µM SB203580 in this experiment was 
associated with a suppression in DNM-induced apoptosis. Similarly, in a chronic dosing model 
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in rats, Lou et al (2005) observed a rise in p38 MAPK phosphorylation over a three-week period 
following Dox treatment. This was associated with an increased phosphorylation of c-JNK-
protein over the same time. However, the authors noted a biphasic response of ERK 1/2 
phosphorylation, with a rise in phosphorylated protein over hours, followed by a decrease in 
phosphorylation over 3 weeks after the final Dox dosage. These changes in protein-
phosphorylation levels were accompanied by a fall in mRNA expression levels of ERK 1/2, and 
the animals were found to be in heart failure with depressed LV end-diastolic pressure (LVEDP), 
symptomatic dyspnoea, and displayed increased mortality by 3 weeks. Potentiating the ERK 
signaling pathway has been suggested to be a possible mechanism of the protective effect, e.g., 
of the fatty acid Oleylethanolamide in in vivo protection against Dox-toxicity (Su et al, 2006). 
Interestingly, the phosphorylation-induction of MAPK ERK 1/2 following anthracycline 
treatment has previously been reported to be deleterious. For example, Liu et al in their 2008 
report noted an increase in apoptosis of H9C2 cardiomyoblasts following Dox-treatment, which 
was associated with an increase in MAPK ERK 1/2 phosphorylation, but not p38 or JNK. Their 
data suggested this increase in apoptosis was mediated by phosphorylation of pro-apoptotic 
proteins BCL-2 associated death X protein (BAX) and BAD by the ERK kinases, in conjunction 
with p53 phosphorylation induction by activated ERK 1/2 (Liu et al 2008). Inhibition of ERK 1/2 
MAPK pathway using the inhibitor U0126 was noted to limit this phosphorylation and nuclear 
translocation of both MAPK ERK 1/2 and p53, and attenuated Dox-induced increases in the 
levels of BAX, of p53 upregulated modulator of apoptosis (PUMA)-α, of cleaved caspase-9, and 
activated caspase-3. Similarly, Gharanei et al (2013b) noted an increased phosphorylation of 
ERK 1/2 proteins when Dox was perfused in isolated Langendorff-perfused rat heart model, 
while phosphorylated p53 levels in isolated adult rat ventricular myocytes were also noted to 
be increased following Dox treatment. In their report, the authors noted that the mitochondrial 
divison inhibitor mdivi-1 was able to prevent upregulation of ERK 1/2 phosphorylation, as well 
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as the phosphorylation induction responses observed for p53 and the mitochondrial pro-fission 
protein dynamin related protein-1 (DRP-1). These data suggest that phosphorylation induction, 
activation, or attenuation of MAPK cascades, including MAP ERK 1/2, p38 MAPK, and the JNK 
pathway may have a role in the toxicity observed as a consequence of ANTC exposure, including 
through induction of mitochondrial stress-responses, induction of cell-death pathways, and 
through altering the balance of proteins involved in cell-death . 
1.2.2. ANTCs modulate Topoisomerase-enzymes and alter mitochondrial metabolomics. 
In addition to altering pro-survival signalling cascades, in cancer cells ANTC inhibit DNA-repair 
mechanisms, triggering cell-death mechanisms secondary to DNA-damage pathways. In this 
regard, the roles of topoisomerase enzyme isoforms have come under particular focus in 
mediating cardiomyocyte toxicity (Nitiss and Nitiss, 2014).  
Supporting the hypothesis of cardiotoxicity secondary to topoisomerase enzyme modulation, 
Dox is known to stabilise a ternary cleavage-complex formed Topoisomerase II (Top2) and DNA 
during DNA-replication, leading to double stranded DNA breaks that can induce cell cycle arrest 
and death. In adult vertebrates, Top2 exists in two isoforms - α and β. Top2α-DNA complex 
stabilisation is thought to be a molecular mechanism of cytotoxicity of ANTC against cancer 
cells. However, only the β isoform (Top2β) is expressed in cardiomyocytes.  ANTC-induced 
Top2β activation in cardiomyocytes has been suggested to be the underlying mechanism of 
altered expression seen in the mitochondrial-genome encoded proteins, including proteins 
involved in the respiratory chain, the mitochondrial biogenesis pathway, and further, for 
activation of proteins involved in the cell-death pathways. In a mouse-model of Dox-toxicity, 
Zhang et al (2012) demonstrated the downregulation of transcript-levels of proteins involved 
in mitochondrial biogenesis, including PPARγ co-activator (PGC) 1α and PGC 1β. Transcript and 
protein levels of PGC-regulated proteins involved in bioreductive pathways and ATP 
 
Angshuman Maulik   Page | 28 
 
biosynthesis were also downregulated, including Ndufa3 (which encodes subcomplex-3 of 
NADH dehydrogenase 1α), SDHA (encoding subunit A of Succinate dehydrogenase complex II) 
and Atp5a1 (encoding ATP synthase subunit α or Atp5a).  Importantly, the authors showed that 
cardiomyocyte-specific deletion of Top2β protected the mice from Dox-induced progressive 
heart-failure seen in wild-type control animals.  
In addition to the above findings, investigations into the role of topoisomerase in ANTC-
cardiotoxicity also reveal a role for other isoforms of the enzyme. Adult vertebrate 
mitochondria express two further topoisomerases- Topoisomerase 3α (Top3α) and 
Topoisomerase 1-mitochondrial isoform (Top1(mt)). Top1(mt) functions solely within the 
mitochondria, while Top3α is also found to have a role in nuclear DNA-replication (Wang et al, 
2002). In 2014, Khiati et al demonstrated that the protein levels of mitochondrial respiration 
complexes III and IV (which are encoded in both nucleus and mitochondria-dependent manner) 
are reduced in a cardiac specific manner in mice receiving Dox-treatment, and this down-
regulation was accentuated in mice lacking Top1(mt). This stands in contrast to the protective 
role of Top2β deletion observed by Zhang et al and, taken together, indicates ANTC-
cardiotoxicity may be the result of alterations in a complex interplay of mitochondria-targeted 
and mitochondria-derived protein expression secondary to topoisomerase poisoning, resulting 
in altered mitochondrial function and biogenesis. 
1.2.3. ANTCs alter mitochondrial structure and function. 
At a subcellular level, the chief sites of ANTC accumulation are the mitochondria, the nucleus, 
and the endoplasmic reticulum (Solem et al, 1994; Berthiaume and Wallace, 2007). The 
accumulation within the mitochondria may partly be a result of affinity of ANTC for cardiolipin, 
a lipid located on the inner mitochondrial membrane. In addition to the alterations in 
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mitochondrial biogenesis and function, ANTC have been shown to alter the structure and the 
transmembrane potential (ΔΨm) of cardiac mitochondria.  
Early after ANTC administration, the mitochondria show swelling, membrane disruption and 
loss of membrane integrity (Cove-smith et al, 2014). Further, acute Dox-stress has been shown 
to upregulate the mitochondrial division protein DRP-1 (Dynamin related protein-1). Inhibition 
of mitochondrial division attenuated contractile dysfunction and infarct size seen in rat hearts 
perfused with Dox in the reperfusion stage of a Langendorff ischaemia-reperfusion model of 
Dox stress (Gharanei et al, 2013a). Khiati et al (2014) demonstrated that Top1(mt) knockout 
mice suffered extensive mitochondrial fragmentation, swelling, altered cristae structure, and 
an attenuated increase in mitochondrial numbers in response to Dox treatment. This suggests 
ANTC induce a direct mitochondrial structural damage, and additionally mitochondria attempt 
increased division in response to Dox. 
ANTC may also alter mitochondrial energetic state by altering the function of mitochondrial 
respiratory complex proteins, leading to loss of the proton-motive force that drives the ATP 
generation. For example, in a rat-model of ANTC-induced cardiomyopathy, Lebrecht et al 
(2010) demonstrated a reduced activity of mitochondrial genome-encoded components of 
respiratory chain. Further, ANTCs have been shown to inhibit the reduced form of 
mitochondrial Nicotinamide Adenine Dinculeotide dehydrogenase (NADH) and Succinate 
dehydrogenase protein, as well as the function of the Magnesium (Mg2+)-dependent F1F0-
ATPase in the mitochondria (Berthiaume et al, 2007). The ΔΨm in cardiomyocytes has been 
demonstrated to fall within 60 minutes of perfusing isolated rat hearts with Dox (Montaigne et 
al, 2010). Similarly, a reduction in ΔΨm in murine cardiomyocytes is observed 72 hours following 
a bolus 25mg/kg of Dox (Zhang et al, 2012). Uncoupling of electrons from the respiratory chain 
leads to depletion of high energy adenine nucleotides, and such uncoupling has been 
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demonstrated in both in vitro as well as in vivo models of ANTC-toxicity (Doroshow et al 1986; 
Lebrecht et al, 2010). 
Interestingly, this collapse of ΔΨm in response to ANTC is prevented by specifically inhibiting 
the mitochondrial permeability transition pore (mPTP), independent of the calcium (Ca2+) 
uptake uniporter and the Sodium(Na+)-Ca2+ exchanger (NCX) (Solem et al, 1993). The mPTP is a 
mitochondrial membrane associated multi-protein complex which is implicated in induction of 
necrotic cell death (Halestrap and Richardson, 2015; Kwong and Molkentin, 2015). Historically 
it has been postulated to be a multimeric channel spanning the outer mitochondrial membrane 
(OMM) and the inner mitochondrial membrane (IMM). The mPTP is a non-selective channel 
which has been noted to have a role in maintaining the permeability barrier of the IMM. In the 
“pore-closed” state, the mitochondrial inner matrix is impermeable to most solutes and ions, 
including Ca2+ and hydrated inorganic ions (Crompton,1999). A number of factors, including 
excessive oxidative stress in the form of accumulation of ROS-species, low pH, Ca2+, as well as 
accumulation of phosphate ions leads to a transition of the pore to an irreversible 
permeabilization of the mPTP, cycling the complex from the “pore-closed” to a “pore-open” 
state. This transition to “pore-open” state is accompanied by uncoupling of oxidative 
phosphorylation and reversal of the activity of the The F1F0-ATP synthase to mediate ATP-
hydrolysis (Halestrap et al, 2004). Further, transition to the “open” state is accompanied by 
increase in permeability and free passage of solutes, allowing diffusion of molecules below 
1.5kDa size (Halestrap et al, 2004; Giorgio et al, 2009). This secondarily increases inner-
mitochondrial osmotic pressure, inducing mitochondrial matrix swelling, unfolding of cristae, 
and outer membrane rupture with consequent nonspecific release of intermembrane-space 
proteins into the cytosoI, including Cytochrome C leading to induction of necrotic cell-death 
(Kinally et al, 2011). The exact structure of the mPTP remains to be determined, but 
considerable evidences have emerged in the recent decade shedding light on the identitiy of 
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the molecular components that form this molecular entitiy. Historically, the mPTP was 
postulated to be composed of at least five proteins suggested to form the core component of 
the mPTP. These were Creatine Kinase (CK, initially postulated to exist in the cytosolic aspect), 
Voltage dependent anion channel (VDAC, located in mitochondrial outer membrane), 
translocator protein (outer membrane), Adenine Nucleotide Translocase (ANT, located in the 
inner membrane) and Cyclophilin D (Cyp D, located in the mitochondrial matrix). However, 
emerging data challenge this view. Evidence indicate that the pore is formed in the IMM, since 
mPTP can be formed in mitochondriae where the outer membrane has been removed, i.e., 
mitoplasts (Silekyte et al, 2011).  Current evidence supports a model where ANT, the inorganic 
phosphate carrier (PiC), and the the F1F0-ATPase complex interact to form a core component 
of the mPTP, with Cyp D acting as a regulator of pore formation in the IMM (Halestrap and 
Richardson, 2015; Kwong and Molkentin, 2015). Reguation of mPTP opening by Cyp D maybe 
dependent on the interactions of this molecule with F1F0 ATP synthase through the lateral stalk 
of the latter complex. VDAC and the inner membrane component of Cyp D have been 
postulated in the past to recruit apoptotic proteins such as the BH3-domain pro-apoptotic 
protein BAX at site of intermembranal interactions where junctional complexes are formed 
(Crompton, 1999 and 2003). A role is now suggested for CK as an intermembrane space protein, 
along with VDAC in the OMM and the protein Hexokinase, in stabilising junction sites in 
interaction with ANT in the IMM (Halestrap and Richardson, 2015). However, an essential role 
for VDAC has been called into question, since murine mitochondriae in which all VDAC isoforms 
are knocked out retain an unaltered capability for mPTP transition (Baines et al, 2007). 
Furthermore, evidence indicate that proteins BAX and BAK (BCL-2 homologous antagonist 
killer) in the outer mitochondrial membrane interact with the core mPTP when the transition 
complex assembles, and may have a role progression of mPTP opening (Karch et al, 2013), 
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independent of the oligomerisation-dependent action of BAX in opening the OMM to release 
cytochrome C in induction of apoptosis.  
The mPTP has been demonstrated to be involved in the induction of cardiomyocyte death 
following ischaemia-reperfusion injury as well as in in heart failure (Elrod et al, 2010). Since the 
collapse of ΔΨm in response to ANTC-treatment is correlated specifically to induction of the 
mPTP (Solem et al, 1993), it may be hypothesised that inhibiting the mPTP induction, along with 
stabilising the mitochondrial transmembrane potential may have a protective influence against 
ANTC-toxicity on cardiomyocytes. 
1.2.4. ANTCs induce cell-death via necrosis, apoptosis, and autophagy.  
Although cardiomyocyte death is believed to be a key component of ANTC-cardiotoxicity, 
investigating the exact mechanism of cell-death offers conflicting explanations. Myocardial 
tissue in Dox-treated animal models exhibits histological signs of necrosis, but biomolecular 
analyses suggest other mechanisms, including programmed cell-death or apoptosis, may also 
be involved. Necrosis, or “unprogrammed” cell-death is characterised by cell-swelling, 
vacuolation, organellar rupture and non-specific karyolysis.  These features were considered to 
delineate it as a death-response to non-specific toxic and lethal insults, distinct from the 
ordered or “programmed” cell-death of apoptosis which is induced by specific death-signalling 
and is dependent on ATP-hydrolysis. Apoptotic cell-death was considered “clean”, 
characterised by cell-shrinkage, pyknosis, karyorrhexis, externalisation of plasmalemmal 
phosphatidylserine residues, protein-crosslinking, and phagocytosis of apoptotic debris (Levin 
et al,1999). However, it is recognised now that necrosis and apoptosis may utilise similar 
biomolecular pathways, including induction of similar caspases, and in execution of the final 
death pathway. It is increasingly recognised that a continuum exists whereby, e.g., early 
apoptosis and mPTP-induction may transform into a necrotic pathway in conditions such as 
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ATP-starvation, culminating in activation of the final activator Caspase-3 (Zeiss,2003; Martel et 
al, 2012). 
Both necrotic and apoptotic cell-death has been described in ANTC-cardiotoxicity models, 
including in in vivo (e.g., Zhang S, et al, 2012) as well as in vitro (e.g., Zhang H et al, 2013). At a 
biomolecular level, necrotic cardiomyocyte-death may be secondary to the effects of ANTC on 
the mitochondria, especially on the mPTP. Mitochondria from rats treated with Dox show an 
increased sensitivity to induction of mPTP opening (Ascensão et al, 2010; Gharanei et al, 
2013a). As described in the above section, In the induced, open, state, there is unrestricted 
movement of molecules smaller than 1.5 kDa accros the mPTP, which dissipates the 
transmembrane potential, inducing mitochondrial swelling, outer membrane rupture, and 
release of Cytochrome C. Caspase-3 activation resulting from Cytochrome C release can 
stimulate mPTP induction, which may act as a feed-forward mechanism for further Cytochrome 
C release. Deletion of mitochondrial Cyp D protects cardiomyocytes from known pore-
induction stimuli, e.g. Ca2+ overload and oxidative stress, but sensitivity of cells to apoptotic-
death stimuli is preserved (Baines et al, 2005). Mitochondrial Cyp D gene deletion in mice has 
been shown by Nakayama et al (2007) to protect from histological changes of necrosis and from 
physiological decline in cardiac function observed in control animals two weeks following a 
single large dose of Dox. Importantly, both oxidative stress and Ca2+ overload are hypothesised 
to be components of ANTC-mediated cardiotoxicity. Interestingly, ANTC-induced induction of 
the pro-inflammatory interleukin (IL) cytokine interleukin-1 (IL-1) β isoform (IL-1β) has been 
previously observed to rise in a dose-dependent manner in murine models of Dox-toxicity, with 
levels of serum IL-1β, IL-1 receptor antagonist (IL-1RA), and cardiomyocyte levels of IL-1 
receptor I (IL-1RI) correlating with degree of myocardial tissue fibrosis, myocyte vacuolisation, 
and degeneration (Zhu et al, 2011).  The necrotic cell-death pathway, therefore, maybe a target 
to explore in protecting against ANTC-cardiotoxicity. 
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In addition to necrosis, however, considerable evidence indicates apoptotic cell-death 
machinery to be involved in cardiomyocyte death in ANTC-toxicity. Apoptosis is an 
evolutionarily conserved active-death mechanism described as mediated via two canonical 
modes- the extrinsic pathway and the intrinsic pathway. The intrinsic pathway is initiated by 
intracellular or mitochondrial signals, and may be triggered by a diverse array of factors 
including non-receptor signalling induced by cellular stress, e.g., withdrawal of pro-survival 
signalling or intracellular stress-responders, e.g., reactive oxygen and nitrite species (ROS and 
RNS respectively), culminating in loss of suppression against apoptosis (Elmore et al, 2007; Yao 
et al, 2017). Early chages induced by activation of the intrinsic pathway results in a shift in the 
cell-death program, normally regulated by a balance of the anti-apoptotic molecules BCL-2, 
BCL-XL, and Mcl-1 and of pro-apoptotic proteins e.g. BAD, BH3 interacting-domain death 
agonist (BID), Bnip3 and Nix. Loss of mitochondrial transmembrane potential and opening of 
the mPTP further allows the release of mitochondrial IMM-sequestered proteins, e.g., high-
temperature requirement 2 (HTRA2)/Omi and direct IAP binding protein with low pI (DIABLO)/ 
second mitochondria-derived activator of caspases (SMAC), inhibiting the activity of the 
inhibitor of apoptosis proteins (IAP) (van Loo et al, 2002) and activate Cytochrome C (Zhang et 
al, 2009). Induction of pro-apoptotic BCL-2 family molecules by cellular-stress stimuli leads to 
translocation of pro-apoptotic molecules e.g. BAX and BAK to the OMM and reinforces 
activation of Cytochrome C, which is able to recruit the Apoptosis protease activating factor-1 
(Apaf-1) and procaspase 9, triggering the apoptosome formation, feed forward auto-activation 
of caspase 9, and subsequently activates procaspase 3. Contrasted with this non-receptor 
signalling that triggers the intrinsic apoptotic pathway, the extrinsic pathway is considered to 
be activated by cell surface death ligands, resulting in activation of cell-surface “death-
receptors” which are characterised by the conserved 80 amino-acid “death-domain” in the 
intracellular aspect and a cysteine-rich extracellular domain (Elmore, 2007). Ligand binding, 
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e.g., by Tumour necrosis factor (TNF), TNF receptor associated factor (TRAF), FAS lIgand (FASL), 
TNF-related apoptosis-inducing ligand (TRAIL) etc. results in trimerization of these cell-surface 
death-receptors allowing recruitment of adaptor proteins, e.g., FAS associated death domain 
(FADD), TNF receptor associated death domain (TRADD) etc., and ultimately activate caspase-
8 to induce the Death Inducing Signalling Complex (DISC), culminating in the activation of 
procaspase-3.  
Increasing evidence indicates that “cross-talk” exists between various different pathways of 
cell-death. Caspase-8 has also been noted to activate BID, BAX and BAK (Gustafsson and 
Gottlieb, 2003), which may be an example of cross-talk between the canonical extrinsic and the 
intrinsic pathways. Caspase-8 induced BID-cleavage results in mitochondrial translocation of 
cytosolic BID and induction of subsequent Cytochrome C release, independent of caspase 
activity (Li et al,1998). Further, emerging evidence indicate that necrotic cell-death may be 
triggered by the same cell-surface receptors (e.g., TNF-α) that trigger apoptosis, e.g., by 
differential energetic states as a result of, e.g., ATP-depletion (Li and Beg, 2000; Lin et al 2004). 
In vitro, TNF-α and TRAIL-induced “programmed necrosis” death pathways have been 
described in cell-lines, which is noted to involve inhibition of Caspase-8 induced cleavage of 
receptor-interacting proteins (RIP) (Chan et al, 2003). This highlights that avenues exist 
whereby necrosis, necroptosis and apoptosis may variably contribute or cross-talk in ANTC-
mediated cardiomyocyte death. 
ANTCs may directly activate promoters of apoptotic pathway. Dox has been shown to induce 
an early upregulation of the p53-pathway and upregulate apoptotic proteins including Apaf-1, 
Fas, MDM2, as well as the p53 inducible gene Trp53inp1 (Zhang et al, 2012). Moreover, ANTC 
are capable of activating the innate immune receptors TLRs-2 and 4 in the myocardium (Ma et 
al, 2012). TLR-4 activation by ANTC inhibits GATA-4, a transcriptional activator of BCL-XL. 
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Notably, TLR-4 deficiency attenuated GATA-4 downregulation, reduced cardiomyocyte 
apoptosis as measured by TUNEL-assay, and reduced myocardial functional decline in a mice 
model of Dox-induced cardiomyopathy (Riad et al, 2008). In animal models of ANTC-toxicity, 
enhanced degradation, e.g. through the ubiquitin-mediated system, of survival factors (e.g., 
apoptosis repressor with caspase recruitment domain, or ARC) and of antagonists of apoptosis 
a (e.g., BCL-2) have been described (Ranek et al, 2009). Further, in in vivo models, mice 
subjected to Dox-treatment has been reported to show an increased level of the pro-
inflammatory cytokine IL-6, and an increased level of BAX/BCL-2 ratio (Westermann et al, 
2008). Interestingly, the IL-1 family cytokine interleukin-33 (IL-33) was recently reported to 
attenuate Dox-induced apoptosis in a murine model of ANTC-cardiotoxicity. IL-33, the ligand 
for the receptor sST-2, was previously reported to suppress cardiomyocyte apoptosis and 
Caspase-3 activation and increased activation of IAP (Inhibitors of Apoptosis Proteins) 
homologues in pressure-overload models of heart failure (Seki et al, 2009). This indicates that 
the inflammatory innate cellular response as well as the paracrine effects of the inflammatory 
milieu elicited by ANTC-chemotherapy may have a role in cardiomyocyte death. Moreover, 
ANTC may alter the transcription of proteins in cardiomyocytes to the advantage of the pro-
apoptotic proteins. DNR has been shown to inhibit the binding of the transcription factor 
CBF/NF-y to a CCAAT-region in the promoter box of GATA-4 in a p53-dependent manner, 
inhibiting the transcription of GATA-4 mRNA (Park et al, 2011). Similarly, Kawamura et al (2004) 
demonstrated reduced mRNA levels of the transcriptional co-activator p300 in a murine model 
of Dox-toxicity. In this experiment, transgenic mice overexpressing p300 displayed increased 
anti-apoptotic BCL-2 and MDM-2 levels, and were protected against Dox induced DNA-cleavage 
and caspase-3 induction (Kawamura et al, 2004). 
In addition to the intrinsic apoptotic pathways, ANTC-toxicity on cardiomyocytes has also been 
demonstrated to involve the induction of extrinsic pathway of apoptosis. In rat-models of 
 
Angshuman Maulik   Page | 37 
 
ANTC-cardiotoxicity, activation of the transcription factor NFƙB has been shown to directly 
activate pro-apoptotic genes, including Fas ligand (FASL), Fas, c-Myc and p53 (Li et al, 2007; 
Zhang et al, 2009). Dox has been shown to activate NFƙB in neonatal rat ventricular myocytes 
in a TLR-2 dependent mechanism, while TLR-2 knock-out attenuates NFƙB activation and lowers 
cardiomyocyte apoptosis in mice treated with Dox (Nozaki et al, 2002). Further, Kalivendi et al 
(2005) observed activation of the transcription factor NFAT4 and an increased FASL expression 
in H9C2 cardiomyoblasts secondary to Dox treatment. Similarly, in in vivo experiments, 
Nakamura et al administered once-weekly doses of Dox (2mg/kg) and observed an increase in 
FAS-mediated cardiomyocytes apoptosis. This could be prevented by the administration of a 
neutralising Anti-FasL-antibody (Nakamura et al, 2000). Further supporting the role of Fas-
mediated death pathway in ANTC-cardiotoxicity, cardiomyocyte-targeted overexpression of 
soluble (s)Fas, a competitive inhibitor of FasL, was shown by Niu et al (2009) to preserve cardiac 
function and reduce apoptotic indices in response to a low-dose Dox regimen in a murine model 
of Dox-toxicity.  
Interestingly, work in animal models support the hypothesis that apoptosis and necrosis are 
part of a more complex explanation of the chronic course of ANTC-mediated injury. For 
example in rat-models, apoptosis peaks at 24-48 hours after bolus Dox-administration before 
declining to baseline levels seen in control animals (Arola et al, 2000). Among other 
mechanisms put forward to explain the chronic course of Dox-toxicity, the contributions of 
autophagy has been emphasised by some experiments. Autophagy is a physiological 
mechanism of bulk-degradation of short-lived organellar structures and proteins by the 
Ubiquitin-proteasomal pathway (UPS). Autophagy may co-exist with apoptosis in the 
metabolically stressed cardiomyocyte (Tacar et al, 2014). Increased protein misfolding; 
enhanced UPS-mediated degradation of key structural proteins, eg, β-catenin; degradation of 
survival factors, e.g., ARC (apoptosis repressor with caspase recruitment domain) and the 
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apoptosis antagonist BCL-2 have been noted in animal models of ANTC-toxicity (Ranek et al, 
2009). In rabbits, the concentrations of poly-ubiquitinated proteins GrP75 and Hsc70, 
mediators of chaperone mediated autophagy, has been shown to be increased (Sterba et al, 
2011). Further, cardiomyocytes from rats receiving high dose Dox have been demonstrated to 
have an increased myosin Light chain II (LCII) to Light chain I (LCI) ratio, an indicator of increased 
autophagic flux (Zhang Y, et al, 2011a). Similarly, inhibiting autophagy has been observed to 
limit autophagic-vacuole formation and mPTP induction, and further protect against decline in 
cardiac function (Ling et al, 2013). Furthermore, ANTC related cardiotoxicity has been shown to 
be exacerbated in mice transgenic for overexpression of Nrdp1, an E3-ligase enzyme that 
mediates ubiquitin-conjugation to target poly-ubiquitinated proteins for proteasomal 
degradation (Zhang et al, 2013). This indicates that autophagy-mediated degradation of key 
structural and functional components may be a component of ANTC-mediated cardiomyocyte 
injury.  
Autophagic pathways, in additon to their role for turnover of cellular machinery, may  moreover 
form a link in the cross-talk between apoptosis and necrosis death, and interact with and 
influence both pathway. For example, the ubiquitinylation state of the Receptor Interacting 
Protein (RIP) group of proteins RIP-1 and RIP-3 has been noted to influence the activation of 
the apoptotic pathways and NFƙB induction, and proteolysis of de-ubiquitinated RIP-3 by 
Caspase-8 in the Death Inducing Signalling Complex (DISC) has been noted as important in 
apoptotic-caspase induction in response to TNF-α as well as Fas mediated apoptosis (He et al, 
2009). In the absence of Caspase-8, TNFR1 activation leads to programmed activation of 
necrosis, or necroptosis. Interestingly, Zhang et al (2016) observed a reduced burden of 
necrotic cardiomyocyte-death as observed by Evans blue staining when RIP-3 null mice were 
subjected to bolus doxorubicin-insult intraperitoneally. This highlights that interplay between 
canonical cell-death pathways and the machinery of molecular turnover may play a significant 
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role in cardiomyocyte-death secondary to ANTC. Targeting key mediators of the necrotic and 
apoptotic pathway, as well as the cellular autophagic flux needs to be explored further in 
delineating the mode of ANTC-Cardiotoxicity. However, given the role of ANTC as 
chemotherapy agents, differentiating between death-pathways in malignant cells and in 
cardiomyocytes is necessary before translational interventions may be explored.  
1.3. Mediators of ANTC-cardiotoxicity. 
Although considerable insights have been made into the mechanisms of ANTC-cardiotoxicity, 
the identity of the trigger(s) that initiate this cardiomyocyte injury remains elusive. Evidence 
have been offered in support of a number of different mechanisms, including a role for reactive 
oxidative and nitrosative species-mediated injury (Weinstein et al, 2000), Ca2+ overload-
mediated cell-death (Doroshow et al, 1986; Solem et al, 1994), and excess iron accumulation 
in the cytosol (Ichikawa et al, 2014). The exact mechanism may be an interaction of a number 
of different key mediators in the metabolically stressed cardiomyocyte, inducing a final 
common pathway of cell-death.  
1.3.1 Reactive oxygen and Nitrogen species. 
The hypothesis of oxidative stress and consequent cellular apoptosis/necrosis was, for a 
considerable amount time, considered the strongest explanation of the mechanisms of 
cardiomyocyte dysfunction/death in ANTC-cardiotoxicity (Minotti et al, 2004; Berthiaume et al, 
2007). Futile redox-cycling of the quinone moieties of the core ANTC-structure (Fig. 1.5) may 
generate excess superoxide anion, hydrogen peroxide, and hydroxyl radicals (collectively 
referred to as Reactive Oxygen Species, or ROS), which saturate the catalase and the 
glutathione (GSH)-mediated ROS-detoxification system. The quinone-semiquinone redox-
cycling may also sustain ROS levels by increasing free cellular iron and potentiating ferrous- 
ferric cycling of molecular iron (Childs et al, 2002; Ichikawa et al, 2012). Since cardiomyocytes 
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are rich in mitochondria and relatively deficient in endoplasmic reticulum-associated 
cytochrome p450 enzymes, substantial burden falls on the mitochondria for bio-reduction of 
ANTC. Excess ROS may allow dissipation of the mitochondrial transmembrane potential. In vivo 
Dox-treated mice show evidence of elevated lipid peroxidation compared to control animals 
(Childs et al, 2002), while free radical scavengers e.g. probucol, and use of DXZ as an iron-
chelator demonstrates a protective effect against Dox-toxicity in in vivo animal models (Konig 
et al, 1991; Kumar et al, 2001). Further, superoxide ROS ions may generate peroxynitrite 
species (or Reactive nitrite species, RNS) through reactions with nitric oxide (Beckman et al, 
1996). RNS are selectively oxidant, reacting slowly with most biological molecules including 
amino acids, and thereby inducing nitrosative stress. In a murine model of Dox-toxicity, 
depression of cardiac function with high dose intraperitoneal injection of Dox has been shown 
by to correlate significantly with nitrotyrosine products (Weinstein et al, 2000; Mihm et al, 
2001; Mihm et al, 2002). Further, promoting peroxynitrite catalysis improves survival and 
attenuates Dox-induced fall in cardiac function in murine models of Dox-toxicity (Pacher et al,   
 
Fig.1.5.  Proposed mechanism of generation of reactive oxygen species from ANTC compounds. 
The quinone group in C12 (ring C) may be capable of undergoing univalent reduction to 
semiquinone radical. In presence of molecular oxygen, the semiquinone auto-oxidises to 
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2003). In clinical practice, however, benefits of ROS-quenching remains unclear. A 2011 
Cochrane review concluded that the use of N-acetyl cysteine (NAC) to restore GSH-reductive 
capacity and reduce ROS-burden shows no significant cardioprotective effect (van Dalen et al, 
2011). Similarly, iron-chelation with DXZ was not observed in this review to offer any excess 
survival benefits compared to control groups. This raises the question whether oxidative and 
nitrosative stress may be the trigger of injury, or a pathological mediator of a separate 
underlying injury mechanism.  
1.3.2. Calcium signalling in ANTC-cardiotoxicity. 
Although Ca2+ is crucial to the contractile function of cardiomyocytes, abnormal Ca2+ cycling 
and altered Ca2+ signalling has been noted in human heart failure. For example, L-type calcium 
channel (LTCC) activity increases in the failing human heart (Luo and Anderson, 2013; Glukov 
et al, 2015).  ANTC have been demonstrated in both in vitro as well as in chronic in vivo models 
to increase mitochondrial membrane permeabilisation and allow Ca2+ release from 
mitochondria (Solem et al, 1994). Cardiac mitochondria from rats subjected to weekly 
treatments of Dox (2mg/kg for 13 weeks) display increased mitochondrial Ca2+ accumulation 
(Solem et al, 1994). Further, mitochondria from Dox-treated animals show increased Ca2+-
induced depolarisation of transmembrane potential. Furthermore, the suspected triggers of 
ANTC-toxicity may also initiate pathological Ca2+ signalling. ROS, for example can activate 
calmodulin dependent kinase II (CAMKII) (Sag et al, 2011). CAMKII has a role in phosphorylation 
and regulation of Ca2+ regulatory proteins including ryanodine receptor 2 (RyR2), Sarcoplasmic 
Reticulum Ca2+-ATPase (SERCA2A), phospholamban, and LTCC (Sag et al, 2011; Luo and 
Anderson, 2013). Excess Ca2+ within the cytosol can activate a number of signalling cascades 
including protein kinase A (PKA), CAMKII and adenosine monophosphate regulated kinase 
(AMPK) (Koval et al, 2011). Abnormal CAMKII activation has been linked to the contractile 
dysfunction in ANTC-induced heart failure secondary to altered sarcoplasmic reticulum Ca2+ 
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release, elevated diastolic Ca2+ content in the sarcoplasmic reticulum, and reduced transient 
Ca2+ amplitude (Olson et al, 2005).  
In addition to aberrant activation of Ca2+-regulated signalling cascades, ANTC may mediate 
cardiomyocyte dysfunction through direct actions on specific Ca2+ regulatory proteins. For 
example, both isoforms of Ryanodine receptor (RyR) are modified by ANTC (Feng et al, 1999; 
Hanna et al, 2011), possibly as a consequence of modification of thiol groups in these proteins, 
or due to drug-protein interaction. The Ca2+ binding capacity of Calsequestrin, for example, is 
decreased in the presence of DNR (Charlier et al, 2005). In rabbit-models of chronic DNR- 
toxicity, protein levels as well as gene expressions of SERCA2A and 2B, RYR2, Calsequestrin, and 
NCX have been shown to be significantly downregulated (Stěrba et al, 2011). Moreover, mRNA 
levels of RYR2, and ryanodine- binding kinetics of the RYR2 protein has been shown to be 
significantly downregulated in response to DNR, particularly in the left ventricle (Lenčová-
Popelová et al, 2014). 
These observations suggest ANTC-cardiotoxicity is very likely a multi-factorial process (Fig.1.6). 
Diverse factors such as altered mitochondrial respiratory function, mitochondrial biogenetic 
pathways, excess oxidative and metabolic stress, altered Ca2+ homeostasis, as well inhibition of 
pro-survival factors and excess of cellular death signals contribute to the final manifestation of 
the ANTC-injured failing heart. 
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Fig 1.6. Postulated mechanisms involved in ANTC-cardiotoxicity. Iron overload and/or futile 
recycling of the quinone moieties of ANTC may lead to generation of ROS/RNS species, which 
directly lead to mPTP induction and necrotic cell-death. Oxidative stress and direct toxic effects 
on Ca2+ regulatory proteins may secondarily lead to aberrant Ca2+ signalling, resulting in 
contractile dysfunction and/or secondarily inducing the mPTP transition. DNA damage and 
Topoisomerase modulation by ANTC may lead to alterations of mitochondrial biogenesis and 
the mitochondrial respiratory chain.  Inhibitions of pro-survival signalling and alterations of 
autophagic fluxes may further alter the balance of apoptosis in favour of pro-apoptotic factors, 
while mitochondrial protein degradations may be responsible for inhibited respiration 
(Abbreviations: ERK=Extracellular signalling related kinase, Ca2+= Calcium, mPTP=Mitochondrial permeability 
transition pore, mt=Mitochondria, PI3K= Phosphoinositide 3-kinase, ROS=Reactive Oxygen Species, RNS=Reactive 
nitrosative species) (Illustration by author). 
1.4. Reperfusion injury.  
It is interesting to note that the cardiomyocyte injury caused by ANTC shares aspects that are 
similar to the mechanism(s) associated with “ischaemia-reperfusion injury”. This includes the 
involvement of ROS, RNS, Ca2+ overload, altered autophagic flux, as well as altered metabolic 
state secondary to modulation of mitochondrial function.  
1.4.1 What is reperfusion injury. 
During myocardial infarction, cardiomyocytes deprived of oxygen due to the absence of blood-
flow undergo cell-death. The gold-standard treatment for an acute-MI is therefore restoration 
of coronary flow by Percutaneous Coronary Intervention (PCI) or by pharmacological 
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thrombolysis. However, even after restoration of blood flow to the ischaemic myocardium, 
further cardiomyocyte injury occurs in the ensuing 24 to 48 hours. Early studies in dogs showed 
coronary occlusion for periods as short as 30-minutes led to histological changes of necrosis 
comparable to permanent ligation of a coronary artery for 24 hours (Reimer et al, 1977). The 
final infarct size may therefore be much larger than what would be predicted for the duration 
of ischaemia. It is estimated that this reperfusion-related injury accounts for nearly 50% of the 
final infarct size (Marber et al, 1993; Hausenloy and Yellon, 2003). A number of explanations 
have been put forward for this paradoxical finding of cardiomyocyte-death despite the relief of 
ischaemia, including postulated roles for injurious triggers, e.g., ROS, RNS, aberrant Ca2+ 
signalling and other mediators that are also hypothesised to play a role in ANTC-cardiotoxicity.  
1.4.2. ROS and RNS in reperfusion injury. 
ROS and RNS have been implicated as a key mediator of ischaemia-reperfusion injury. In the 
oxygen-deprived state of ischaemia, oxidative phosphorylation is inhibited. Re-initiation of 
oxidative phosphorylation at the onset of reperfusion, however, has been noted to be 
accompanied by the generation of ROS. For example, xanthine dehydrogenase, which converts 
Nicotinamide Adenine Dinucleotide (NAD) to its reduced form of NADH, has been suggested to 
undergo proteolytic cleavage during ischaemia to form Xanthine oxidase, which may be 
responsible for generation of reactive superoxide radicals in the post-ischaemic 
cardiomyocytes (Thompson-Gorman et al, 1993; Xia et al 1995). As with its putative role in the 
aetiology of ANTC-cardiotoxicity, excessive ROS may lead to mitochondrial matrix swelling, 
collapse of ΔΨm, and induction of transition of the mPTP to the open state. Further, ROS may 
also cause phosphorylation and degradation of anti-apoptotic proteins e.g. BCL-2 (Juhaszova et 
al, 2004). Furthermore, mPTP induction by ROS may in turn be caused by inhibition of the 
respiratory chain, and allow further ROS formation by the mitochondria. This phenomenon of 
ROS-induced ROS release has been suggested to function as a feed forward loop that may 
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exacerbate the process of reperfusion injury (Zorov et al, 2000; Halestrap and Pasdoi, 2009). 
Supporting a role for ROS-species in reperfusion-injury, application of antioxidants, e.g., N-
acetyl cysteine in chick cardiomyocyte model of ischaemia-reperfusion protects against cell-
death (Levraut et al, 2002). Therefore, similar to the proposed mechanism of Reactive-species 
mediated ANTC-cardiotoxicity, ROS and RNS species may mediate reperfusion-injury through 
induction of the mPTP, and/or by potentiating the induction of the apoptotic pathway which 
may ultimately lead to cardiomyocyte death.  
1.4.3. Calcium signalling in reperfusion injury. 
In addition to reactive radicals, aberrant Ca2+ signalling has been strongly suggested to be 
involved in the molecular pathology of reperfusion-injury. While alterations in levels and 
function of Ca2+-regulating proteins may lead to excess mitochondrial Ca2+ accumulation in 
ANTC-toxicity, the mechanism of Ca2+-mediated toxicity in reperfusion injury that has been 
described share similarities as well as differences. The loss of oxidative phosphorylation during 
ischaemia leads to lactate accumulation, leading to an excess cumulative proton (H+) burden 
during ischaemia and an excess intracellular Na+ ([Na+]i) accumulation as a consequence of 
increase in the Na+-H+ exchanger (NHE) activity (Murphy and Eisner, 2009). The increase in 
[Na+]i may secondarily stimulate NCX, which leads to intracellular Ca2+ accumulation at 
reperfusion (Garciarena et al, 2013). NCX has been shown to be capable of activating Ca2+ 
related CAMKII cascade (Villa-Petroff et al, 2007). Further, Ca2+ entry via sarcolemmal L-type 
Ca2+ channels (LTCC) and deficient import of cytosolic Ca2+ into the sarcoplasmic reticulum (SR) 
by SERCA2A promotes Ca2+ overload in the cardiomyocyte. Intracellular Ca2+ ([Ca2+]i) is 
therefore elevated during reperfusion— either as a consequence of reversal of the NCX, or 
secondary to activation of the LTCC during ischaemia (Zhang H et al, 2013). 
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Fig.1.7. Postulated mechanisms of Reperfusion-mediated injury to cardiomyocytes. Calcium and 
ROS species are among key mediators considered to be mediators of ischaemia-reperfusion 
(IR)-injury. Generation of Xanthine Oxidase during ischaemia is a postulated mechanism of 
generation of ROS species during reperfusion. ROS species are capable of inducing mPTP 
transition, e.g., through molecular switches like GSK-3β. Similarly, intracellular calcium overload 
may occur due to LTCC activation during ischaemia. Alternatively, lactate build up maybe 
capable of activating the NHE, and build up Na+, leading to secondary activation of the NCX. 
This excess calcium may lead to loss of mitochondrial transmembrane potential, or directly lead 
to transition of the mPTP. Alternatively, aberrant signalling due to ROS and/or calcium may also 





= Intracellular calcium, LTCC= L-type Calcium Channel, [Na +]i = Intracellular Sodium Concentration, mPTP= 
Mitochondrial permeability transition pore, NCX=Sodium Calcium Exchanger, NHE= Sodium Hydrogen Exchanger, 
ROS=Reactive Oxygen species, XO=Xanthine Oxidase) (Murphy et al, 2009). 
 
Furthermore, reduced Ca2+ uptake by the SR, reduced Ca2+ release, and reduced activity of the 
Ryanodine receptor (RyR) has been observed in isolated Langendorff-perfused heart models of 
IR injury, along with reduced mRNA and protein levels of SERCA2A and RyR (Temshah et al, 
1999). In these experiments, the authors were able to demonstrate partial rescue against the 
decrease of mRNA and protein-levels by perfusing with superoxide dismutase and with 
catalase, suggesting a causal role for ROS-species in the alterations of Ca2+ regulatory proteins 
during reperfusion injury. Therefore, pathological role for deleterious Ca2+ signalling and ROS 
species may be interlinked.  Further supporting a role for aberrant Ca2+-signalling in reperfusion 
injury, Ca2+-induced signalling cascades, e.g., CAMKII have been shown to be capable of 
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contractile function and reduces markers of necrosis, e.g., Cytochrome C levels, as well as 
apoptosis, e.g., BAX/BCL-2 ratio, in ex vivo animal models (Salas et al 2010). Specifically, the 
delta subunit of CAMKII has been suggested to activate NFƙB through phosphorylation and 
inhibition of IƙB (Ling et al, 2013; Zhang XQ et al, 2013). Ca2+-related signalling, e.g., Calcineurin 
cascade and AMPK signalling may also be capable of inhibiting autophagy, which has been 
suggested to have a role in reperfusion injury (Huang et al, 2010, He et al 2014). Inhibiting 
aberrant calcium-mediated signalling therefore has been a target in mitigating reperfusion 
injury.  
In summary, the mechanisms postulated to lead to the altered cardiomyocyte survival in ANTC 
toxicity share key mediators that appear to have a role in the toxicity in ischaemia-reperfusion 
injury. This includes ROS/RNS species and altered Ca2+ signalling, which may secondarily 
activate cell-death mechanisms, including by mPTP induction and by activation of the 
apoptosome and of necrosis. Interventions directed at limiting ischaemia-reperfusion injury 
may therefore offer also offer a protective-effect against ANTC toxicity.  
 
1.5. Ischaemic preconditioning. 
Ischaemic preconditioning (IPC), i.e., subjecting a target organ to brief periods of 
hypoxia/ischaemia followed by reperfusion, is another paradoxical aspect of the puzzle of 
reperfusion injury and its salvage. Murry et al (1986) described what is considered the first 
published evidence that preconditioning a canine heart with short periods of ischaemia offers 
a protective effect against a subsequent prolonged ischaemic insult by limiting infarct size. 
Since then, the IPC phenomenon has been confirmed to exist in different species, including in 
porcine heart, rat heart, murine heart and bovine myocardium (Iliodromitis et al, 2007). 
Circumstantial evidence further points to an IPC effect existing in humans, since pre-infarction 
 
Angshuman Maulik   Page | 48 
 
angina has been reported to be associated with smaller infarct sizes and more rapid 
revascularisation following thrombolysis (Andreotti et al, 1996; Kloner et al, 1995a; Kloner et 
al, 1995b).  
1.5.1. IPC-mediated cardioprotection. 
In order of cardioprotective potential, IPC is described by some authors as weaker only to 
myocardial revascularisation (Yellon and Baxter 1995). It offers a strong protection against 
progression of the ischaemic wave front and limits infarct size (Yellon and Baxter 1995; Downey 
et al, 2007). The initial protection offered by IPC was observed to be immediate but transient, 
lasting between 2 and 4 hours before subsiding. However a second window of protection, albeit 
less robust, was subsequently identified in the research investigating the mechanism of 
protection mediated by IPC, which reappears after 12-24 hours and persists for nearly 72 hours 
(Marber et al, 1993; Yellon and Baxter 1995; Kis et al, 2003). A number of preconditioning 
mimetics have been identified which offer similar protection against ischaemia-reperfusion 
injury as seen with IPC. These include diverse insults such as heat stress, hypothermia, sepsis, 
myocardial stretch etc., as well as various pharmacological agents e.g. volatile anaesthetics, 
opioids, nitrates (Cohen et al, 2001; Downey et al, 2007, Illiodromitis et al, 2007). 
1.5.2. Signalling pathways in IPC.  
Multiple, redundant, cell-surface receptors have been identified as triggers of IPC. This includes 
Adenosine A1, A2B and A3 receptors, Bradykinin receptors, Cannabinoid CB2 receptors, delta-
opioid receptors, muscarinic receptors, natriuretic peptides receptors etc. (Cohen et al 2001; 
Solenkova et al, 2006). These triggers activate a complex network of pro-survival signalling 
cascades, and protects the cardiomyocyte from death-stimuli during the reperfusion phase of 
a subsequent prolonged ischaemic episode (Hausenloy et al, 2005). G-protein coupled receptor 
(GPCR)-linked signalling, as well as receptor tyrosine kinase mediated signalling arising from 
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these receptors have been identified as the most common trigger which serve to initiate a 
protective signalling cascade (Cohen et al 2000). 
1.5.3. The “RISK” pathway. 
Evidence to date implicates a complex signalling cascade involving PI3 Kinase (PI3K), Protein 
Kinase C (PKC), and MAP kinase pathways, e.g., MAPK ERK 1/2 as mediators of IPC-induced 
protection (Hausenloy, 2013). Identified by the Yellon group in 2002 (Schulman et al, 2002) and 
collectively termed the “Reperfusion Injury Salvage Kinase” (or “RISK”) pathway, these cascades 
interact at multiple levels.  
PI3K, for example, is known to be activated by a number of preconditioning triggers. Class IA 
PI3Ks (which includes the PI3K α, β and δ isoforms) can be activated by receptor tyrosine 
kinases and by cytokine receptors, while GPCRs have been shown to activate Class IB isoforms 
(e, PI3K γ) (Oudit et al, 2004). Inositol trisphosphate (IP3), generated by PI3K, is the activator of 
a diverse and complex array of downstream cascades which includes PDK1, Akt/PKB isoforms, 
as well as monomeric G-protein regulated signalling (Datta et al, 1999). For example PDK-1, 
after binding to PI3K, activates Akt/PKB, p70S6K and glucocorticoid-regulated kinase-1 (SGK1) 
(Biondi et al, 2001; McManus et al, 2004). Further, Akt can subsequently activate ERK. The 
targets of these cascades include Glycogen Synthase Kinase (GSK)-3β, the mammalian target of 
Rapamycin (mTOR) C1 pathway, eNOS, as well as specific caspases (Oudit et al, 2004). PI3K 
inhibition, e.g., by Wortmannin, has been shown to abrogate IPC-mediated protection (Tong et 
al, 2000; Hausenloy et al, 2005). Similarly, P70S6K was shown to have an essential role in the 
delayed phase of protection offered by preconditioning (Kis et al, 2003). 
Furthermore, signalling cascades downstream of PI3K, as well as phosphoinositoltrisphosphate 
(PIP3) derivatives like Diacylglycerol (DAG), PIP2 and Phosphatidylcholine etc. can activate 
additional downstream cascades implicated in IPC-mediated protection. PKC, for example, has 
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been shown to be a downstream mediator of PI3K-mediated protection (Tong et al, 2000), 
while both p38 MAPK and ERK 1/2 have been shown to be a part of the signalling cascades 
mediating early as well as delayed protection offered by IPC (Fryer et al, 2001). 
These data show that the RISK pathway of IPC-mediated protection involves a complex network 
of signalling cascades. PI3K plays a central role as the initial activator, and subsequently 
activates further downstream kinases, e.g., ERK 1/2 and PKC which form an interacting complex 
of pro-survival signalling cascades in protecting against reperfusion injury.  
1.5.4. Mechanisms of IPC-mediated protection.  
The exact mechanism(s) of the protection offered by the activation of pro-survival signalling 
cascades is yet to be clearly defined, but appear to converge on stabilisation of the 
mitochondrial transmembrane potential, preventing induction of the mPTP, preventing 
apoptosis, and improved mitochondrial stress response (Maulik et al, 1999; Fryer et al, 2001; 
Lacerda et al, 2009).  
IPC has been shown to preserve mitochondrial transmembrane potential, preserve 
Cytochrome C levels, and prevent pathological induction of the mPTP in ischaemia-reperfusion 
(Costa et al 2008; Hausenloy and Yellon, 2003; Illiodromitis et al, 2007). This preservation may 
be secondary to limiting Ca2+ overload during reperfusion. In isolated Langendorff-perfused 
hearts, IPC has been observed to attenuate the ischaemia-induced decline in Ca2+ content in 
the SR, improve SR Ca2+ release and uptake, as well as preserve protein content of SERCA and 
Phospholamban (Osada et al, 1998, Temshah et al, 2002). Moreover, IPC has been shown to 
modulate the transcription and synthesis of proteins involved in the apoptotic pathway. IPC 
limits nuclear translocation of NFƙB, and upregulates BCL-2 in rat models of ischaemia-
reperfusion injury (Maulik et al, 1999). Of particular note, GSK-3β is a phosphorylation-target 
of key IPC-induced signalling cascades including PI3K. GSK-3β inhibition has been shown to 
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protect against the induction of the mPTP in ischaemic preconditioning (Tong et al, 2002). 
Similarly, STAT3 may mediate protection by phosphorylating and inhibiting GSK-3β, which has 
been suggested to be independent of the DNA binding activity of this transcription factor 
(Pedretti and Raddatz, 2011). STAT3 has also been shown to upregulate transcription of anti-
apoptotic BCL-2 and downregulate BAX (Hattori et al, 2001), while STAT3-dependent 
phosphorylation may be a mechanism of inhibition of the pro-apoptotic factor BAD (Lecour et 
al, 2005). Further, STAT3 has been suggested to protect the mPTP induction directly, which 
maybe a consequence of its interactions with Cyp D (Boengler et al, 2010).  
The known pathways triggered by IPC have also been shown to be initiators of the delayed 
protection observed with preconditioning. Increases in the expression of anti-oxidant 
pathways, e.g., Manganese superoxide dismutase (MnSOD), glutathione peroxidase and 
catalase has been noted with IPC (Das et al, 1993), which may hold particular relevance to 
protection against the postulated mechanism of toxicity of anthracyclines on cardiomyocytes. 
MnSOD and Haem oxygenase 1 (HO-1) are among factors suggested to be mediators of this 
delayed protective effect (Hausenloy and Yellon, 2010). STAT3, for example, activates MnSOD 
(Lecour et al, 2011).  Further, MnSOD is also upregulated by a number of cytokines including 
IL-1β and TNF-α (Yamashita et al, 2000). Inhibiting MnSOD transcription has previously been 
shown to abrogate delayed IPC-mediated protection in rat cardiomyocytes (Yamashita et al, 
1994). Similarly, siRNA mediated inhibition of HO-1 has also been shown to block delayed 
protection conferred by simulated IPC as well as by pharmacological preconditioning agents 
(Jancsó et al, 2007). 
In addition to altering the balance of death-signalling pathways, end-effectors of IPC may 
protect mitochondrial function and alter autophagic flux. For example, IPC has been shown to 
improve mitochondrial H+ leak in response to ischaemia-reperfusion (Quarrie et al, 2011). 
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Further, mitochondrial high energy phosphate content and oxidative phosphorylation pathway 
is preserved in the preconditioned myocardium (Kobara et al, 1996). Delayed ischaemic 
preconditioning has been shown to activate the expression of nucleus-encoded components of 
the electron transfer chain (McLeod et al, 2004), which results in improved ADP-sensitive 
respiration and electron transfer chain activity. Furthermore, IPC has been demonstrated to 
increase transcript levels PGC-1 and Nrf1  ̶ both components of nuclear encoded regulators of 
mitochondrial biogenesis (McLeod et al, 2004). IPC also improves autophagic flux, while Beclin 
1 inhibition by BCL-2 has been demonstrated in rat models of limiting reperfusion injury with 
IPC (Peng et al, 2013).  
1.6. Summary. 
ANTC-induced cardiomyocyte injury remains incompletely understood, but many postulated 
aspects of the biomolecular pathology are similar to the injury inflicted during reperfusion 
following an ischaemic insult. This includes aspects of toxicity associated with highly reactive 
species e.g. ROS and RNS, the mechanisms initiated by pathological Ca2+ overload, alterations 
of mitochondrial transmembrane potential (ΔΨm), and induction of cell-death by apoptosis and 
necrosis through, e.g., induction of mitochondrial permeability transition pore (mPTP) or 
through induction of the apoptosome. Similarly, alterations are also noted in the metabolic 
pathway in the cardiomyocyte including inhibitions of the respiratory complexes, and of 
alteration to autophagic flux. However, multiple interventions including ROS-scavenging with 
N-acetyl cysteine (NAC) or iron-chelation with Dexrazoxane have failed to translate clinically to 
providing meaningful protection against cardiotoxicity caused by Dox (an anthracycline 
compound) (van Dalen et al, 2011). Moreover, Dox has been shown to modulate a number of 
pro-survival signalling cascades. For example, phosphorylation induction of PI3K/Akt and 
MAPK/ ERK 1/2 has been observed in response to doxorubicin-insult in ischaemia-reperfusion 
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stressed myocardium (Ghanaranei et al, 2013a), while other groups have reported 
dephosphorylation of PI3-Kinase (PI3K)/Akt after Dox exposure which may lead to activation of 
apoptotic pathways (Fan et al, 2008). Induction of PI3K signalling, e.g. by decreasing the 
recruitment of the phosphatase PTEN to the plasma membrane, has been demonstrated to 
ameliorate doxorubicin-induced cardiomyopathy in vivo (Kitamura et al, 2014). Other 
experiments have implicated the MAPK ERK 1/2 pathway in protection against Dox-induced 
cardiotoxicity (Lou et al, 2005; Zhu et al, 1999; Su et al, 2006). 
A protective effect against lethal ischaemic injury is observed at cellular and organ levels when 
cardiomyocytes are subjected to brief non-lethal hypoxic insults followed by short periods of 
reperfusion before lethal ischaemia is inflicted. This powerful protective phenomenon, termed 
hypoxic preconditioning (HP) or ischaemic preconditioning (IPC), protects cardiomyocytes 
against hypoxia-reperfusion injury and subsequent cell-death by activating potent pro-survival 
signalling pathways. A complex of signalling cascades, collectively termed the Reperfusion 
Injury Salvage Kinase (RISK)-pathway has been implicated in the protection observed with HP 
(Yellon et al, 2015; Davidson et al 2006). Interestingly, the RISK pathway involves the same 
signalling cascades that are observed to be modulated by anthracycline treatment, e.g., PI3-
Kinase (PI3K), Protein Kinase C (PKC), and MAP kinase pathways, and the end-effect of these 
cascades are postulated to act on similar molecular mediators, e.g., ROS and RNS species and 
further protect organellar structures, e.g., mPTP, that are modulated in the pathogenesis of 
anthracycline cardiotoxicity. We therefore explored the hypothesis that HP may offer 
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Chapter 2. Hypotheses and objectives. 
 
2.1. Hypotheses. 
The overall research hypothesis of the work presented in this thesis explored whether hypoxic 
preconditioning (HP) can protect cardiomyocytes against anthracycline-mediated injury. 
Doxorubicin was used as a representative anthracycline, and the hypothesis was explored using 
isolated adult rat ventricular myocytes (ARVM) model. 
 
 
Fig.2.1. Main research hypotheses explored in the presented work. In an Adult Rat Ventricular 
Myocyte (ARVM) model, we explored the toxicity of doxorubicin, using cell-death as a marker 
of injury. On doxorubicin-stressed cells we explored the effect of iscahemia-reperfusion injury 
(IR-injury), the role of N-acetyl cycsteine (a known ROS-scavenger),and alterations of 
mitochondrial transmembrane potential (ΔΨm). To explore the role of mitochondrial 
permeability transition pore (mPTP) on doxorubicin-induced injury, we investigated mPTP-
induction and cell-death in presence of Ciclosporine A (CsA), since CsA is known to increase the 
stimulus-threshold required for induction of the mPTP. To probe if hypoxic preconditioning (HP) 
was protective against doxorubicin-injury, we characterised an in vitro HP stimulus, and 
investigated if a preceding HP stimulus could protect against subsequent doxorubicin-toxicity. 
We further explored the role of the signalling pathways induced by the Reperfusion injury 
salvage kinases (RISK) in their potential to protect against doxorubicin-mediated cardiomyocyte 
death in this model. 
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As explained in introduction, there is a lack of clarity and consensus on the mechanism of 
anthracycline cardiotoxicity. Cell models offer the advantage that the toxicity of the compound 
on isolated cardiomyocytes can be studied, independent of the effect on other cell-types and 
any compounding physiological variables. We therefore aimed to establish a consistent 
reproducible model of toxicity of Dox in vitro, and investigate the possible mechanisms of 
cardiomyocyte-death in anthracycline-mediated cardiomyocyte injury. This model will further 
allow us to explore the protective potential of HP and the pathways of protection, if any. The 
hypotheses can therefore be broken down into two individual lines of investigation (Fig. 2.1). 
2.2. Objectives 
2.2.1. Objective 1. To investigate mechanisms of anthracycline-cardiotoxicity in an isolated 
ARVM cell model.   
Our first objective is to explore the mechanisms cardiomyocyte- injury due to Dox, using cell-
death as a reflection of anthracycline-injury. The involvement of mediators, e.g., oxidative 
stress, Ca2+, etc, as well as cell-death pathways, e.g., mitochondrial pore transition will be 
explored.  
2.2.2. Objective 2: Hypoxic preconditioning protects cardiomyocytes against toxicity of 
doxorubicin.  
Our second objective is to evaluate whether hypoxic preconditioning may offer protection 
against anthracycline-cardiotoxicity. Further, we aim to explore the phosphorylation status of 
PI3K/Akt and MAPK ERK 1/2 and the respective changes in response to Dox and to HP 
independently and in combination. Since Dox modulates signalling cascades including PI3K/Akt 
and MAPK ERK 1/2 that form the the RISK pathway induced by HP, differentially inhibiting the 
respective cascades with LY294002 and PD98059 and re-examining the influence on cell-death 
due to Dox will offer potential insights into the role of these kinases in protection or 
pathogenesis of anthracycline cardiotoxicity.  
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Male adult Sprague-Dawley rats (150g-450g weight) were obtained from the UCL biological 
Services Unit for use in this experiment. All animals were housed in a temperature, humidity 
and light cycle controlled environment. All animal experiments were carried out in accordance 
with the UK Home Office Guide on the Operation of Animal (Scientific Procedures) Act of 1986 
under home office licence PPL 70-8556 
3.1.2. Cell culture medium. 
Medium 199 with Earle’s salt and L-glut (Invitrogen Catalogue number: 31150-030) was 
supplemented with Creatine (5 mM), Carnitine (2 mM) and Taurine (5 mM). 5 ml of 100x 
Penicillin/Streptomycin solution (Sigma CAS: P4333) was added directly to the final 
supplemented solution. 
3.1.3. Ciclosporine A.  
Ciclosporine A (CsA) from Tolypocladium inflatum (Merck Millipore, CAS No. CAS 59865-13-3) 
was dissolved in DMSO per manufacturer’s instructions. Further dilution was carried out in 
medium 199 for use in cell-survival experiments, or in Tyrode’s solution (137 mM NaCl, 2.7 mM 
KCl, 1 mM MgCl2, 1.8 mM CaCl2, 0.2 mM Na2HPO4, 12 mM NaHCO3, 5.5 mM D-glucose, pH 7.4) 
with or without 3 μM Tetramethyl rhodamine methyl ester (TMRM) for use in mPTP induction 
assays. Final concentration of CsA used was 1 μM. 
3.1.4. Doxorubicin. 
Doxorubicin hydrochloride (Sigma Aldrich, catalogue no. D1515) was dissolved in DMSO per 
manufacturer’s instructions. This was further diluted in medium 199 to the indicated 
concentrations and used immediately. 
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3.1.5. Hydrogen peroxide. 
30% Hydrogen peroxide (H2O2) solution in deionised H2O (Sigma-Aldrich, CAS Number 7722-
84-1) was further dissolved in medium 199 to 100 µM, 50 µM and 1 µM solutions and used 
immediately. 1 µM H2O2 solution was used with or without dissolved N-acetyl cysteine (NAC) 
as indicated.  
3.1.6. Hypoxic buffer. 
A buffer was prepared containing 127.8 mM NaCl, 14.8 mM KCl, 1.2 mM KH2PO4, 1.2 mM 
MgSO4, 2.2 mM NaHCO3, 1.0 mM CaCl2, 10 mM Sodium-lactate in deionised water as previously 
described (hypoxic buffer, Ong et al, 2010). The buffer was gassed with 95% N2-5% CO2 (N2-
CO2) immediately before use and pH was adjusted to 6.4 at 37 °C. Fresh buffer was prepared 
on the day of use. 
3.1.7. Insulin.  
Insulin is a known inducer of the RISK kinases, and was therefore used as a positive control to 
induce PI3K/Akt ohosphorylation and MAPK/ ERK 1/2 phosphorylation. Human insulin 
(Invitrogen, Paisley, UK) was dissolved in medium 199 to obtain a final concentration of 275 
u/ml and used immediately. 
3.1.8. LY294002. 
LY294002 is a selective PI3K/Akt inhibitor. LY294002 hydrochloride (Sigma Aldrich, CAS 934389-
88-5) was dissolved in DMSO per manufacturer’s instructions before final dilution in medium 
199 or in normoxic buffer, as appropriate respectively, to obtain a final concentration of 10 µM.  
3.1.9. N-acetyl cysteine. 
N-acetyl cycsteine (NAC) (Thermo Fisher Scientific, CAS No. 616911) was dissolved in DMSO per 
manufacturer’s instructions. This was further dissolved in medium 199 to obtain a final 
concentration of 250 μM NAC. 
 
Angshuman Maulik   Page | 60 
 
3.1.10. Normoxic buffer. 
Normoxic buffer was prepared by dissolving 10 mM Glucose, 118 mM NaCl, 1.2 mM KH2PO4, 
1.2 mM MgSO4, 22 mM NaHCO3, 1.0 mM CaCl2, in deionised water. The solution was gassed 
with carbogen and pH adjusted at 37 °C to pH 7.4 before use. 
3.1.11. PD98059.  
PD98059 is a MAPK ERK 1/2 inhibitor. PD98059 (Sigma Aldrich, CAS No. 167869-21-8) was 
dissolved in DMSO per manufacturer’s instructions, before final dilution in medium 199 or in 
normoxic buffer as appropriate respectively to obtain a final concentration of 30 µM. 
3.1.12. Propidium iodide. 
Propidium Iodide (PI) crosses the depolarised cellular and nuclear membrane and intercalates 
with doubles stranded nucleic acid, staining DNA in dead cells which can be identified by its 
fluorescence. PI (1 mg/ml) (Thermo Fisher. Catalogue No. P3566) was used at a final 
concentration of 5 µg/ml. 
3.1.13. Tetramethyl rhodamine methyl ester. 
Tetramethyl rhodamine methyl ester (TMRM) perchlorate (Thermo Fisher Catalogue no. T-668) 
was dissolved in DMSO per manufacturer’s instructions. Further dilution in Tyrode’s solution 
yielded a final concentration of 30 nM TMRM solution to estimate mitochondrial 
transmembrane potential, or a 3μM TMRM solution used in mPTP-induction assay. 
3.1.14. Antibodies. 
Primary antibodies to Total-Ak (t-Akt), Phospho-Akt (Ser 473) (p-Akt), Total ERK p44/42 (t-ERK) 
and Phospho-ERK p44/42 (Thr202/Tyr204) (p-ERK) were obtained from Cell Signalling 
Technologies and used at a dilution of 1:1000. Antibodies to Glyceraldehyde 3-
Phosphodehdrogenase (GAPDH) and α-tubulin were obtained from Abcam and used at a 
dilution of 1:1000. 
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3.2. Methods. 
3.2.1. Isolation of ventricular cariomyocytes and assessment of cell-death 
3.2.1.1. Isolation of adult rat ventricular cardiomyocytes. 
Adult male Sprague-Dawley rats (150-450g weight) were administered terminal anaesthesia 
with 65 mg/kg Pentobarbital injected intraperitoneally. The anaesthetised rats were monitored 
till cessation of peripheral and central nervous system reflexes but before cardiac arrest. The 
thoracic cavity was opened by clamshell thoracotomy and the pericardial sac opened to access 
the heart and ascending aorta. The heart was stabilised by the base with index and second 
finger and incised immediately below the aortic arch. The heart was then immersed in ice-cold 
isolation buffer. The aortic trunk was identified and cannulated rapidly (<3 mins excision to 
cannulation) and placed on a modified Langendorff apparatus maintained at 37  ̊C, and 
retrogradely perfused with myocyte isolation buffer containing 0.75 M Ca2+ (Solution 1, 
appendix a) delivered at a constant rate of 10 ml/ min to clear the heart of blood. This was 
followed by chelation of Ca2+ and sinus arrest with 100 µM EGTA-buffered solution (Solution 2) 
perfused at the same rate, before introduction of collagenase solution containing 100 mM Ca2+. 
The extracellular matrix was subjected to digestion for 10-12 minutes till visually estimated 
alteration of solution viscosity and/or ventricular pallor. The ventricles were then excised, 
dissected into smaller pieces, and gently bathed in collagenase solution until a colloidal 
suspension of cardiomyocytes was obtained. The cells were subsequently allowed to 
precipitate into a pellet by standing. The supernatant was discarded, and the pellet re-
suspended in myocyte buffer containing increasing concentrations of Ca2+ (solutions 4 and 5, 
final Ca2+ concentration 1 M) before re-suspending in supplemented cell culture medium 
(M199).  
The cells were seeded onto laminin coated cell-culture dishes and left to adhere undisturbed 
for 60 minutes. Excess, non-adherent cells were washed away with 1 ml medium per well, and 
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the wells replenished with 2 ml medium 199. These were allowed to rest for a further one hour 
before any further experiments were carried out. Cell isolations yielding an excess of 20% death 
under basal conditions at the end of experimental protocols were excluded from experiment 
and interpretation.  
3.2.1.2. Assessment of cell-death. 
Each experiment was set-up in duplicate. Cell-death analysis was carried out in a blinded 
fashion. Each treatment group in an experiment was randomised to a numerical value with the 
aid of a publicly available, free-to-use, list-randomisation service provided by Randomness and 
Integrity services Ltd (https://www.random.org/lists/). A key to this randomised list was 
maintained in Microsoft excel software. Analysis of cell-death in ImageJ software was carried 
out in numerical order, before de-randomisation according to the key.  
At the end of cell-survival experiments, PI was introduced into cell-culture plate and allowed to 
incubate for at least 30 s before microscopic analysis. Representative images were recorded 
using a Nikon Eclipse TE200 microscope, and analysed using ImageJ. Cells were considered dead 
according to the following criteria (Goto et al, 2009) (representative image shown in fig.3.11): 
a. Evidence of staining of nuclei with propidium iodide. 
b. Morphological changes, including evidence of membrane blebbing in the presence or 
absence of PI uptake. 
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Fig.3.1. Evaluation of cell-death. Cardiomyocytes were considered as dead on the basis of 
nuclear staining with propidium iodide (PI), on observation of morphological changes including 
membrane blebbing and alterations of the cellular architecture. Example photomicrograph 
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3.2.2. Investigation of in vitro toxicity of increasing doxorubicin-concentrations on isolated 
cardiomyocytes. 
Isolated cardiomyocytes were transferred from medium 199, unless otherwise specified, to a 
medium containing Dox. The toxicity was evaluated for two different exposure-times. Cells 
were treated with 0.5 µM, 1 µM, 2 µM, and 5 µM, 7.5 µM, 10 µM, 15 µM and 20 µM Dox and 
cell-death evaluated after 4 hours. In a second experiment, cardiomyocytes were incubated 
with 1 µM, 2 µM, and 5 µM, 7.5 µM, 10 µM, 15 µM and 20 µM and cell-death evaluated after 
18 hours (Fig. 3.2). As control, basal cell-death was evaluated from cardiomyocytes incubated 
in medium 199 for matched incubation periods. 
 
 
Fig. 3.2. Protocols for model of doxorubicin-induced cell-death. Cardiomyocytes were subjected 
to increasing concentrations of doxorubicin over 4 hours and 18 hours, and cell-death 
evaluated. Basal cell-death was evaluated in cardiomyocytes maintained in cell-culture medium 
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3.2.3. Evaluating the effect of concomitant ischaemia-reperfusion and doxorubicin-injury on 
isolated cardiomyocytes. 
 
3.2.3.1. Characterisation of a model of in vitro ischaemia-reperfusion injury in isolated 
cardiomyocytes.   
 
Fig. 3.3. Schematic diagram of protocols tested for ischaemia-reperfusion injury in vitro. 
Cardiomyocytes were subjected to hypoxia (simulated ischaemia, SI) in a hypoxic buffer for 3 
hours (SI3) or 4 hours (SI4). Reoxygenation was carried out in normal environment in a 
normoxic buffer for 1 hour in both protocols. The control (Cont) was incubated in normal 
atmosphere in a normoxic buffer.  
 
To explore the hypothesis that ischaemia-reperfusion (IR) injury may exacerbate the injury 
inflicted by exposure to Dox-treatment, we first developed a protocol to simulate IR-injury in 
vitro. Cardiomyocytes were transferred from medium 199 to a hypoxic buffer and subjected to 
hypoxia for 3 hours (SI3) or 4 hours (SI4) before transferring to normoxic buffer and normal 
environment for 1 hour to initate reoxygenation for both groups. Control cardiomyocytes were 
subjected to normoxic buffer in normal environment for 4 hours (Fig. 3.3). 
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3.2.3.2. Investigation of the effect of ischaemia-reperfusion injury on doxorubicin-stressed 
cardiomyocytes. 
 
Fig.3.4. Experimental layout for evaluating the effect of ischaemia-reperfusion injury in 
cardiomyocytes treated with doxorubicin. Cells were incubated in 2 µM doxorubicin for 4 hours 
or 18 hours, before subjecting these in the presence of doxorubicin to 4 hours hypoxia 
(similualted ischaemia, or SI) followed by 1 hour reoxygenation (denoted simulated 
reperfusion, or SR) (Dox IR). Doxorubicin pre-treated normoxic controls (Dox N) were 
transferred to normoxic buffer in presence of doxorubicin, and incubated for 5 hours. In 
untreated controls, cardiomyocytes were incubated in medium 199 and transferred to 
normoxic buffer alone for 5 hours (Cont); subjected to IR (Cont-IR); or evaluated in a positive 
control experiment by subjecting to 4 hours hypoxia followed by reoxygenation in normoxic 
buffer with insulin (Ins).  
 
Cardiomyocytes were incubated for 4 hours or 18 hours in 2 µM Dox, then transferred to 
hypoxic buffer with 2 µM Dox and subjected to hypoxia for 4 hours (Dox IR) (Fig 3.4). Cells were 
then transferred to normoxic buffer with 2 µM Dox to initiate reoxygenation, and incubated for 
1 hour in a normoxic environment. Pre-treated normoxic controls (Dox N) were transferred to 
normoxic buffer containing 2 µM Dox, and incubated for 5 hours.  
Untreated controls were incubated in medium 199 alone for 4 or 18 hours, then transferred to 
normoxic buffer for 5 hours (Cont), or subjected to IR-injury (Cont IR). As a positive protective 
agent against IR-injury, insulin (275u/ml) was used. A control group was established in 
 
Angshuman Maulik   Page | 67 
 
untreated cells subjected to SI4, which where transferred to normoxic environment in 
normoxic buffer with dissolved insulin (Ins) after hypoxia.   
3.2.4. Investigating the effect of co-incubation with NAC on doxorubicin-induced 
cardiomyocyte-toxicity. 
 
3.2.4.1. Estimation of cardiomyocyte toxicity in response to increasing H2O2 concentrations 
over time. 
To investigate the effect of increasing concentrations of H2O2 on cell-death, cardiomyocytes 
were transferred from medium 199 to a solution of medium 199 containing H2O2 at 
concentrations of 1 μM, 50 µM and 100 µM H2O2. These were incubated for 4 or 18 hours. 
Incubation in cell culture medium alone served as control. Cell-death was evaluated at the end 
of incubation (Fig. 3.5). 
 
Fig. 3.5. Schematic diagram of experimental design for estimating H2O2 induced cell-death. H2O2 
in medium 199 at the indicated concentrations were used to incubate cardiomyocytes for 4 or 
for 18 hours. Cell-death was evaluated at the end of this incubation period.  
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3.2.4.2. Evaluating the effect of co-incubation with NAC on doxorubicin toxicity. 
 
Fig. 3.6. Experimental layout for investigating the effect of N-acetyl cysteine on doxorubicin 
toxicity. Cardiomyocytes were transferred into medium 199 with 1 µM H2O2 alone (H2O2), 7.5 
µM doxorubicin alone (Dox), doxorubicin with 250 µM NAC (Dox NAC), or 1 µM H2O2 with NAC 
(H2O2 NAC). As control, cardiomyocytes were incubated with medium 199 alone (Cont) or with 
250 µM NAC (Cont NAC). 
 
To probe the effect of potential ROS-scavenging on Dox-induced cardiomyocyte injury, we 
evaluated cell-death in cardiomyocytes incubated for 18 hours in 7.5 μM Dox alone (Dox), or 
with 250 µM NAC (Dox NAC), since NAC is known to be a potent ROS-scavenger. As positive 
control, cardiomyocytes were incubated with 1 μM H2O2 alone (H2O2) or with 250 μM NAC 
(H2O2 NAC) dissolved in medium 199. As a third control, cardiomyocytes were incubated with 
250 μM NAC (Cont NAC) dissolved in medium 199 alone. Basal cell-death was evaluated in cells 
incubated in medium 199 alone (Cont). Cell-death was evaluated after 18 hours incubation 
(Fig.3.6). 
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3.2.5. Investigation of effect of doxorubicin treatment on mitochondrial transmembrane 
potential.  




Fig. 3.7. Experimental layout for assessment of ΔΨm collapse with FCCP. Cardiomyocytes were 
incubated in the indicated treatment for 18 hours. TMRM loading was achieved by incubating 
for 30 minutes in Tyrode’s solution with dissolved 30 nM TMRM. Imaging was performed on 
the platform of a Leica SP5 confocal microscope. Mitochondrial respiration was arrested using 
200 nM FCCP, and TMRM fluorescence recorded every 10 seconds using 10% He-Ne laser for 
80 seconds or till complete loss of fluorescence signal.  
 
To investigate the mitochondrial transmembrane potential (ΔΨm), temporal collapse and the 
residual fluorescence of TMRM was evaluated after arresting mitochondrial respiration with 
the uncoupling agent FCCP at a concentration of 200nM. Cardiomyocytes were plated in a 32 
mm glass-bottomed cell-culture plate and incubated with 7.5 μM Dox in medium 199 for 30 
minutes (Dox 0h), 4 hour (Dox 4h) and 18 hours (Dox 18h). Corresponding controls were 
incubated in medium 199 alone (Cont 0h, Cont 4h and Cont 18h respectively, Fig. 3.7). At the 
end of treatment period, incubating solution was discarded and cells were loaded with TMRM 
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by incubating in 30 nM TMRM dissolved in Tyrode’s solution for 30 minutes. Excess dye was 
discarded, and the cells were washed with 1ml TMRM-free Tyrode’s solution three times. The 
wells were then replenished with Tyrode’s solution and the plates mounted on the stage of a 
Leica SP5 confocal microscope (Leica, Wetzlar, Germany) equipped with ×40 oil immersion 
objective lens (numerical aperture 1.0).  Baseline ΔΨm was estimated by measuring the 
fluorescence of TMRM using an incident He-Ne laser at 543 nm (10% maximum intensity) as a 
light source. The intensity of emitted light was recorded between 580-596nm (line average of 
2 scans). FCCP was then introduced to the solution at a final concentration of 200 nM, and 
images obtained every 10 seconds for 80 seconds or till complete loss of fluorescence. The 
images were deconstructed to red, green, and blue channels in ImageJ software and intensity 
of emitted light in the red channel was measured. Optical fluorescence was plotted against 
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3.2.4.2. Estimation of ΔΨm variation in response to doxorubicin treatment. 
 
 
Fig 3.8. Experimental layout for assessment of ΔΨm. Cardiomyocytes were incubated in the 
indicated treatment for 18 hours. Medium 199 was exchanged for Tyrode’s solution with 30 
nM TMRM and allowed to incubate for 30 minutes before exchanging for dye-free Tyrode’s 
solution. Imaging was performed on the platform of a Leica SP5 confocal microscope and 
images recorded of the fluorescence intensity of TMRM using 10% He-Ne laser incident laser.  
 
To evaluate ΔΨm variation, cardiomyocytes from treatment groups Dox 0h, Dox 4h and Dox 18h 
(section 3.2.4.1.) were loaded with 30 nM TMRM as above, and the emited fluorescence 
recorded at 580-596 nm after focussing 543 nm 10% He-Ne laser on the stage of a Leica SP5 
confocal microscope (×40 oil immersion objective lens, numerical aperture 1.0) (Fig. 3.8). 
Corresponding controls (Cont 0h, Cont 4h and Cont 18h respectively) were incubated in 
medium 199 alone. Images were deconstructed to red, green, and blue channels in ImageJ 
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software and intensity of emitted light in the red channel was measured. This approach to ΔΨm 
measurement has been described previously both form our own lab (Sidall et al, 2010) as well 
as by other groups (Juhaszova et al, 2004). 
3.2.6. Investigation of the role of the mitochondrial permeability transition pore in doxorubicin 
toxicity. 
 
3.2.5.1. Measurement of time taken to mitochondrial permeability pore induction following 
doxorubicin treatment. 
To assess the influence of Dox treatment on the transition of the mitochondrial transition 
permeability pore (mPTP), cardiomyocytes were incubated with 7.5 μM Dox for 18 hours 
(Dox).   
 
Fig. 3.9. Experimental layout for estimating time taken to mPTP induction. Cardiomyocytes were 
incubated in the indicated treatment for 18 hours. Medium 199 was exchanged for Tyrode’s 
solution with 3 µM TMRM, and allowed to incubate for 30 minutes. Cells were then subjected 
to 40% intensity incident He-Ne laser with continuous recording of the emission spectra at 580 
nM-596 nM. Time taken to reach half of maximum fluorescence-intensity was recorded as time 
taken to mPTP induction (T). 1 µM CsA was used a positive control, and loaded with TMRM and 
subsequently maintained in Tyrode’s solution. 
 
Angshuman Maulik   Page | 73 
 
Cells were loaded with a higher concentration of 3 µM TMRM, using a similar protocol as above. 
Plates were subjected to 40% intensity incident He-Ne laser on the imaging platform of a Leica 
SP5 confocal microscope, and continuous recording of the emission spectra at 580 nM-596 nM 
was undertaken (Fig. 3.9). Time taken to complete de-quenching of TMRM fluorescence from 
mitochondria to cytosol was taken as complete transition of the mitochondrial pore. Time taken 
for fluorescence in each cardiomyocyte to reach half of maximum intensity was recorded as 
time taken to mPTP induction (Fig.3.9, T). Control (Cont) cardiomyocytes were incubated with 
medium 199 only. Ciclosporine A (CsA) is a compound that increases the threshold of induction-
stimulus required for mPTP-transition to “open” state, which is detected as an increase in the 
time taken to mPTP induction. Therefore, 1 µM CsA was used as positive control in this 
experiment, and loaded in Tyrode’s solution with TMRM after Dox treatment (Dox CsA), or after 
incubation in medium 199 alone (Cont CsA). For these positive controls, imaging was carried 
out in Tyrode’s solution with dissolved 1 µM CsA. 
3.2.5.2. Investigating the effect of CsA co-treatment on doxorubicin-toxicity. 
 
Fig. 3.10. Experimental design for investigating the effect of CsA on doxorubicin-induced cell-
death. Cardiomyocytes were incubated with 7.5 µM doxorubicin alone or with 1 µM CsA for 18 
hours and cell-death assessed. As control, cardiomyocytes were incubated in medium 199 
alone or with dissolved 1 µM CsA for 18 hours. 
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Cardiomyocytes were incubated in 7.5 µM Dox alone (Dox) or co-incubated with Dox and 1 µM 
CsA (Dox CsA) for 18 hours before assessment of cell-death. Control cardiomyocytes were 
incubated in medium 199 alone (Cont) or with 1 µM CsA (Cont CsA) for 18 hours (Fig.3.10). 
3.2.7. Investigation of the effect of hypoxic preconditioning on doxorubicin-induced cell-death. 
 
Fig. 3.11. Protocol for evaluating the influence of hypoxic preconditioning on doxorubicin-
induced toxicity. Cardiomyocytes were subjected to 30 minutes hypoxia followed by 10 minutes 
reoxygenation, then transferred to medium 199 with dissolved doxorubicin (concentrations 
indicated) for 18 hours. As control, cells were subjected to a control protocol and incubated 
with the indicated concentrations of doxorubicin for 18 hours. (Abbreviations Dox= Doxorubicin, 
H=Hypoxic buffer, N=Normoxic buffer). 
 
To investigate the effect of hypoxic preconditioning (HP) on Dox mediated cell-death, 
cardiomyocytes were maintained in medium 199 for 1 hour, then transferred to hypoxic buffer 
in a hypoxic airtight chamber at 37 °C, and incubated for 30 minutes before exchanging into 
normoxic buffer in normal atmosphere at 37 °C for 10 minutes. Cells were then transferred into 
medium 199 alone (Cont HP, Fig, 3.11) or with Dox at concentrations 2 µM, 5 µM, 7.5 µM, and 
10 µM (Dox HP) and incubated for 18 hours. Normoxic controls were established by incubating 
cardiomyocytes in normoxic buffer alone for 40 minutes, then transferred to medium 199 alone 
(Cont) or into respective Dox concentrations (Dox, Fig, 3.11).  
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3.2.8. Investigation of the reperfusion injury salvage kinase components involved in hypoxic 
preconditioning mediated protection against doxorubicin-toxicity. 
  
Fig. 3.12. Experimental set-up for inhibition of PI3K/Akt and of MAPK ERK 1/2 respectively. Cells 
were pre-incubated with 10µM LY294002 to inhibit PI3K/Akt, or with 30µM PD98059 to inhibit 
MAPK ERK 1/2. Hypoxic stimulus was delivered in vitro and the inhibitors reintroduced at 
reoxygenation. Cells were incubated in a bathing media with dissolved doxorubicin and 
LY294002 or PD98059 as appropriate respectively (Abbreviations: Dox= Doxorubicin, 
H=Hypoxic buffer, LY=LY294002, N=Normoxic buffer, PD=PD98059). 
 
To delineate the involvement of the reperfusion injury salvage kinase (RISK) pathway HP-
mediated protection, cardiomyocytes were pre-incubated in medium 199 for one hour with 10 
µM LY294002 to inhibit induction of PI3K/Akt, or with 30 µM PD98059 to inhibit MAPK ERK 1/2 
respectively. Cells were then subjected to hypoxia for 30 minutes in an inhibitor-free hypoxic 
buffer. LY294002 and PD98059, as appropriate, were reintroduced in normoxic buffer and cells 
incubated for 10 minutes in normal atmosphere before exchange into the respective inhibitors 
dissolved in medium 199 alone (Cont HP LY and Cont HP PD respectively), or with 7.5 μM Dox 
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(Dox HP LY and Dox HP PD respectively, Fig. 3.12) and incubated for 18 hours. Preconditioned 
controls were established by incubating cardiomyocytes in inhibitor-free medium 199 alone, 
then eliciting hypoxic preconditioning with 30 minutes hypoxia in hypoxic buffer followed by 
reoxygenation for 10 minutes in normoxic buffer in a normal atmosphere. Cells were then 
transferred to medium 199 alone (Cont HP) or 7.5 μM Dox (Dox HP, Fig. 3.12) and incubated 
for 18 hours. As normoxic controls for inhibitor-treatment, cardiomyocytes pre-incubated with 
LY294002 and PD98059 as above were transferred to inhibitor-free normoxic buffer in normal 
atmosphere and incubated for 30 minutes, then exchanged into normoxic buffer with dissolved 
LY294002 or PD98059 as appropriate and incubated for 10 minutes. Cells were then transferred 
in presence of the respective inhibitors to medium 199 alone (Cont LY and Cont PD), or into 
7.5μM Dox (Dox LY and Dox PD, Fig. 3.12) and incubated for 18 hours. Basal cell-death was 
evaluated after incubating cells in normoxic buffer in normal atmosphere for 40 minutes, then 
transferring to medium 199 alone for 18 hours (Cont). Reference Dox-toxicity was established 
by incubating cells in 7.5 µM Dox for 18 hours after 40 minutes incubation in normoxic buffer 
(Dox, Fig. 3.12).  
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3.2.9. Western blot analysis  
3.2.9.1. Analysis of induction of phospho-Akt and phospho-ERK in response to hypoxic 
preconditioning. 
  
Fig.3.13. Protocol for collection of Western blot sample to analyse protein kinase induction 
following preconditioning. Cardiomyocytes were pre-incubated with 10 µM LY294002 (LY) or 
with 30µM PD98059 (PD) then subjected to 30 minutes hypoxia before transfer to 
reoxygenation buffer in normoxic environment. Samples were collected by lysing cells 120s 
after completion of hypoxic phase of preconditioning, within the time zone of simulated 
reperfusion. Insulin treatment was used as a positive inducer of phospho-Akt and phospho-ERK 
1/2, and in positive controls, cells were lysed after 10 minutes of insulin (275u/ml) treatment, 
following 1 hour of treatment with the inhibitors LY294002 or PD98059, as appropriate. 
 
The activation of PI3K/Akt pathway and MAPK ERK 1/2 by HP was analysed by Western blot 
analyses following characterisation (Chapter 4, section 4.3). Cardiomyocytes were pre-
incubated for one hour in medium 199, then provided a hypoxic stimulus by incubating in a 
hypoxic buffer in hypoxic atmosphere for 30 minutes. These were then transferred into a 
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normoxic buffer in normal atmosphere, and cells lysed at 120 seconds after hypoxia (HP, Fig. 
3.13). Pre-incubation in 10 µM LY294002 or 30µM PD98059 was used to inhibit PI3K/Akt and 
MAPK ERK 1/2 respectively before inducing hypoxic-stimulus in an inhibitor-free hypoxic buffer 
in hypoxic atmosphere for 30 minutes. Cells were then transferred into normoxic buffer with 
10 µM LY294002 (HP( LY)), or with 30µM PD98059 (HP( PD)) respectively and reoxygenated for 
120 seconds before cell lysis. As non-preconditioned inhibitor-treated controls, cardiomyocytes 
were incubated in medium 199 with the respective inhibitors, then transferred into normoxic 
buffer in a normal atmosphere for 30 minutes. These were then transferred to normoxic buffer 
with dissolved inhibitors and lysed at 120 seconds as above (Cont(LY) and Cont(PD) 
respectively, Fig. 3.13). Phosphorylation of both PI3K/Akt and MAPK ERK 1/2 under basal 
conditions was evaluated in cells incubated in normoxic buffer alone for 30 minutes, then lysed 
after an additional 120 seconds (Cont, Fig.3.13). 
As positive control, cardiomyocytes were treated to medium 199 with 275u/ml insulin in 
medium 199 for 10 minutes to induce the RISK kinases, and samples lysed as described below. 
Insulin-induced RISK kinase induction was inhibited by pretreating cardiomyocytes to medium 
199 with LY294002 or with PD8059 for one hour, then transferred to medium with insulin and 
the respective inhibitors. 
Cell lysis was carried out with boiling 1x SDS-PAGE sample loading buffer, and harvesting of the 
lysate carried out using a cell-scraper. The samples were boiled at 100 ̊ C for two minutes to 
inhibit protein phosphatases. Samples were resolved by standard SDS-PAGE and transferred to 
a nitrocellulose membrane using standard Western blotting protocol. The membrane was 
blocked with 5% Bovine serum albumin for one hour before incubating with respective primary 
antibodies, and allowed to adhere overnight. Primary antibodies were then discarded and 
membrane washed and loaded with respective species-specific secondary antibodies using 
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standard Western blot protocol. The membranes were then recorded using Li-COR Odyssey® 
imaging system and software, before further analysis using imageJ. The protein content for 
each treatment group were evaluated using standard imageJ Western blot analysis approach.   
To evaluate PI3K/Akt phosphorylation induction, phosphorylated and non-phosphorylated 
protein levels (p-Akt and t-Akt levels) was determined for each sample group. Both p-Akt and 
t-Akt were normalised to the respective levels of the housekeeping protein Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) in each well, i.e., p-Akt:GAPDH and t-Akt:GAPDH ratios 
were identified. Phosphorylation induction in the respective groups were then determined as 
the ratio of p-Akt:GAPDH to t-Akt: GAPDH. Similarly, to evaluate phosphorylation of MAPK ERK 
1/2, phosphorylated and non-phosphorylated protein content of ERK 1/2 were normalised to 
the content of the housekeeping protein α-tubulin in each well (p-ERK: α-tubulin and t-ERK: α-
tubulin respectively) and the ratio of p-ERK: α-tubulin to t-ERK: α-tubulin evaluated.  
 
3.2.9.2. Analysis of PI3K/Akt and MAPK ERK 1/2 induction in response to doxorubicin 
treatment. 
 
To analyse the induction PI3K/Akt and MAPK ERK 1/2 in response to Dox-treatment, cells were 
subjected 7.5 µM Dox for 15 minutes, 4 hours or 18 hours (Dox 0h, Dox 4h and Dox 18h, 
Fig.3.14). Control cardiomyocytes were incubated in medium 199 alone (Cont 0h, Cont 4h and 
Cont 18h). Cells were lysed with boiling SDS-PAGE and probed using standard Western blotting 
protocol, before recording in Li-COR® odyssey as described above. Blots were analysed using 
ImageJ as above. 
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Fig.3.14. Experimental layout for protein collection and analysis of phosphorylation-induction of 
Akt and ERK 1/2 following doxorubicin treatment. Cardiomyocytes were incubated with 7.5µM 
doxorubicin for 15 minutes, 4 hours or 18 hours. Control Cardiomyocytes were incubated in 
medium 199 alone. Cells were lysed with boiling SDS-PAGE and analysed by standard western 
blotting protocol. 
 
3.2.10. Statistical analysis. 
All data were analysed using Graphpad prism (version 5.0). Values are expressed as mean ± 
Standard error of the mean (SEM). Analysis of statistical significance where carried out with 
multiple Students t-test where samples where small to the order of n=2, or using Repeated-
measures ANOVA where sample sizes were larger. Where F achieved P<0.05 for ANOVA table, 
Tukey’s post-hoc comparison test was carried out and differences were considered significant 
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Chapter 4. Characterisation and development of models and 
protocols. 
 
4.1. Model of doxorubicin toxicity. 
4.1.1. In vitro model of doxorubicin toxicity. 
Although anthracycline cardiotoxicity has been investigated in in vivo, in vitro, as well as in ex 
vivo models, a number of different hypotheses are offered to explain the aetiology of 
cardiomyocyte injury. The various different models in which investigations into anthracycline-
injury has been described, along with the varying modes, models and time-periods to elicit 
significant injury, makes investigating the toxicity of these compounds challenging using any 
single reproducible model of toxicity. Different animal models as well as cell systems have been 
used to investigate the cardiotoxicity of anthracyclines (Stěrba et al, 2011).  Reports from in 
vivo as well as in vitro models reveal a dose-dependent effect in the toxicity of doxorubicin, and 
a high concentration of anthracyclines may induce cardiac dysfunction where low dose 
concentrations show no apparent effect. For example, Edwards et al (2016) failed to observe 
any significant cardiac dysfunction in a murine model with 1-15 mg/kg intraperitoneal Dox after 
6 to 8 months, but achieved cardiac failure in mice injected with higher concentrations of up to 
45 mg/kg doxorubicin. Similarly, reports from in vivo models have shown large single bolus 
doses of anthracyclines achieve symptomatic heart failure within a short span of time, typically 
in the order of 72 hours (Zhang et al, 2012, Chatterjee et al, 2010). Other investigators have 
reported data from small animal models using low dose, interrupted dosing, mimicking human 
chemotherapy protocols which demonstrate evidence of early structural changes before overt 
heart failure symptoms manifests. In a Dox-induced model of toxicity in rats, for example, 
evidence of histological and organellar changes along with myofibrillar disarray were noted 
within a period of six weeks, before evidence of cardiac failure were noted (Cove-Smith et al,  
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2014). Similarly, proteomic analysis in a rabbit model of daunorubicin toxicity similarly showed 
evidence of altered gene expression and mRNA translation of cardiac structural proteins 
immediately after cessation of an interrupted dosing regimen (Lenčová-Popelová et al, 2014). 
An early increase in apoptotic proteins was previously reported in a very similar model (Stěrba 
et al, 2011). Furthermore, emerging data in human subjects show early evidence of 
asymptomatic- and therefore subclinical- cardiac dysfunction within weeks to months of 
cessation of anthracycline chemotherapy, which in some cases may improve spontaneously 
(Cardinale et al, 2015). Of particular note however, anthracyclines are retained within 
cardiomyocytes more than in other cells (Johnson et al, 1986). Reports using in vitro models of 
Dox toxicity reveal a dose-response effect on cell-death and in cellular injury, e.g., in the 
cardiomyocyte-toxicity of anthracyclines in human induced pluripotential stem cells (Zhao and 
Zhang, 2017). Importantly, cardiomyocyte injury in response to Dox begins early under 
experimental conditions and may precede induction of cell-death. Even very low 
concentrations of Dox may have early effect on physiological pathways, e.g., cellular respiratory 
pathways (Darrabie et al, 2012), while in isolated adult rat cardiomyocyte models, degradation 
and proteolysis of intracellular structural proteins may begin as early as one hour, before cell-
death induction takes place (Lim et al, 2004). This suggests that anthracycline toxicity may be a 
dynamic process that begins early and is sustained in the cardiomyocyte, which is likely to be 
more vulnerable due to preferential accumulation of the compound. In this context, for our 
experimental aims ex vivo models, e.g., human atrial muscle models, were considered less 
appropriate, since anthracyclines show greater accumulation within the ventricle (Lencova-
Poppelova et al, 2014) and, further, the limited extracorporeal viability of tissues such as the 
human atrial muscle or rodent isolated Langendorff perfused heart limited the time-period for 
which the tissue may be exposed to anthracyclines. We therefore chose an in vitro cell model 
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to investigate the toxicity of anthracyclines. We used Dox as a representative anthracycline 
compound, with cell-death as a representative marker of cardiomyocyte injury. 
4.1.2. Adult rat ventricular myocytes. 
We used freshly isolated primary adult rat ventricular myocytes as the in vitro cellular model as 
they are the most appropriate model for these studies. This model offers a highly pure system, 
with low numbers of contaminating cells. The cells are non-dividing terminally differentiated 
cells like the adult human heart, and, further, it is a relatively inexpensive and efficient model 
that offered high throughput for reproducing experiments (Fearon et al, 2013). In contrast, 
neonatal rat ventricular myocytes are a mixed isolate containing fibroblasts, and continue to 
undergo some proliferation after isolation; cardiomyocytes derived from induced pluripotential 
stem cells (iPSCs-CM) have an immature phenotype; and cardiomyoblast tumour-derived cell 
lines are dedifferentiated and rapidly dividing cell models. We therefore reasoned that adult 
cardiomyocytes reproduced a mature cardiomyocyte at risk of doxorubicin-injury more 
accurately. Further, this cellular model offered a potential for continuum in developing future 
ex vivo and in vivo models in which this work may be further explored. 
4.1.3. Concentrations of doxorubicin investigated during characterisation experiments. 
Peak plasma concentration of Dox is typically in the range of 5 μM in humans (Minotti et al, 
2001), and falls to a steady-state concentration of 1 μM to 500 nM Dox over 48 hours. Some 
basal cell-death is observed in the in vitro ARVM model due to the isolation process. We 
therefore tested a range of Dox concentrations for their effect on cell-death in this model in 
order to identify the minimum toxic dose that manifested a significant rise in cell-death relative 
to basal cell-death. Specifically, we tested from 0.5 μM up to the peak 24 hour concentration 
observed in humans (5 μM). We also incubated cardiomyocytes with supraphysiological 
concentrations of Dox (7.5 μM, 10 μM, 15 μM and 20 μM) in order to maximize the possible 
effect on survival within a relatively short culture period.  
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4.1.4. Overall cell-death as an index of doxorubicin toxicity. 
Dox has been described variously as capable of inflicting necrotic as well as apoptotic 
cardiomyocyte-death (Zhang et al, 2009). The individual contributions of necrosis and apoptosis 
to doxorubicin-induced cardiomyocyte death is unclear, and both types of cell-death have been 
reported in adult rat ventricular myocytes (Delpy et al, 1999; Lim et al, 2004). Furthermore, in 
cultured endothelial cells, a transition from apoptosis to necrosis has been reported as Dox 
concentration increases above 5 µM (Kotamraju et al, 2000). Certain apoptotic assays, e.g., 
TUNEL staining may overestimate proportion of cardiomyocytes undergoing apoptotic death 
(Tokarska-Schlattner et al, 2006). Therefore, we assessed the overall cardiomyocyte-death 
using two different modalities. We assessed irreversible permeabilization of cell membrane by 
using propidium iodide (PI) staining. We further used morphological changes including cell-
membrane blebbing as a marker of cell-death (Goto et al, 2009). 
 
4.1.5. Characterisation of a model of doxorubicin-induced toxicity. 
Initial experiments were designed to establish a model of injury where the toxicity of Dox on 
isolated adult rat ventricular myocytes could be reproduced. This is discussed in detail in 
subsequent sections. 
4.1.5.1. Toxicity of doxorubicin on cardiomyocytes after 4 hours of treatment. 
We first investigated the effect of increasing concentrations of Dox on cardiomyocyte death 
after a treatment period of eight hours, as described section 3.2.2. and Fig. 3.2.  
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Fig. 4.1. Toxicity of doxorubicin over 4 h. No significant differences were identified with any 
concentration of doxorubicin (indicated in Arabic numerals) compared to the basal cell-death 
(Cont). Mean cell-death remained below in each treatment remained below 20% (n=2 for Dox 
0.5, Dox 7.5, Dox 15 and Dox 20. n=4 for all other treatments, p>0.05) (representative 
photograph of cell-death in top panel, see also Appendix B, Fig. I). 
 
Fig. 4.1 shows the results of these experiments. The basal level of cell-death remained below 
the exclusion criterion of 20% (Cont, mean cell-death 15.0 + 2.9 %). No significant differences 
were identified between Cont and any of the concentrations of Dox to which cardiomyocytes 
were exposed (ANOVA p>0.05). 
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4.1.5.2. Toxicity of doxorubicin on cardiomyocytes in the presence of an additional insult of 
ischaemia-reperfusion injury. 
 
Ischaemia-reperfusion injury (IR) has been postulated to share some common mechanisms of 
toxicity with anthracycline-mediated cardiomyocyte injury, as explained in introduction. This 
includes injury secondary to generation of ROS-species, alterations of the Ca2+ signalling 
pathways and Ca2+ sensitive channels, alterations of the mitochondrial respiratory pathways, 
and activation of cell-death mechanisms regulated at the level of the mitochondrial inner and 
outer membranes. Since the toxicity of anthracyclines on cardiomyocytes are slow, inflicting IR-
injury on cardiomyocytes stressed by concomitant non-toxic concentration of Dox may uncover 
latent or subthreshold injury due to anthracyclines. Since we did not observe any significant 
differences in doxorubicin-induced cell-death after 4 hours, we investigated if Dox might cause 
a subthreshold injury that would be revealed after a “second hit”, i.e., additional injury in tne 
form of IR.  
4.1.5.2.1. Ischaemia-reperfusion injury model. 
We first evaluated and characterised an in vitro model of cell-death due to IR with two different 
hypoxia times of 3 hours (SI3) and 4 hours (SI4), comparing the cell-death to basal-levels 
observed in cardiomyoytes incubated in m199 alone (Cont). Fig.4.2 shows the results of these 
experiments. Only a protocol with 4 hours hypoxia (SI4) and 1 hour reoxygenation resulted in a 
statistically significant injury (mean cell-death 36.3 + 4.1%) compared to basal cell-death (Cont, 
19.5 + 1.2%; p<0.05 Cont vs SI4, n=5) (Fig. 4.2). The data we obtained in these characterisation 
experiments are consistent with results described by our lab using the same model previously 
(Smith et al, 2010). We therefore considered these results robust and reproducible, and 
adopted this protocol of 4 hours hypoxia and 1 hour reperfusion (SI4 protocol) to inflict IR-
injury in subsequent experiments. 
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Fig. 4.2. Cell-death with increasing time of hypoxia with a maintained period of reoxygenation in 
ischaemia-reperfusion. With reoxygenation period maintained at 1 hour, SI4 (4 hours hypoxia) 
but not SI3 (3 hours hypoxia) showed a statistically significant increased cell-death compared 
to Cont (p<0.05, n=5) (Abbreviations: SI= simulated ischaemia) (representative photograph of cell-
death in top panel). 
 
4.1.5.2.2. Effect of addition of ischaemia-reperfusion injury on cell-death subjected to 
doxorubicin treatment for 4 hours. 
Having identified 4 hours hypoxia as an optimum insult for significant injury, we next 
investigated the effect of inflicting this additional insult on cardiomyocytes subjected to Dox 
treatment (Fig. 3.4). We therefore subjected cells to IR after pre-treating them with 2 µM Dox 
for 4 hours, as described in section 3.2.3 (Fig. 3.4). The pre-treatment period was incorporated 
 
Angshuman Maulik   Page | 89 
 
to allow for accumulation of the drug or its potential metabolites within the cardiomyocytes, 
and alterations to metabolic or cell-survival pathways, if any, to be initiated (Olson et al, 1988; 
Charlier et al, 2005). Further, this protocol mimicked the situation where the myocardium that 
has been stressed by anthracyclines may subsequently be subjected to an additional insult such 
as ischaemia and reperfusion that occurs as the result of myocardial infarction. We used a 
concentration of 2 µM Dox since this is close to half peak plasma levels, and may therefore 
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Fig. 4.3. Effect of ischaemia-reperfusion injury on cardiomyocytes after 4 h doxorubicin 
treatment. Compared to ischaemia-reperfusion in untreated cells (Cont IR), 2µM doxorubicin 
pre-treatment resulted in no significant difference in cell-death (Dox IR).  The presence of the 
positive control insulin (Ins) rescued untreated cardiomyocytes from IR-injury, and no 
significant differences were noted between basal cell-death (Cont) and Ins (ANOVA p<0.05, 
n=3) (representative photograph of cell-death in top panel, see also Appendix B, Fig. III). 
 
Fig. 4.3 shows the results of these experiments. Analysis of cell-death revealed that IR alone 
(Cont IR, mean cell-death 38.9 + 2.8%) and IR after Dox pre-treatment (Dox-IR, 30.9 + 3.1%) 
resulted in no significant differences. Both treatments resulted in significantly greater toxicity 
compared to basal cell-death (Cont, 9.4 + 1.0%) (Fig 4.3). For comparison, untreated controls 
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reoxygenated with the positive control insulin after hypoxia were protected (Ins, mean cell-
death 18.2 + 4.7%), and no significant differences were identified compared to control. 2 µM 
Dox alone (Dox N, 16.0 +1.6%) did not exhibit any significant toxicity. The results presented are 
a mean of three different repeat experiments (n=3). We concluded with reasonable confidence 
therefore that Dox at the concentration(s) and incubation periods we explored, did not inflict 
any significant overt or subthreshold injury.   
4.1.5.3. Toxicity of doxorubicin over 18 hours. 
Our experiments suggested that 4 hours may not be an appropriate time in which any potential 
pathways for cardiomyocyte toxicity could manifest in this model.  Therefore, we explored if 
prolonging the time of exposure to Dox to 18 hours would result in any increase in 
cardiomyocyte death. This incubation period was chosen partly due to methodological 
limitations. Beyond this, primary adult rat ventricular myocytes begin to reach the limits of 
viability in vitro and display dedifferentiation, and therefore may yield inappropriate and 
inconsistent conclusions if significantly prolonged (Louch et al, 2011).  Since cell-death was 
minimal at the lowest concentration, we excluded 0.5 μM Dox in subsequent experiments 
(section 3.2.2, Fig. 3.2).   
Fig. 4.4 shows the results of these experiments. A significant rise in cell-death was identified 
after incubation with 7.5 μM Dox (Dox 7.5, mean cell-death 37.0 + 4.9%), 10μM Dox (Dox 10, 
43.1 + 4.7%), 15 μM Dox (Dox 15, 56.7 + 7.3%) and 20 μM Dox (Dox 20, 49.7 + 4.1%). Compared 
to basal cell- death (Cont, mean cell-death 15.6 + 1.2%), 1 μM Dox (Dox 1, 14.6 + 2.8%), 2 μM 
Dox (Dox 2, 16.2 + 1.8%) and 5 μM Dox (Dox 5, 30.9 + 2.9%) showed no significant difference 
in cell-death following incubation for 18 hours (ANOVA p<0.05, n=7) (Fig. 4.4)). 
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Fig. 4.4. Mean cell-death after 18 h incubation with various concentrations of doxorubicin. A 
trend in increase in cell-death was noted with doses excess of 5 µm doxorubicin (Dox 5), but 
only reached statistical significance with 7.5 μM (Dox 7.5) and higher concentrations. 1 μM 
doxorubicin (Dox 1) and 2 μM doxorubicin (Dox 2) exposure showed no difference compared 
to basal cell-death (Cont) (ANOVA p<0.05, n=7) (representative photograph of cell-death in top 
panel, also see Appendix B, Fig. II). 
 
We considered the possibility that the lack of difference in cell-death with 1-5 µM Dox may be 
explained by wash-off of detached, dead cells during introduction of PI and consequent 
agitation of cell culture wells. To assess this, we counted the total number of cells in each 
treatment group (i.e., both live and non-viable cells), normalized to the number of cells in the 
control group (Cont) (Fig 4.9). This revealed no significant differences or variations in the final  
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Fig. 4.5. Variations in total cell-count with increasing doxorubicin at the end of 18 h, normalised 
to control. Total cumulative counts of live and non-viable cells were calculated for each 
treatment group and expressed as ratio to control (Cont). No significant differences were 
identified on statistical analyses of the variations (ANOVA p>0.05, n=7). 
 
cell-count relative to control (ANOVA p > 0.05, n=7) (Fig. 4.5), suggesting that differential wash-
off did not contribute to the different survival observed. 
4.1.5.4. Effect of ischaemia-reperfusion on cardiomyocytes after 18 hours doxorubicin pre-
treatment. 
Since we did not observe any evidence of toxicity below 5 μM (peak physiological plasma 
concentration), we re-explored the hypothesis that a latent subthreshold injury may exist with 
lower concentrations of doxorubicin. For reasons described above, we pre-treated isolated 
cardiomyocytes with 2 µM Dox for 18 hours, before subjecting these cells to IR- injury using the 
protocol described in section 3.2.3.2 (Fig. 3.2) 
 Fig. 4.6 shows the results of these experiments. IR alone (Cont IR, mean cell-death 48.5 + 
1.9%), and after Dox pre-treatment (Dox IR, 48.1 + 1.8%) both resulted in comparable cell-
deaths, significantly higher than basal cell-death (Cont, 16.3 + 1.6%) (Fig. 4.6). In the positive 
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control experiment, insulin protected untreated cardiomyocytes from IR-injury (Ins, 20.6 + 
0.9%), with no significant differences observed compared to Cont. Dox alone was not toxic to 
cardiomyocytes (Dox N, 12.9 + 1.7%) (ANOVA p<0.05, n=3). 
 
Fig. 4.6. Effect of IR after 18h pre-treatment with doxorubicin. Cell-death after IR showed no 
difference between untreated cardiomyocytes (Cont IR) and after 2µM doxorubicin pre-
treatment (Dox IR). In the positive control experiment, 275u/ml insulin (Ins) protected 
untreated cells from IR-injury, and no differences were identified compared to basal basal cell-
death (Cont) (ANOVA p<0.05, n=3) (representative photograph of cell-death in top panel, see 
also Appendix B, Fig. IV).  
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4.1.6. Final protocol of model of doxorubicin-induced cardiomyocyte toxicity. 
Our experiments described above showed that in this in vitro ARVM model, Dox inflicted a 
significant injury only when cardiomyocytes were incubated with a minimum of 7.5 μM 
concentration, over a period of 18 hours. Additional insults in the form of IR-injury failed to 
uncover any latent toxicity in cells pre-treated for both 4 hours and over 18 hours with a lower 
concentration of 2 µM doxorubicin. Based on these data, unless otherwise indicated in the 
experiments, we used the toxicity of a concentration of 7.5 μM Dox on cardiomyocytes 
incubated over a period of 18 hours as the standardised model of doxorubicin-cardiotoxicity. 
 
4.2. Characterisation and development of protocol for hypoxic preconditioning. 
In subsequent chapters, we explore the potential protective effect of in vitro preconditioning 
against Dox-induced cardiomyocyte death. For these experiments, we characterised and 
standardised an in vitro protocol for hypoxic preconditioning (HP) that could protect 
cardiomyocytes against IR-injury. We therefore characterised the protocols by evaluating their 
capacity to protect against IR-injury in the SI4 model we had developed earlier (Fig 4.3). We 
evaluated two different protocols of in vitro HP, as described below. 
4.2.1. Choice of hypoxic preconditioning stimulus. 
A number of different methods have been described for preconditioning isolated 
cardiomyocytes in vitro. This includes, for example, use of pharmacological agents e.g. 
Adenosine receptor agonists (Liu et al, 1991), α1-adrenergic receptor agonists (Bannerjee et al, 
1993), Bradykinin B2 receptor agonists (Brew et al, 1995) etc. Previous reports from in vitro 
models of IR-injury, e.g. human atrial trabecular models, suggest ischaemic/hypoxic 
preconditioning confers a stronger protection and greater recovery from reperfusion injury 
compared to preconditioning by pharmacological agents alone (Cleveland et al, 1997). This may 
be a consequence of the activation of multiple redundant pathways that HP initiates, compared 
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to initiation of unitary cascades by activation of receptor-linked signalling. Similarly, work in in 
vivo and ex vivo models show ischaemic preconditioning offers greater protection against 
reperfusion injury compared to known preconditioning stimuli such as hypothermia (van den 
Doel et al, 1998) or LPS (Rowland et al, 1997). Ischaemic/hypoxic preconditioning has therefore 
been considered one of the most powerful cardioprotective factors (Illiodromitis et al, 2007), 
and was considered the preferable preconditioning stimulus for our experimental purposes. 
A number of different preconditioning protocols have been described, which confer protection 
by simulating the metabolic conditions and/or the physiological insult of ischaemia/hypoxia. 
These protocols differ in the species of cardiomyocytes used, mode of delivering hypoxia, 
hypoxic protocol-length etc (Wu, 1999; Marber 2000; Diaz and Wilson, 2006). For example 
Armstrong and Ganote (1994) compacted freshly isolated adult rabbit cardiomyocytes by 
centrifugation and subjected these to substrate deprivation and hypoxia by discarding excess 
supernatant and introducing an oil-layer as barrier to gaseous exchange. Similarly, Rakhit et al 
(2001) subjected neonatal rat ventricular myocytes to 90 minutes hypoxia (95% argon-5% CO2 
atmosphere with <1% O2) in a buffer with high lactate, low pH and high potassium (K+) to 
precondition these cells before replacing this “hypoxic buffer” with normal cell-culture medium. 
In our own lab, Hausenloy et al (2010) bathed isolated murine cardiomyocytes in a low pH buffer 
(pH 6.2) with high lactate and high K+, and subjected these cells to 10 minutes hypoxia in an 
airtight chamber before replacing the buffer with normal cell-culture medium. These 
differences in protocols and modalities highlighted the need to construct a HP-protocol specific 
to the cell-model that we were using, i.e. isolated adult rat ventricular cardiomyocyte model.  
We therefore chose a model for HP where cardiomyocytes were incubated in a hypoxic 
environment, using a buffer with low pO2 (<10.0 kPa), no glucose, high lactate, high K+ and low 
pH to simulate the hypoxic environment as a preconditioning stimulus. This was followed by 
incubation in a normoxic buffer with normal glucose and normal pH to simulate reperfusion. 
 
Angshuman Maulik   Page | 97 
 
This model of hypoxic preconditioning has been used in this lab as an HP-stimulus against IR-
injury (Hausenloy et al, 2010). 
4.2.2. Protocols 1 and 2 for hypoxic preconditioning. 
The two protocols for HP that we evaluated differed in the time-period that cardiomyocytes 
were subjected to hypoxia during the preconditioning phase (Fig. 4.7). To simulate hypoxia, the 
cardiomyocytes subjected to preconditioning (samples designated HP Protocol 1 and HP 
Protocol 2, Fig. 4.7) were incubated in hypoxic buffer, placed in an airtight hypoxic chamber, 




Fig. 4.7. Experimental layout for Protocol 1 and Protocol 2 for hypoxic preconditioning. 
Cardiomyocytes were subjected to hypoxia for 15 minutes in hypoxic buffer in a sealed hypoxic 
environment in Protocol 1 (Protocol 1), followed by transfer to a normoxic buffer in normal 
atmosphere for 10 minutes. Cardiomyocytes in Protocol 2 (Protocol 2) were subjected to 
hypoxia incubated in hypoxic buffer for 30 minutes, followed by transfer to normoxic buffer in 
a normal atmosphere for 10 minutes. Controls were incubated in normoxic buffer for 25 
minutes (Protocol 1) or 40 minutes (Protocol 2). Cells were transferred to medium 199 after 
both protocols, and left undisturbed for 18 hours before further experiments. 
In the first protocol we tested (Protocol 1), the cardiomyocytes were incubated in this 
simulated hypoxic environment for a total of 15 minutes, then transferred to normoxic buffer 
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and incubated in normoxic atmosphere at 37 °C for 10 minutes to simulate the reperfusion 
phase. In the second protocol (Protocol 2), the cardiomyocytes were subjected to simulated 
hypoxia for 30 minutes, before transferring to normoxic buffer in normal atmosphere at 37 °C 
for 10 minutes as for Protocol 1. For each protocol, controls (designated Cont) were incubated 
in normoxic buffer, in normoxic atmosphere, for the respective matched time, i.e., 25 minutes 
for Protocol 1 and 40 minutes for Protocol 2. Preconditioned cells and controls were transferred 
to medium 199 and incubated for 18 hours (Fig. 4.7).   
4.2.3. Evaluation of hypoxic preconditioning protocols in protecting cardiomyocytes against 
ischaemia-reperfusion-injury. 
 
As shown in Fig.4.8, 18 hours after preconditioning, cardiomyocytes death due to IR was 
evaluated using the SI4 model previously developed. Preconditioned cells were subjected to  
Fig. 4.8. Schematic diagram depicting evaluation of the protective potential of hypoxic 
preconditioning protocols 1 and 2. Cells were preconditioned (HP) using Protocol 1 or Protocol 
2. Control cardiomyocytes (Cont) were treated with normoxic buffer in a normoxic environment 
for matched times. 18 hours after preconditioning, both HP and Cont were subjected to 4 hours 
hypoxia (SI) followed by 1 hour reperfusion (SR). As positive control, insulin was introduced at 
reoxygenation (Ins) in a subgroup of control non-preconditioned cells (Abbreviations: HP=Hypoxic-
preconditioned, Cont=Control, Prot 1= Protocol 1, Prot 2= Protocol 2, SI=Simulated ischaemia, SR=Simulated 
reperfusion). 
IR-injury (HP-IR) or incubated for 5 hours in normoxic buffer in normal atmosphere (HP-N).  
Non-preconditioned controls were subjected similarly to IR-injury (Cont-IR), or incubated in 
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normoxic buffer in normal atmosphere for 5 hours (Cont). As a positive control against 
reperfusion injury, a further subgroup from non-preconditioned control (Ins) was subjected to 
4 hours hypoxia, but reoxygenation was carried out in normoxic buffer with dissolved insulin 
(Fig. 4.8). 
4.2.3.1. Protocol 1 does not protect cardiomyocytes from ischaemia-reperfusion injury. 
 
Fig. 4.9. Protocol 1 fails to protect cardiomyocytes from ischaemia-reperfusion injury. Cell-
death after ischaemia-reperfusion (IR) was similar in cells subjected to both Protocol 1 (HP-IR) 
and control protocol (Cont-IR), and significantly higher that basal cell-death (Cont). By 
contrast, the positive control insulin (Ins) protected non-preconditioned cardiomyocytes from 
IR (Multiple t-Test p<0.05 Cont vs Cont-IR and Cont vs HP-IR, n=2) (representative photograph 
of cell-death in top panel, see also Appendix B, Fig.V). 
Fig.4.9 shows the results of these experiments. Subjecting cardiomyocytes to IR-injury after 
protocol 1 showed a significantly higher cell-death in both preconditioned cells (HP-IR, mean 
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cell-death 53.3 + 1%) and non-preconditioned controls (Cont-IR, 53.3 + 1.4%) compared to 
normoxic control (Cont, 17.2 + 1%) (Fig. 4.9).  No significant differences existed between the 
Cont-IR and HP-IR groups. By comparison, presence of insulin protected non-preconditioned 
control cardiomyocytes from IR-injury (Ins, mean cell-death 31.1 + 0.5%.). Preconditioned 
cardiomyocytes incubated in normal atmosphere did not show any significant differences 
compared to control (HP-N, mean cell-death 18.2 + 1.5%). The cell-death observed for both 
Cont-IR and HP-IR differed significantly from basal cell-death and insulin control upon multiple 
t-tests (p<0.05, n=2).  
The results described are observation of two repeat experiments (n=2). Although this is a small 
sample size, the data showed very close consistency between the experiments and, moreover, 
we observed a very high consistency in cell-death observed with the positive control insulin, 
allowing us a measure of confidence to conclude that Protocol 1 did not hold an appropriate 
protective potential, at least in a window 18 hour after preconditioning. We therefore 
proceeded to evaluate protection offered by Protocol 2. 
4.2.3.2. Protocol 2 protects cardiomyocytes from ischaemia-reperfusion injury. 
When Protocol 2 was used as a preconditioning stimulus (Fig. 4.10), IR-insult after 18 hours 
resulted in a significant rise in cell-death in control cardiomyocytes only (Cont-IR, mean cell-
death 41.2 +6%) but not preconditioned cells (HP-IR, 20.2 + 5%, p<0.05 Cont-IR vs HP-IR). HP-
IR showed no significant differences compared to basal cell-death (Cont, mean cell-death 18.1 
+ 3.1%), or to cell-death observed in non-preconditioned cells subjected to the positive control 
agent insulin during reoxyegnation (Ins, mean cell-death 31.1 + 0.5%, p<0.05 Cont-IR vs Ins).  
HP alone did not inflict any significant injury (HP-N, mean cell-death 10.5 + 1.7%). The results 
are the mean of three repeat experiment (n=3) (ANOVA p<0.05, n=3) (Fig. 4.10). This  
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Fig. 4.10. Protocol 2 protects cardiomyocytes from ischaemia-reperfusion injury 18 h after 
preconditioning. Ischaemia-reperfusion (IR)-injury 18 hours after preconditioning (HP) induced 
a significant injury in non-preconditioned cardiomyocytes (Cont-IR), but not in cardiomyocytes 
subjected to Protocol 2 (HP-IR). No differences were identified between basal cell-death (Cont), 
HP-IR and the levels of cell-death observed in non-preconditioned cells when the protective 
agent insulin was introduced at reoxygenation (Ins) (ANOVA p<0.05, n=3) (representative 
photograph of cell-death in top panel. See also Appendix B, Fig. VI).  
 
experiment confirmed that Protocol 2 was an appropriate stimulus for hypoxic preconditioning 
that could confer protection against IR-injury in a window 18 hour after HP. 
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4.2.3.3. Protocol 2 also confers protection against ischaemia-reperfusion within a shorter 
window after preconditioning. 
Ischaemic preconditioning confers a biphasic protection against IR-injury with an initial 
protective effect that is initiated immediately, and lasts between 8 hours to 12 hours. This is 
followed by a second peak in protective effect that is noted 18 to 24 hours, and may last for up 
to 48 to 72 hours (Kis et al, 2003). The above experiments were carried out during the window 
typically associated with this latter second window. In the next experiment, therefore, we 
wanted to confirm whether Protocol 2 could protect against IR-injury within the first window. 
Therefore, 4 hours after preconditioning with Protocol 2, cell-death following IR-injury was 
evaluated using the SI4 model. Preconditioned cells were subjected to IR (HP-IR), or incubated 
in normoxic buffer in normal atmosphere (HP-N) for 5 hours. Non-preconditioned controls 
 
Fig.4.11. Schematic diagram of experimental setup for validation of Protocol 2 in the “classical” 
window of preconditioning. Cardiomyocytes preconditioned with Protocol 2 were subjected to 
IR-injury 4 hours after hypoxic preconditioning (HP) to confirm that classical HP-mediated 
protection is preserved. 
 
were subjected to IR (Cont-IR), or incubated in normoxic buffer in normal atmosphere for 5 
hours (Cont) to evaluate basal cell-death. We used insulin as positive control in these 
experiment as described in the preceding experiment. Therefore, a subgroup from control (Ins) 
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was subjected to 4 hours hypoxia of the SI4 protocol, but reoxygenation was carried out in 
normoxic buffer containing dissolved insulin (Fig. 4.11). 
 
Fig. 4.12. Protocol 2 protects cardiomyocytes against ischaemia-reperfusion injury in the acute 
window.  4 hours after preconditioning (HP), ischaemia-reperfusion (IR) inflicted a significant 
injury in non-preconditioned control cells (Cont-IR) only. Cells subjected to Protocol 2 were 
protected from ischaemia-reperfusion injury (HP-IR), with no differences identified between 
basal cell-death (Cont), HP-IR and non-preconditioned controls protected by insulin (Ins) 
(ANOVA p<0.05, n=4) (representative photograph of cell-death in top panel. Also see Appendix 
B Fig.VI). 
Fig. 4.12 shows the results of these experiments. Only non-preconditioned control group 
displayed evidence of significant rise in cell-death with IR (Cont-IR, mean cell-death 37.5 + 7%). 
Preconditioned cardiomyocytes were however protected (HP-IR, mean cell-death 20.5 + 4.4%), 
and showed no evidence of significant injury (p<0.05 Cont-IR vs HP-IR, n=4) (Fig. 4.12). No 
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significant differences were identified between HP-IR and basal cardiomyocyte death (Cont, 
mean cell-death 11.4 + 2%, n=4). Insulin protected non-preconditioned controls from IR-injury, 
and no differences were identified between HP-IR, Cont and Ins (Ins, n=3, mean cell-death 18.2 
+ 4.8%, p<0.05 Cont-IR vs Ins) (ANOVA p<0.05) (Fig. 4.12). 
4.2.4. Final protocol for Hypoxic preconditioning.  
Based on the above experiments we adopted Protocol 2 as the stimulus for HP.  Therefore, 
where cardiomyocytes were preconditioned in subsequent experiments, we subjected the cells 
to 30 minutes hypoxia, followed by 10 minutes reoxygenation. 
4.3 Characterisation of Western blot protocol. 
In the subsequent chapter (section 5.2) we describe the results of inhibition of PI3K/Akt and 
MAPK ERK 1/2 on the effect of hypoxic preconditioning on Dox-induced cell-death. We 
consolidated these data by exploring the phosphorylation state of Akt (p-Akt) and of ERK 1/2 
(p-ERK) as described in section 5.2.3. However, achieving optimum Western blotting conditions 
from the in vitro cell culture experiments were difficult, necessitating a characterisation 
approach before we obtained any clear signal indicating protein content. In our initial Western 
blots, cell-cultures were established in 32 mm culture dishes. We explored the content of p-Akt 
in these preliminary experiments. Cells were subjected to HP, and 7.5 µM Dox introduced after 
reoxygenation. Cells were lysed 5 minutes after completion of reoxygenation and introduction 
of Dox (15 minutes after completing the hypoxia phase of preconditioning) (Dox HP, Fig.4.13). 
As untreated controls, cells were transferred into medium 199 after HP (Cont HP) before lysis. 
PI3K/Akt was inhibited by preincubating cells for 1 hour in 10 µM LY294002. Cells were then 
subjected to hypoxia in inhibitor-free hypoxic buffer for 30 minutes, followed by reoxygenation 
in the presence of 10 µM LY294002 in normoxic buffer. 
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Fig. 4.13. Experimental setup for Western blot analysis sample collection. Cardiomyocytes were 
incubated in medium 199 alone, or with the kinase inhibitors 10 µM LY294002 to pre-inhibit 
PI3K/Akt. These were then subjected hypoxic preconditioning by incubating in inhibitor-free 
hypoxic buffer, before transferring to normoxic buffer with or without LY294002. Cells were 
subjected to 7.5µM Dox treatment alone or with the LY294002 at the end of reoxygenation 
phase of preconditioning. Control cardiomyocytes were incubated in medium 199 alone or with 
LY294002 after HP and lysed 5 minutes after starting Dox treatment.  
 
After reoxygenation, inhibitor was maintained along with Dox (Dox (LY)), or medium 199 (Cont 
(LY), Fig.4.13). Akt phosphorylation in non-preconditioned cells, in the presence of Dox and 
under basal conditions, were probed by incubating cardiomyocytes in normoxic buffer alone 
for 40 minutes, then transferring to 7.5 µM Dox (Dox), or medium 199 (Cont). Protein levels 
were probed using standard Western blot conditions, and Glyceraldehyde 3-phosphate 
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Fig. 4.14.  Result of protein-collection from 32mm cell-culture dish. Example western blot is 
shown exploring induction of p-Akt and GAPDH after sample lysis in 32mm cell-culture dishes 
5 minutes following Dox treatment. No individual signal for either the p-Akt, nor the 
housekeeping gene GAPDH could be identified. 
 
Fig. 4.14 shows an example blot from this experimental set-up. We failed to identify any 
discernible signals for either p-Akt, or of GAPDH housekeeping protein, in these experiments. 
Indicating the sample collected during cell lysis contained no significant protein content of 
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Fig. 4.15. Different cell-culture volumes explored to obtain suitable protein yield during Western 
blot characterisation. Following yield of very low concentration of proteins from 32-mm dishes 
(Panel A), experiments were set-up in 64 mm-dish (Panel B) and subsequently 100mm cell-
culture dish (Panel C). In each experimental set-up, cells were lysed 15 minutes after end of 
hypoxia, corresponding to a time point 5 minutes after completion of simulated reperfusion 
and 5 minutes after the time point Dox is added as an insult. 
 
Since these initial western blot experiments were setup using 32 mm cell-culture dishes (Fig. 
4.15 A), we hypothesised that the lack of any significant signals for proteins may be due to low 
protein-content and yield obtained from the cultures established in a small volume cell-culture 
dish. We therefore established the ARVM primary cultures for the respective treatments in 
larger diameter dishes of 64 mm and 100 mm to obtain greater volume, and therefore higher 
protein content (Fig. 4.15 B and 4.15 C) and re-explored the content p-Akt and GAPDH.  
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Fig. 4.16. Western blot highlighting differences in protein content between different volumes of 
cell-culture dishes.  A. Western blots exploring the content of p-Akt and GAPDH after collecting 
lysate from cells incubated in 64 mm cell-culture plates. A faint signal for GAPDH is observed 
but no clear signal for p-Akt is noted. B. Western blot exploring the content of p-Akt and GAPDH 
in lysates from cell-culture established in 100 mm cell-culture dishes. A prominent signal for 
GAPDH was noted. No clear signal for p-Akt could be identified. 
 
Fig. 4.16 shows the result of this Western blot. Lysing cells in 64mm culture dish showed a faint 
signal for the housekeeping gene GAPDH, but no signal was observed for p-Akt. However, lysing 
the cells following incubation in 100mm cell culture dishes yielded a robust signal for the 
housekeeping gene GAPDH. Despite this prominent signal for the loading control, however, we 
failed to observe any significant signal for the p-Akt protein. These experiments did, however, 
indicate that the ideal volume for obtaining an appropriate protein yield to detect by Western 
blot required a 100 mm cell-culture plate. 
In subsequent Western blots, therefore, all treatment groups were established in 100 mm 
culture dishes. However, in light of persisting absence of any signal for p-Akt in response to HP, 
we hypothesised that the phosphorylation response may occur early after preconditioning, 
much earlier than the time point at which we were lysing the cell-culture for protein collection. 
We therefore conducted a time course experiment, where cells were subjected to hypoxic 
phase of HP, followed by cell-lysis through specific time-intervals of 60 seconds through the  
 




Fig.4.17. Harvestation of protein samples through different time-points to analyse Akt content. 
Cells were lysed immediately after completing hypoxia, and subsequently at 60 second intervals 
up to 300 seconds. Protein lysates were probed with Western blot for housekeeping genes 
GAPDH and t-Akt and p-Akt. 
 
reoxygenation phase, upto 5 minutes. These samples were then probed to assess the p-Akt 
content at each time-point (Fig. 4.17). The total Akt protein (t-Akt) content was also explored 
in these samples, and the ratio of total and phosphorylated Akt respectively were normalised 
to GAPDH content in each sample, i.e., t-Akt:GAPDH and p-Akt:GAPDH ratio evaluated. 
Phosphorylation response of Akt at each time point was then evaluated as the ratio p-
Akt:GAPDH ratio to t-Akt:GAPDH. 
Fig. 4.18 shows the result of this experiment. The ratio of phosphorylated protein normalised 
to GAPDH rose to approximately 1.8 times that of total Akt, peaking at 120 seconds before 
declining towards baseline at 300 seconds. This experiment showed that the peak in p-Akt 
content after HP occurred before the conclusion of reoxygenation phase (10 minutes 
reoxygenation) of our experimental protocol of hypoxic preconditioning, and therefore before 
Dox had been introduced to preconditioned cells. Therefore as final protocol, in further 
Western blots where the phosphorylation induction of Akt and MAPK ERK 1/2 in response to 
HP were explored, cell lysis was carried out at 2 minutes (120 seconds) after completing hypoxic 
phase, as shown in Fig. 3.13. In subsequent experiments, we used insulin as a positive control,  
 




Fig.4.18. Western blot analysis of phosphorylation induction of Akt over time following hypoxia 
phase of preconditioning. Total Akt protein content (normalised to GAPDH, panel A) and 
phosphorylated protein content (normalised to GAPDH, panel B) both showed an increase 
noted to be peak at 120 seconds after end of hypoxia, before declining in the following 180 
seconds.  
 
since it is a known inducer of the reperfusion injury salvage kinase (RISK) pathway. Cells were 
incubated with insulin (275u/ml) for ten minutes before they were lysed and prepared for gel-
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4.4. Discussion. 
4.4.1. Characterisation of doxorubicin toxicity on cardiomyocytes. 
In developing an in vitro model of Dox-induced cell-death, we observed a dose-dependent and 
time-dependent rise in the cytotoxic potential of doxorubicin, which is consistent with the 
results reported by other groups in various different in vitro cardiomyocyte models including 
adult rat ventricular myocytes (Lim et al, 2004), Neonatal rat ventricular myocytes (e.g., 
Ichikawa et al, 2014) as well as human induced pluripotential stem cells (Maillet et al, 2016). 
We observed no significant toxicity in cardiomyocytes subjected to any of the Dox 
concentrations we tested up to 4 hours (Fig. 4.1). It ought to be mentioned that the sample size 
from which we drew this conclusion varied from 2 to 4, and therefore statistical power was low 
for the higher concentrations of Dox. Therefore, in subsequent experiment we re-explored cell-
death with similar concentrations of doxorubicin, but after prolonging the exposure time to 18 
hours.  
In this second group of experiments, we observed statistical significance in cell-death at and 
above 7.5 μM doxorubicin. The data shown here represent a sample size of seven repeat 
experiments (n=7), which may be considered an adequately large sample size for an in vitro 
experiment to draw confident conclusions. Moreover, the results are consistent with toxicity 
observed in other in vitro systems which report similar dose-dependent rise in cardiomyocyte-
death. For example, Zhang and Zhao (2017) observed a rise in cell-death with increasing Dox 
concentrations in human induced pluripotential stem cells (iPSCs) after incubating these cells 
for 48 hours, with IC50 of 3.5 µM. In the same experiment, assessment of cardiac troponin as a 
marker of cell-injury showed some damage at low concentrations up to 1.2 µM but further 
significant injury above 2.5 µM doxorubicin. Similarly, Yan et al (2015) found a dose-dependent 
fall in cell viability and an increase in the apoptotic index of TUNEL-staining after incubating of 
H9C2 cardiomyoblasts with 1-20 µM doxorubicin. Criticisms have been made of in vitro and in 
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vivo models of anthracycline toxicity where very high concentrations of anthracyclines, many 
times higher than peak physiological values, have been used (Stěrba et al, 2011). For example 
Chatterjee et al (2008) reported significant rise in cell-death in an in vitro murine cardiomyocyte 
model with 26 µM to 36 µM doxorubicin. Similarly, Zhang et al (2012) induced cardiotoxicity in 
their in vivo murine model using a bolus dose of 25 mg/kg in an in vivo murine model. Therefore, 
it is important to highlight that the toxicity we see in this model manifests at a concentration 
close to and immediately above peak plasma concentrations of doxorubicin, which is typically 
around 5 µM. We were therefore satisfied that this model allowed close and adequate in vitro 
replication of the postulated toxic effects of anthracyclines on cardiomyocytes.  
4.4.2. Ischaemia-reperfusion injury in doxorubicin stressed cells.  
Our initial experiments failed to display significant rise in cell-death with concentrations of Dox 
lower than peak plasma values. This result was consistent after both 4 hours, and after 18 hours 
incubation. We considered the possibility that a latent injury process may exist with lower 
concentrations below 5 µM doxorubicin, which was not sufficient to manifest in excess cell-
death, and therefore used IR-injury as a “second hit”, or an additional insult, to test this 
hypothesis.  We used a concentration of 2 µM doxorubicin. This is a concentration immediately 
below half the peak-plasma concentration of Dox in humans. Since Dox accumulates in the 
cardiomyocyte, and since the toxicity is a long-term process, it has been argued that 
accumulation of Dox or its metabolites, e.g., the alcohol derivative doxorubicinol, may hold a 
pathological role in mediating the long-term toxicity of anthracyclines (Bertihaume et al, 2007). 
Moreover, long-term concentration of Dox in the plasma and in the myocardium will, logically, 
be below the peak plasma concentration. Furthermore, previous reports exploring doxorubicin-
toxicity have noted an injurious toxic effect with concentrations as low as 1 µM Dox (Gharanei 
et al, 2013b; Montaigne et al,2010). In our initial characterisation experiments, we observed 
no significant toxicity at similar concetrations of Dox alone over incubation periods of 4 hours 
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and of 18 hours. We therefore chose 2 µM Dox as a concentration below peak plasma 
concentration, but higher than that reported in literature, e.g., by Montaigne et al and Gharanei 
et al, in order to probe any latent sub-threshold injury. The pre-treatment period was 
incorporated to allow for accumulation of the drug or its potential metabolites within the 
cardiomyocytes, and alterations to metabolic or cell-survival pathways, if any, to be initiated 
(Olson et al, 1988; Charlier et al, 2005). Further, this protocol mimicked the situation where the 
myocardium that has been stressed by anthracyclines may subsequently be subjected to an 
additional insult such as ischaemia and reperfusion that occurs as the result of myocardial 
infarction, which may reflect the increased risk of anthracycline-induced heart-failure in 
patients with underlying ischaemic heat disease (Curigliano et al, 2016). However, we failed to 
observe any significant rise in IR-induced cardiomyocyte death when cells were pre-treated 
with doxorubicin. This observation was consistent after a pre-treatment period of 4 hours, and 
after a pre-treatment period of 18 hours. The results for each incubation period are collated 
data from three repeat experiments (n=3). This sample size is relatively small, and this may be 
considered a limitation of these experiment. However, in these same experiments, we were 
consistently able to reproduce robust and significant protection against IR-injury using the 
positive control insulin, allowing further confidence in the results of these experiments.  
The lack of any significant increase in IR-injury on Dox pre-treated cells may be interpreted in 
two different ways. One possibility is that in this in vitro model, Dox does not trigger cell-death 
pathways in common with IR-injury and, therefore, any subthreshold toxicity due to Dox is not 
revealed due to the added stress in the form of IR. However, an alternative hypothesis may also 
be considered.  The complex intracellular interactions initiated by Dox pre-treatment may 
compensate or alter potential pathways of cell-injury due to IR. For example, Dox increases 
autophagic flux in vivo (Zhang et al, 2011a), while autophagy may be beneficial against IR-injury 
(Yitzhaki et al, 2010). Similarly, doxorubicin-induced degradation of survival factors e.g. BCL-2 
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noted in in vitro models (An et al, 2009) may attenuate the inhibition of pathways deleterious 
in IR-injury, e.g., those initiated by Beclin 1 (Peng et al, 2013). This highlights that competing 
pathways may compensate and alter the sensitivity of cardiomyocytes to cell-death when both 
anthracycline and IR-injury is present. 
Our results and experimental set-up ought to be contrasted with the approach taken by other 
groups who have observed an exacerbation of IR-injury in the presence of Dox. Gharanei et al 
(2013b) for example, observed an increase in infarct size in the intact myocardium in an isolated 
and perfused rodent heart model when Dox was introduced during 120 minutes of reperfusion 
after a preceding of 35 minutes of ischaemia, compared to infarct sizes due to ischaemia and 
reperfusion alone. For comparison, in our protocol IR-injury was inflicted on isolated cells as an 
after-treatment, following a preceding period of doxorubicin-pretreatment. Wether this 
difference in protocol and timing of doxorubicin-insult with relation to reperfusion injury may 
be a factor in the differences in the results would require further analysis. Interesingly, pre-
existing coronary artery disease is recognised as a risk factor for development of heart failure 
after ANTC-chemotherapy (Pinder et al, 2007; Harbeck et al, 2011). However, Moser et al (2006) 
analysed the risk of cardiovascular disease in a Danish and Belgian population based registry of 
476 patients with aggressive Non-Hodgkins Lymphoma who received ANTC-based 
chemotherapy with or without radiotherapy between 1980 and 2000. They concluded the risk 
of coronary artery disease after ANTC-treatment in this group of patients was similar to the 
population risk of coronary artery disease over a followup period up to 20 years. The risk 
associated predominantly to ANTC-chemotherapy was, however, of chronic heart failure. It may 
therefore be hypothesised that the ischaemia-stressed myocardium is more vulnerable to Dox-
injury, although Dox (and indeed anthracyclines) may not increase the risk of ischaemic heart 
disease. Clarification of this hypothesis with further work, and alteration of treatment protocols 
may be explored in future works to explore similar hypotheses. 
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4.4.3. Limitations of in vitro model of doxorubicin toxicity used.  
Our model maybe criticised in light of the fact that we have used cell-death alone to assess 
injury. Further, the assessment of cell-death was made on the basis of nuclear staining with 
propidium iodide (PI), along with morphological changes previously described as associated 
with apoptosis in cardiomyocytes (Gotto et al, 2008). it ought to be noted that the 
permeabilization of the plasma membrane and the nucleolemma that is demonstrated by 
propidium iodide intercalation with nucleic acid and staining of the nuclei is a feature of 
necrosis or a very late feature of apoptosis (Cummings et al, 2004; Riccardi and Nicoletti, 2006), 
while structural and morphological changes are also late features of necrotic cell-death 
associated with ATP depletion and disruption of cytoskeleton (Cummings et al, 2004). Since PI 
intercalates with helical double-stranded (ds) nucleic acid, staining of dsRNA in the cytoplasmic 
compartment may, moreover, yield false-positive results. By the estimates of some authors this 
false positive may be as high as 40% false events reported in published ltierature (Rieger et al, 
2010). However, this artefactual result as a consequence of dsRNA staining is particularly a 
problem in proliferating cells and cells with a large nucleus-to-cytoplasmic ratio (characterised 
as nucleus:cytoplasm ratio <0.5)  and was a factor, in association with available technology ad 
expertise, in guiding us to adult rat ventricular myocytes in preference over neonatal rat 
ventricular myocytes in establishing our model.   
In establishing the model of toxicity, the contributions of apoptosis and of necrosis due to Dox 
were not delineated in detail in the model. As explained earlier in introduction (section 1.2.4), 
ANTC may induce necrotic as well as apoptotic cell-death. Apoptosis is typically described as 
caspase-dependent, or caspase-independent. Caspase-independent programmed cell-death 
may, further, be cathepsin-dependent, or cathepsin-independent but calpain-dependent 
(Nicoletopolou et al, 2013). Necrosis is typically deemed to be ATP-independent. Concomitant 
probing for Annexin V and PI may shed some light into the time course of apoptosis in the 
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model we developed and describe above. Early apoptotic cells are typically observed to be 
positive for Annexin V but not PI, while late apoptotic cells as well as primary necrotic cells are 
dually positive for both PI and Annexin V (Brauchle et al, 2014). Other approaches to 
characterising apoptosis (early or late) and necrosis may also have been adopted. For example, 
concomitant and time-course analysis of other markers of apoptosis, e.g., analysis of nuclear 
membrane integrity with 4′,6′-diamidino-2-phenylindole (DAPI) (Cummings et al, 2004), 
apoptosis measurement with Caspase-3 assay, or TUNEL staining (indicating Karyorrhexis), or 
investigation of karrhyyorrhexis with, e.g., bromodeoxuridine assays (Darzynkiewicz and Zhao, 
2011) may have allowed us to shed more light on the course, mechanism and contribution of 
apoptosis in this model. Similarly, correlation of PI staining with a second-dye, e.g., Evans-blue, 
or estimation of levels, e.g., Lactate dehydrogenase (LDH) release or estimation of high-
mobillity group box 1 protein (HMGB1) levels may have allowed further clarity and more 
sensitive quantification particularly of cumulative primary necrotic cell-death (Marshal et al, 
2014). This would have allowed consolidation of the observations recorded on cell-death, and 
shed some light on the predominant mode of cell-death and the relative induction of these 
pathways in the model described above. This is a limitation of our experiments, and ought to 
be addressed in future course of work. 
The lack of clarification of the mode(s), or co-existence of modes of any of the cell-death 
pathways in the model we describe above limits any further deductions or insights into the 
possible mechanisms of ANTC-toxicity in the model. Further of note, changes observed with 
low concentrations of Dox may occur without induction of cell-death mechanism, and include 
degradation of structural and functional proteins and alterations in metabolic pathways 
including cellular respiration which may occur independent of induction of cell-death pathways 
observed with higher concentrations. It is possible to, e.g., identify titin degradation products 
(T2) after incubating with Dox in this model for the above experiments.   
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However, the overall hypothesis of the work presented in this report was to explore the 
protective potential of preconditioning against doxorubicin-induced injury, and cell-death 
offered a sensitive marker for both the injury process and HP-mediated protection. We 
therefore considered detailed exploration of the metabolic effect of Dox to be beyond the 
scope of our work at this stage.  It ought to be noted however that Dox possesses intrinsic auto-
fluorescence characteristics, which is quenched by binding to DNA. When excited by incident 
light in visible range, a concentration dependent increase is noted in the intensity of emitted 
fluorescence peaking between 540 and 680nM (Gnapareddy et al, 2015), which may interfere 
with absorbance-based assays which utilise absorbances around this wavelength.   
4.4.4. In vitro hypoxic preconditioning protocol. 
HP is well characterised as a protective modality against IR-injury (Hausenloy et al, 2005). 
However, the experiments we describe explored the protective potential of HP against a 
different trigger of injury, i.e., drug-induced injury. Further, characterisation of the Dox-toxicity 
model indicated that the time-scale a protective stimulus was required to last was in the order 
of 18 hours, which is typically associated with what is termed the second window of 
preconditioning (SWOP) (Yellon and Baxter, 1995). Therefore, we first evaluated and 
characterised a specific protocol for HP that could protect cardiomyocytes against IR-injury in 
this second window, before evaluating the potential for this stimulus to protect against Dox-
toxicity. 
We evaluated two different hypoxic preconditioning protocols for their potential to protect 
cardiomyocytes against IR-injury. In these experiments, we used insulin as a positive control to 
protect against reperfusion injury, which is well described in our own lab (Davidson et al, 2006) 
as well as by other groups (Aikawa et al, 2000). This therefore allowed us to standardise the HP-
protocol to a known cardioprotective agent. The first protocol we tested, namely 15 minutes 
hypoxia followed by 10 minutes reoxygenation, failed to show any protection against IR-injury 
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inflicted 18 hours after preconditioning. This observation in two repeat experiments (n=2) led 
us to alter the protocol and extend the hypoxia time. Although n=2 is a small sample size, the 
data showed very close consistency between the experiments and, moreover, we observed a 
highly consistent protection from cell-death with the positive control, allowing us a measure of 
confidence to conclude that Protocol 1 did not hold an appropriate protective potential. For 
comparison Protocol 2, which had an extended hypoxia time of 30 minutes, showed a consistent 
and reproducible protection from IR-injury 18 hours after preconditioning, and matched the 
positive control insulin in protecting from IR-induced cardiomyocyte death.  This data was 
obtained from a sample size of three (n=3), and allowed us to conclude with confidence that 
protocol 2 conffered a suitable protective stimulus in the second window of preconditioning. In 
the next experiment, we confirmed that Protocol 2 could protect against IR-injury within the 
shorter or first window time-period, associated with the conventional observations of 
immediate protective effect of HP. We repeated this experiment for four different isolations 
(n=4), which allowed us to conclude confidently that the stimulus offered “classical” first 
window preconditioning stimulus.  
Our experiments show that there exists a threshold injury, below which the hypoxia stimulus 
does not offer any protective potential at 18 hours. This is likely to be a manifestation of what 
is called the threshold phenomenon (Faircloth et al, 2004; Diaz and Wilson, 2006). For example, 
Hale and Kloner (1999) had previously observed that preconditioning with two cycles of 7 
minutes ischaemic preconditioning reduced infarct size due to prolonged coronary artery 
occlusion in an in vivo rabbit model, whereas one cycle of 5 minute ischaemic preconditioning 
did not.  A corollary conclusion that may be drawn is that activation of pro-survival signalling is 
absent or insufficient below a threshold level, and is therefore incapable of protecting 
cardiomyocytes from IR-injury. A similar conclusion maybe drawn from previous observations 
in animal models of ischaemic preconditioning which have investigated the early window of 
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preconditioning. For example, Tsuchida et al had previously observed that a short ischaemic 
preconditioning stimulus of 2 minutes, along with concomitant activation of Adenosine A1 
receptors with acadesine, limited infarct size in rabbit hearts in vivo in an infarct delivered 
immediately after preconditioning. Neither acadesine alone, nor 2 minutes ischaemic 
preconditioning alone could limit infarct size in this report (Tsuchida et al, 1993). Similarly, 
Sandhu et al (1997) reported a lower protective potential with one cycle IPC, compared to three 
cycles before an IR-injury was inflicted in a rabbit model (Sandhu et al, 1997).  Bell and Yellon 
had shown that in a murine model, four cycles IPC protected eNOS knockout (eNOSKO) mice to 
similar extent to wild type, but this protection was abrogated in eNOSKO mice when less than 
four cycles of IPC was used (Bell and Yellon, 2001).  We did not examine whether prolonging the 
hypoxia time in the preconditioning phase offered similar protection or was deleterious, since 
this was beyond the scope of the experiments described. However, this may be investigated in 
future work for further characterisation of the second window of preconditioning (SWOP). 
4.4.5. Western blot. 
Our experiments characterising a Western blot protocol to explore the levels of proteins of 
interest demonstrate, understandably, that the volume of protein in the lysate is dependent 
on the volume used to establish the initial cell-culture. Of note, initial cell-seeding 
concentrations and volume were established using an estimated confluency from the  
concentration of cells observed in the final suspension of cardiomyocytes during the isolation 
procedure, and not calculated or quantified. This may be considered a limitation of the work 
described in these experiments. Since ARVMs are a monoculture, a level of confidence could 
be adopted regarding the expression levels of housekeeping genes. Normalisation of protein 
levels to housekeeping gene-product is an established method of estimating protein content in 
Western blot protocols (Lo et al, 2015), although varied differences, e.g., differences in 
conditions of lysis, sample preparation, loading, antibody-affinity, as well as variations in 
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conditions of blotting and analysis can all affect the final result. It is therefore necessary to 
optimise the conditions under which sample collection and Western blotting is carried out, and 
the observations from our experiments reinforces this. The initial Western blot using a small 
volume cell-culture dish (32 mm) showed diffuse non-specific signals when probed for protein 
content. However, by progressively increasing cell-culture volumes using larger culture plates 
(64 mm and 100 mm), we were able to obtain more robust signals for the housekeeping 
proteins GAPDH. GAPDH was used in blots exploring Akt phosphorylation since the molecular 
weight of GAPDH (37 kDa) is distinct from that of Akt (56 kDa) and in well resolved SDS-PAGE 
blot would be expected to appear as a distinct signal with greater migration distance than Akt. 
GAPDH is known to be expressed abundantly in adult rat ventricular myocytes, perform 
housekeeping roles (Diez and Simm, 1998), and has been probed in reports from our lab 
previously (Hausenloy et al, 2005, Davidson et al, 2006). It ought to be highlighted that we did 
not attempt to quantify the protein content from the different cell-culture dish volumes against 
a known standard, which may be considered a limitation of our experiment. However, cell-
seeding density may vary between experiments, and further the final volume of cell lysate 
obtained after introduction of boiling SDS-PAGE buffer may differ by factors of microliters, even 
with strict optimisation. We therefore correlated both total and phospho-protein content of 
Akt to the loading control GAPDH as a common reference value. In light of robust signal for 
GAPDH, we were satisfied that the initial characterisation experiments optimised the volume 
as well as sample preparation conditions to probe the expression of the proteins of interest. 
Future work may address the question of protein content, but this would require further 
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Chapter 5. Results. 
5.1. Investigation of the mechanism of doxorubicin-induced cardiomyocyte 
toxicity. 
 
5.1.1. Cardiomyocyte-death increases with H2O2 concentrations and increase in incubation-
time. 
Having established a reproducible model of Dox-toxicity, we first probed the potential role of 
reactive oxygen species in Dox-toxicity in this model by exploring the effect of co-incubation 
with N-acetyl cysteine (NAC), which is a known potent ROS-scavenger. We used H2O2 as a 
positive control in these experiments.  
We first sought to identify a concentration of H2O2 that closely mimicked the toxic effect of 7.5 
µM Dox. We therefore investigated the effects of 1 µM H2O2, 50 µM H2O2 and 100 µM H2O2 on 
cardiomyocyte death (Fig.5.1). After incubating cells for 4 hours (Fig. 5.1 A), a significant rise in 
cell-death was observed only with 50 µM H2O2 (mean cell-death 83.3 + 11.0%) and 100 µM 
H2O2 (91.6 + 4.1%). However, 1 µM H2O2 (mean cell-death 20.2 + 2.0%) showed no significant 
difference from basal cell-death (Cont, 13.1 + 2.3%) (ANOVA p<0.05, n=3). Incubating with the 
same three concentrations over 18 hours (Fig. 5.1B), however, resulted in a significant rise in 
cell-death with all concentrations of H2O2. Incubation with 1 µM H2O2 resulted in a rise in mean 
cell-death to 42.6 + 1.1%, significantly higher than basal cardiomyocyte death (Cont, 15.5 + 
2.1%) and comparable to levels previously observed with 7.5 µM Dox during initial 
characterisation experiments. 50 µM H2O2 (cell death 99.3 + 0.6%) and 100 µM H2O2 (cell death 
96.8 + 3.1%) both resulted in very high levels of toxicity (ANOVA p<0.05, n=3). 
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Fig. 5.1. Cardiomyocyte death induced by different concentrations of H2O2 over two different 
incubation periods. (A) Cell-death over 4 hours following treatment with 1 µM, 50 µM and 100 
µM H2O2. Both 50 µM H2O2 and 100 µM H2O2 resulted in significant rise in cell-death (ANOVA 
p<0.05, n=3). For comparison, 1 µM H2O2 did not differ significantly from basal cell-death 
(Cont). (B) Cell-death over 18 hours with same concentration of H2O2. All three concentrations 
resulted in a significant rise in cell-death. Toxicity of 1 µM H2O2 was lower than 50 µM H2O2 or 
100 µM H2O2, and was comparable to levels previously observed with 7.5 µM doxorubicin 
(ANOVA p<0.05, n=3) (representative photographs of cell-death displayed in top panels). 
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5.1.2. Effect of co-treatment with N-acetyl cycsteine on Dox-toxicity.  
Fig. 5.2. Effect of presence of N-acetyl cysteine on doxorubicin-induced toxicity. Treatment with 
7.5µM doxorubicin alone (Dox) and in the presence of 250 µM NAC (Dox NAC) both resulted in 
significant rise in cell-death after 18 hours. For comparison, 1 µM H2O2 alone (H2O2) resulted in 
a significant rise in mean cell-death compared to basal cell-death (Cont), but the presence of 
NAC rescued cardiomyocytes from H2O2-induced cell-death (H2O2 NAC) (p<0.05, n=4) (example 
photographs of cell-death displayed in top panels, see also Appendix B, Fig. VIII).  
 
We next investigated the effect of co-incubation with N-acetyl cycsteine (NAC) on Dox toxicity 
after an 18 hours exposure (Fig. 5.2). Based on the previous experiment, 1 µM H2O2 was used 
as a positive control. In these experiments, Dox alone (Dox, mean cell-death 40.0 + 3.7%) and 
presence of NAC during Dox-treatment (Dox NAC, 41.4 + 2.8%) both resulted in significant rise 
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in cell-death compared to basal cell-death (Cont, 16.6 + 2.7%) (Fig.5.2). No statistical 
significance was identified in the difference between Dox and Dox NAC. For comparison, the 
toxicity of 1 µM H2O2 (H2O2, 43.4 + 4.5%) was abrogated in the presence of NAC (H2O2 NAC, 
mean cell-death 25.3 + 4%; p<0.05 H2O2 vs H2O2 NAC, n=4) (ANOVA p<0.05, n=4).  
These experiments indicated that presence of NAC did not offer any protective effect against 
the toxicity of Dox on cardiomyocytes. 
5.1.3. Effect of doxorubicin on cardiomyocyte mitochondrial transmembrane potential (ΔΨm). 
Alterations of mitochondrial transmembrane potential (ΔΨm) has been hypothesised to be a 
potential process involved in mediating cardiotoxicity due to Dox treatment. We therefore 
investigated the state of the mitochondrial transmembrane potential in this model after 
subjecting cardiomyocytes to Dox pre-treatment for 30 minutes, 4 hours and 18 hours. The 
rhodamine ester tetramethyl rhodamine methyl ester (TMRM) crosses the mitochondrial 
membrane proportional to the ΔΨm, and at nanomolar concentrations aggregates in the 
mitochondria. Measurement of fluorescence of TMRM in response to incident light, therefore, 
allows an estimation of the ΔΨm. We therefore imaged cardiomyocytes with 10% He-Ne 
incident laser after loading with 30 nM TMRM and recorded the intensity of the emitted light. 
This approach to evaluate the ΔΨm has been reported previously from our lab (Sidall et al, 2013) 
as well as by other groups (Juhaszova et al, 2004). 
5.1.3.1. TMRM loading in cardiomyocyte mitochondria is not influenced by doxorubicin 
treatment. 
To ensure TMRM accumulation in the mitochondria and fluorescence intensity of the emitted 
light was not altered by the presence of Dox, we first evaluated the temporal collapse of 
fluorescence of 30 nM TMRM in control cells (Cont) and in doxorubicin-treated cardiomyocytes 
(Dox) after introducing 200 nM of the mitochondrial uncoupling compound FCCP (Fig. 5.3). The 
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fluorescence was recorded for 80 seconds after introducing the uncoupling agent. The 
experiment was repeated in cells subjected to 7.5 µM Dox for 30 minutes (Fig. 5.3A, Cont T0 
and Dox T0), 4 hours (Fig.5.3B, Cont T4 and Dox T4) and 18 hours (Fig.5.3C, Cont T18 and Dox 
T18). 
 
Fig 5.3. TMRM fluorescence does not vary after mitochondrial uncoupling between control cells 
and cells subjected to doxorubicin treatment. Fluorescence of 30nM TMRM in control 
cardiomyocytes and cells subjected to 7.5µM doxorubicin after treatment with 200 nM FCCP 
showed no variation in the presence and absence of doxorubicin. This was consistent with 
doxorubicin exposure over 30 minutes (Fig. 5.3A, Cont T0 and Dox T0), 4 hours (5.3B, Cont T4 
and Dox T4) and 18 hours (5.3C, Cont T18 and Dox T18).   
 
For each treatment period, statistical analysis failed to reveal any significant differences in 
TMRM fluorescence between control and doxorubicin-treated cardiomyocytes at the recorded 
time intervals, indicating Dox treatment did not alter accumulation or fluorescence intensity of 
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TMRM (ANOVA, p>0.05, n =2). Therefore, TMRM can be reliably used to measure mitochondrial 
membrane potential in these cells even in the presence of doxorubicin. 
5.1.3.2. Resting ΔΨm does not vary in response to doxorubicin treatment over time.  
 
 
Fig. 5.4. Mitochondrial transmembrane potential variation over time with doxorubicin treatment. 
ΔΨm after treatment with 7.5 µM doxorubicin for 30 minutes (Dox 0h), 4 hours (Dox 4h) and 18 
hours (Dox 18h) and ΔΨm in time-controlled basal cardiomyocytes (Cont 0h, Cont 4h and Cont 
18h) showed no significant variation. (ANOVA p=0.1, n=6) (example photographs of 
fluorescense after TMRM staining displayed in top panels). 
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We next investigated variation in baseline ΔΨm by measuring fluorescence intensity of TMRM 
after Dox-treatment (Fig. 5.4). No variation was noted in ΔΨm over time, as measured by TMRM 
fluorescence (in arbitrary fluorescence units) after Dox-exposure for 30 minutes (Dox 0h, 
101055 + 8979), for 4 hours (Dox 4h, 83864 + 11754) and 18 hours (Dox 18h, 67562 + 5143). 
Similarly, in control cells, fluorescence at baseline (Cont 0h, 79719 + 5812), after 4 hours (Cont 
4h, 72169 + 9236) and after 18 hours (Cont 18h, 86962 + 5877) did not exhibit any significant 
variations. Treatment and control groups showed no statistical variations (ANOVA P=0.1, n=6). 
This suggested that in this in vitro model, 7.5 µM Dox did not induce significant ΔΨm variations. 
5.1.4. Time taken to mitochondrial permeability transition pore opening does not alter with 
doxorubicin treatment. 
Having ruled out any significant alterations in the ΔΨm over time as a consequence of Dox 
exposure, we explored the role of mitochondrial permeability pore (mPTP) transition in 
induction of the cell-death due to Dox in this model. A positive control, Ciclosporine A (CsA), 
was used in these experiments at 1 µM concentration, since CsA is known to raise the threshold 
of stimulus required for induction of mPTP transition, which reflects as a significantly prolonged 
time taken for mPTP transition when CsA is present. We used 3 µM TMRM in these 
experiments. TMRM acts as a photosensitiser for ROS. At micromolar concentrations, TMRM 
quenches in the mitochondria. Progressive ROS accumulation consequent to phototreatment 
leads to mPTP opening associated with depolarisation of the mitochondrial transmembrane 
potential and free passage of ions across the mPTP. This is detected by rapid dequenching of 
TMRM fluorescence as the probe is released into the larger volume of the cytosol. Therefore, 
subjecting cardiomyocytes to a high intensity laser allows a real-time measurement of the 
temporal induction of the mPTP. This approach to evaluation of mPTP vulnerability has been 
reported from this lab before (Davidson et al, 2006). We therefore measured the time taken to 
mPTP induction after Dox exposure for 18 hours. In positive control experiments, 1 µM CsA  
 




Fig. 5.5. Doxorubicin does not influence mPTP transition in vitro. Time taken to mPTP induction 
in cells treated with 7.5µM doxorubicin (Dox) failed to show any significant differences 
compared to control (Cont). Presence of 1µM Ciclosporine A (CsA) prolonged time taken for 
mPTP-transition in control cardiomyocytes (Cont CsA), but not in cells pre-treated with 
doxorubicin (Dox CsA) (p<0.05, n=7) (representative trends to fluorescence-dequenching 
shown in top panel). 
 
was introduced during TMRM probe loading, and maintained in solution during the generation 
of oxidative stress leading to mPTP induction.Fig. 5.5 shows the results of these experiments. 
Dox pre-treated cardiomyocytes did not undergo mPTP transition with any significant 
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difference (Dox, mean time to mPTP induction 842.1 + 103 s) compared to control (Cont, 972.1 
+ 74 s) (Fig. 5.5). The positive control CsA prolonged time taken to mPTP induction in basal 
cardiomyocytes only (Cont CsA, 1304 + 111.4s). Surprisingly, this protective effect was 
abrogated in cells subjected to Dox pre-treatment (Dox CsA, mean time to mPTP transition 901 
+ 58.7s; p<0.05, Cont CsA vs Dox CsA) (ANOVA p<0.05, n=7).  These experiments indicated 
vulnerability of the mPTP to transition to the open state was not increased due to Dox-
treatment in this model. 
5.1.5. Presence of Ciclosporine A does not alter doxorubicin-induced cardiomyocyte death in vitro.  
 
Fig. 5.6 Doxorubicin-induced cell-death in the presence of Ciclosporine A. Treatment with 7.5µM 
doxorubicin alone (Dox) and in the presence of 1 µM Ciclocsporine A (Dox CsA) both resulted 
in similar levels of cardiomyocyte-death. Compared to basal cell-death (Cont), presence of CsA 
alone (Cont CsA) showed no significant difference in cell-death after 18 hours (ANOVA p<0.05, 
n=7) (representative photographs of cell-death displayed in top panels. See also Appendix B. 
Fig. IX).  
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Since CsA-mediated mPTP-protection was abrogated in cells pre-treated with doxorubicin, we 
investigated the effect of co-treatment with 1 µM CsA on Dox-toxicity and on untreated 
cardiomyocytes.  The results are shown in fig. 5.6. Analysis of cell-death showed a similar and 
significant rise in cell-death in cells exposed to Dox alone (Dox, mean cell-death 46.9 + 3.3%), 
and in cells subjected to Dox in the presence of CsA (Dox CsA, 45.3 + 1.6%). CsA alone (Cont 
CsA, 19.5 + 1.2%) was not toxic and displayed no significant differences in survival compared to 
control (Cont, 15.6 + 2.1%) (ANOVA p<0.05, n=7). This showed presence of CsA could not 
protect against nor exacerbate Dox-toxicity, but CsA alone was not toxic at the concentrations 
used.   
 
5.2. Effect of hypoxic preconditioning on doxorubicin-mediated cardiomyocyte 
death. 
Having explored the potential mechanisms leading to cell-death, we investigated hypoxic 
preconditioning (HP) as a mechanism of protection against doxorubicin-induced injury in this 
model of in vitro toxicity. We had previously characterised a protocol to deliver an in vitro HP 
stimulus that protected cardiomyocytes against IR-injury (Chapter 4, section 4.2.3). We 
therefore used this protocol, and investigated cell-death after incubating cardiomyocytes with 
different concentrations of Dox after this preconditioning HP stimulus. As control for HP, 
cardiomyocytes were incubated in normoxic buffer for 40 minutes and subjected to identical 
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5.2.1. Hypoxic preconditioning protects cardiomyocytes from doxorubicin-toxicity. 
 
Fig. 5.7. Effect of hypoxic preconditioning on subsequent doxorubicin-mediated cardiomyocyte 
toxicity. In non-preconditioned cells, a dose dependent rise in cell-death was observed with 
doxorubicin treatment, which achieved statistical significance with 7.5μM doxorubicin (Dox 7.5) 
and 10µM doxorubicin (Dox 10).  For comparison, preconditioned cardiomyocytes were 
protected across all doxorubicin concentrations, with no difference in cell-death compared to 
control (ANOVA p<0.05, n=5) (representative photographs of cell-death displayed in top panels. 
See also, Appendix B Fig. X).  
 
In non-preconditioned controls cell-death was noted to be significantly high, but only with 
concentrations of 7.5 µM Dox (Dox 7.5, 35.4 + 1.7%) and 10 µM Dox (Dox 10, 44.9 + 4.3%) (Fig.  
5.7). HP protected against the toxicity of both Dox 7.5 µM (Dox 7.5 HP, 14.7 + 10.5%) and 10 
µM (Dox 10 HP, 24.6 + 4.0%), and no differences were observed when compared to basal cell-
death (Cont, 14.3 + 5.3%). HP alone did not influence cell-death in basal cardiomyocytes (Cont 
HP, 13.6 + 1.8%) (ANOVA p<0.05, n=5).  
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5.2.2. Protection against doxorubicin-injury due to hypoxic preconditioning is dependent on 
PI3K/Akt cascade, but independent of MAPK-ERK. 
In light of the above results, we investigated the role of the RISK pathway in the protective 
effect of HP observed against toxic concentrations of doxorubicin. Pre-treatment with the 
reversible inhibitor 10 µM LY294002 was used to inhibit the PI3K/Akt pathway, while MAPK  
  
Fig. 5.8. Effect of inhibiting PI3K/Akt pathway and MAPK ERK 1/2 on preconditioning-mediated 
protection against Doxorubicin-induced cell-death. Excess cell-death due to treatment with 
7.5µM doxorubicin (Dox) did not manifest in cells subjected to a preceding hypoxic 
preconditioning (HP) stimulus (Dox HP). Pre-treatment with 10µM LY294002 before HP (Dox 
HP (LY)) abrogated this protective influence, but the protection persisted in Dox HP group pre-
treated with 30µM PD98059 (Dox HP (PD)). LY294002 and PD98059 alone did not have any 
significant effects (ANOVA p<0.05, n=5) (representative photographs of cell-death displayed in 
top panels, see also Appendix B Fig. XI). 
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ERK 1/2 was inhibited using 30 µM PD98059 before subjecting cells to HP. The protective effect 
of preconditioning on cardiomyocytes was then re-explored using 7.5 µM Dox as a toxic 
anthracycline concentration. Fig. 5.8 shows the results of these experiments. Compared to basal 
cell-death (Cont, mean cell-death 11.2 + 1.2%), Dox alone resulted in significant toxicity after 
18 hours (Dox, 39.3+ 3.4%), which was not observed in preconditioned cells (Dox HP, 16.9 + 
1.5%). However, this protective effect of HP was abrogated in cells pre-treated with 10µM 
LY294002 before preconditioning (Dox HP(LY), 38.5 + 3.3%; p<0.05, Dox HP vs Dox HP(LY)), but 
not 30µM PD98059 (Dox HP (PD) 15.9 + 1.3%; p<0.05, Dox HP(LY) vs Dox HP (PD)).  Neither 
LY294002 alone (Dox (LY), mean cell-death 36.8 + 3.1%), nor PD98059 alone (Dox (PD), 38.4 + 
3.1%) altered the toxicity of Dox significantly (ANOVA p<0.05, n=5).  
5.2.3 Western blots. 
Having observed the effect of differential inhibition of PI3K/Akt and MAPK ERK 1/2 on 
doxorubicin-toxicity following HP, we used Western blotting to confirm the induction of the 
respective kinases by HP, and their respective inhibitions with LY294002 and PD98059. Insulin 
was used as a positive control to induce the respective protein cascades in these experiments. 
5.2.3.1. PI3K/Akt phosphorylation in response to hypoxic preconditioning. 
Fig. 5.9 panel A shows a representative Western blot investigating the expression levels of 
phosphorylated Akt (p-Akt). An increase in phosphorylated protein content was noted in cells 
subjected to HP (HP, lane 6). A more prominent increase in levels of p-Akt with the positive 
control insulin (Ins, lane 4) was also noted. 10µM LY294002 pre-treatment inhibited the 
increase in p-Akt in response to HP (HP(LY), lane 7), and attenuated the phosphorylation 
induction in insulin-treated cells (Ins(LY), lane 5). No prominent signal for p-Akt was identified 
in control cells under basal conditions (Cont, lane 2) or after LY294002 treatment alone 
(Cont(LY), lane 3). 
 
Angshuman Maulik   Page | 135 
 
 
Fig. 5.9. Western blot analysis of hypoxic preconditioning-induced phosphorylation of Akt. (A) 
Representative blot showing expression of p-Akt induction. Both insulin (Ins) and hypoxic 
preconditioning (HP)-induced an increase in p-Akt, which was attenuated by 10µM LY294002 
treatment. (B) Expression of the housekeeping gene GAPDH in the same blot as A. (C) 
Expression of t-Akt protein in the same samples as shown in panel A, run on a different Western 
blot membrane, along with the expression of GAPDH. (D) Mean p-Akt to t-Akt ratios obtained 
from Western blot analyses. Compared to resting state, HP resulted in an increased expression 
level of p-Akt that was inhibited by LY294002 pre-treatment. The positive control insulin 
showed a strong induction of p-Akt, which was also inhibited by LY294002 pre-treatment (n=3). 
 
 Fig.5.9 panel B shows the content of housekeeping gene GAPDH in the same samples as panel 
A. The GAPDH protein content was used as a loading control in these experiments, and a signal 
was identified across all samples. Fig. 5.9 panel C shows expression of total Akt (t-Akt) and 
GAPDH in the same samples shown in panel A, analysed on a separate Western blot. Prominent 
signals for both t-Akt and GAPDH were identified across all samples. To identify the ratio of p-
Akt to t-Akt in each treatment group, p-Akt levels (Fig.5.9 panel A) were normalised to GAPDH 
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content (Fig. 5.9 panel B) in each sample well (i.e., expressed as p-Akt: GAPDH). Similarly, t-Akt 
levels were normalised to GAPDH (i.e., t-Akt: GAPDH ratio identified from Fig. 5.9 panel C). Fig. 
5.9 panel D shows the ratio of p-Akt and t-Akt normalised to GAPDH (p-Akt: GAPDH :: t-Akt: 
GAPDH) in the respective treatment groups, as a mean of three different repeat experiments. 
HP resulted in a mean 17-fold increase in the ratio of p-Akt to t-Akt compared to resting 
expression levels (Cont). This induction response was attenuated when cells were pre-treated 
with LY294002 before preconditioning (HP(LY)). The positive control Insulin (Ins) resulted in a 
mean increase of 200-fold in p-Akt to t-Akt ratio compared to control, and LY294002 pre-
treatment attenuated this to 75-fold of basal levels. However, statistical analysis failed to show 
significance in the differences observed in the ratios of p-Akt to t-Akt in the various treatment 
groups (p>0.05, n=3). 
5.2.3.2 Phosphorylation induction of MAPK ERK 1/2 in response to hypoxic preconditioning. 
We next explored the phosphorylation of the ERK 1/2 proteins in response to HP. Fig. 5.10 panel 
A shows a representative Western blot for phosphorylated ERK 1/2 (p-ERK) and the 
housekeeping gene α-tubulin. Prominent signal for p-ERK content was observed after HP (HP, 
lane 6), which was attenuated by pre-treatment with PD98059 (HP (PD), lane 7). Increase in p-
ERK content was also observed after insulin-treatment (Ins, lane 4), and in protein isolate from 
resting cardiomyocytes (Cont, lane 2). PD98059 pre-treatment resulted in attenuated p-ERK 
levels in both groups (Cont (PD), lane 3; and Ins (PD), lane 5). Fig. 5.10 panel B shows expression 
levels of total ERK 1/2 (t-ERK) in the same samples shown in panel A, analysed in a separate 
western blot. Although the blot gave a weak signal, t-ERK signal was observed across all groups. 
Analysis on imageJ software showed a dual peak at the expected molecular weight range of 
42/44 kDa in all samples. 
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Fig. 5.10. Western blot analysis of hypoxic preconditioning induced phosphorylation induction of 
MAPK ERK 1/2. (A) Representative Western blot displaying expression levels of p-ERK and the 
housekeeping gene α-tubulin under basal conditions (Cont, lane 2), after pre-treatment with 
PD98059 alone (Cont(PD), lane 3), insulin treatment alone (Ins, lane 4), PD98059 pre-treatment 
with insulin (Ins(PD), lane 5), HP (lane 6), and cells pre-treated with PD98059 before HP (HP(PD), 
lane 7). (B) Western blot displaying expression levels of α-tubulin and t-ERK in the same samples 
as in Panel A. (C) Mean cumulative expression levels of p-ERK to t-ERK in three different 
experiments. HP showed a 2.7-fold elevation in p-ERK to t-ERK ratio compared to control, which 
was attenuated in the presence of PD98059. The positive control insulin 1.7-fold elevation of 
p-ERK to t-ERK ratio compared to control. PD98059 pre-treatment attenuated the p-ERK 
expression levels in all experimental groups (n=3). 
 
The phosphorylation induction of MAPK ERK 1/2 was evaluated as relative ratios of p-ERK and 
t-ERK normalised to α-tubulin in each well. Therefore p-ERK: α-tubulin and t-ERK: α-tubulin 
ratios were identified for each individual treatment group, and the ratio p-ERK: α-tubulin:: t-
ERK: α-tubulin evaluated. Fig. 5.10 panel C shows the results of these analyses in the respective 
groups, expressed as mean of three different experiments. A 2.7-fold increase was observed 
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after HP, compared to control. PD98059 pre-treatment attenuated this HP-induced 
phosphorylation induction to 0.36-fold of control (HP (PD)). Similarly, a 1.7-fold increase in p-
ERK to t-ERK ratio was observed with the positive control agent insulin (Ins), which in PD98059 
pre-treated cells was attenuated to 0.2-fold the ratio observed in control. PD98059 attenuated 
p-ERK levels in resting cells (Cont (PD)) to 0.3-fold the levels observed in control. However, 
statistical analysis failed to show significance in the differences in ratios of p-ERK to t-ERK in the 
between the various treatment groups (p>0.05, n=3). 
 
5.2.3.3 Effect of doxorubicin treatment on PI3K/Akt and MAPK ERK 1/2 phosphorylation. 
Having analysed the phosphorylation response of for PI3K/Akt and MAPK ERK 1/2 in response 
to HP, we briefly explored the induction of the respective kinases following Dox- treatment 
 
 
Fig. 5.11. Analysis of doxorubicin-induced phosphorylation of PI3K/Akt. A. A signal could be 
identified for t-Akt and the house keeping gene GAPDH at all time-points of treatment. B. No 
signal was identified for p-Akt. C. Analysis of GAPDH content showed a clear discernible signal 
in the same samples as shown in Panel B. 
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alone 15 minutes, 4 hours and 18 hours after initiation of drug-treatment. We explored the 
induction of PI3K/Akt and of MAPK ERK 1/2 (Fig.5.12) in two repeat experiments (n=2). Upon 
analysis of t-Akt and the housekeeping gene GAPDH, distinct signals were identified (Fig.5.11, 
panel A). However, no signal for p-Akt could be identified, although clear signal was evident for 
GAPDH in the respective samples (Fig.5.11, Panels B   and C) on imageJ analysis. Similarly, on 
Western blot analysis for MAPK ERK 1/2, a bimodal signal corresponding to the molecular 
weight for ERK (42 and 44kDa) was identified upon probing for t-ERK, along with a robust signal 
for the housekeeping gene α-tubulin (Fig.512 panel A). Western blot for p-ERK however failed 
to show any clear evident signal, although a robust signal for the housekeeping gene α-tubulin 
was identified (Fig. 5.12 Panel B) in the respective samples. Statistical analysis was not carried 
out for the protein bands identified in these blots. 
 
 
Fig. 5.12. Analysis of phosphorylation induction of MAPK ERK 1/2 in response to doxorubicin 
alone. A. A robust signal for the α-tubulin and weak but evident signal for the total isoform of 
ERK 1/2 were identified at all time points. B. Probing for phosphorylated ERK 1/2 (p-ERK) and 
α-tubulin revealed a robust signal for α-tubulin only, but no evident signal for the p-ERK. 
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5.3 Discussion. 
5.3.1. Doxorubicin-toxicity is not altered by co-incubation with NAC.  
The generation of ROS species has been postulated to be a mechanism mediating 
anthracycline-cardiotoxicity (Minotti et al, 2004; Berthiaume et al, 2007), which includes a 
proposed direct role for anthracyclines in generation of ROS and RNS species through futile 
cycling of the quinone-semiquinone moiety of the C-ring of the anthracycline core structure 
(Beckman et al, 1996; Weinstein et al, 2000; Mihm et al, 2001). An indirect role has also been 
proposed in generating ROS from enzymatic sources (Zhou et al, 2001). This enzymatic 
generation of ROS-species may be secondary to saturation of the cellular bioreduction 
pathways, or attenuation of the mitochondrial and cellular bioenergetic pathways including 
Complex I, NAD(P)H and NAD(P)H-dependent dehydrogenases, α-ketoglutarate 
dehydrogenase, etc. (Blanco et al, 2008). As a first step to identifying possible toxicity 
mechanisms of Dox in the model described, we explored if potential ROS scavenging could 
protect against in vitro cardiomyocyte death. We used N-acetyl cysteine (NAC) to probe our 
hypothesis, at a concentration of 250 µM. NAC is a direct acting antioxidant which is also a non-
specific scavenger capable of scavenging several different ROS species including peroxide ions, 
·hydroxide ions, and peroxynitrite ions (Day, 2008). These reactive species have been reported 
in literature as possible mediators of cardiomyocyte toxicity due to Dox (Pacher et al, 2003; 
Mihm et al, 2002). Further, NAC has been observed to exert ROS scavenging properties against 
ROS-species generated from respiratory complexes (Taddei et al, 2012) as well as from 
enzymatic sources (Peng et al, 2011). 250 µM is a high concentration of NAC, and has been 
reported previously to be capable of attenuating markers of ROS-expression, e.g. the levels of 
glycosylated subunit of NADPH (gp91PHOX) (Peng et al, 2011). We used H2O2 as a positive control 
to generate oxidative stress in these experiments. The initial experiments showed 50 µM and 
100 µM H2O2 resulted in cell death approaching or greater than 90% at both 4 hours and 18 
hours. However, 1 µM H2O2 more closely replicated the toxicity of 7.5 µM doxorubicin, since 
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cardiomyocyte death failed to show any statistically significant difference at 4 hours, but 
approached levels observed with 7.5 µM Dox during initial characterisation of the model of 
doxorubicin-toxicity (Figs 5.1, 4.1 and 4.8). We therefore used 1 µM H2O2 as a positive control.  
Our experiments suggest that in this in vitro model, ROS-species may not be the mediator of 
doxorubicin-toxicity. This differs from observations reported previously. For example, Deres et 
al (2005) had previously reported increased lipid peroxidation and protein oxidation in 
response to perfusion with Dox in an isolated Langendorff-perfused rat heart model. Similarly, 
Ichihahra et al (2007) noted an increase in lipid peroxidation in left ventricular tissue in an in 
vivo model where they injected mice intraperitoneally with doxorubicin, which correlated with 
cardiac dysfunction. The authors noted protection from both depressed cardiac function, as 
well as from increase in levels of lipid peroxidation products with polyethyleneglycated-
Superoxide dismutase (PEGylated-SOD or PEG-SOD) as well as with fenofibrate. It ought to be 
highlighted that we did not directly visualise the generation of ROS-species in response to Dox 
treatment, instead using H2O2-induced cell-death as a positive control and surrogate marker 
for oxidative stress. Considering a second surrogate marker of oxidative stress, e.g., expression 
levels of proteins responsive to oxidative stress (for example gp91PHOX) or direct visualisation of 
the content of ROS-species in response to H2O2 treatment, Dox-treatment, and the respective 
changes upon coincubation with NAC would have consolidated the results we observed and 
improved the robustness of the experimental design and the conclusions. This is a limitation of 
our experiment. Moreover, the sample size of these experiments was four (n=4). We did not 
pre-calculate the sample size for the experiments, which may be considered a limitation of the 
experiments. However, the protective role of NAC in the positive control experiment allows a 
substantial measure of confidence in the cell-survival data we observed.  Supporting this 
observation, another investigator in our laboratory (Dr Piowtroska) observed no ROS-
production following Dox treatment in cardiomyocytes. In her experiments, she used the dye 
 
Angshuman Maulik   Page | 142 
 
CM-H2DCFDA (DCF). DCF is a fluorescein diacetate probe sensitive to ROS-species (Kristiansen 
et al, 2009; King and Oh, 2004). In Dr Piowtrowska’s experiments, cardiomyocytes were loaded 
with 8.5 μM DCF after incubating with 7.5 µM Dox for 4 hours or 18 hours, and DCF-
fluorescence analysed using a 488 nm Argon laser in a Leica SP5 confocal microscope equipped 
with ×20 oil immersion objective lens (numerical aperture 1.0). As control, cardiomyocytes 
were incubated in medium 199 only.  She observed no significant differences in the 
fluorescence of DCF after Dox treatment compared to control (Dr Piowtroska, personal 
communication). This supported the suggestion we draw from cell-death analyses that 
doxorubicin-mediated cardiomyocyte death in the particular model we explored was 
independent of ROS-species mediated toxicity.  
In support of our observations, ROS-independent cell-death pathways have been implicated in 
Dox-toxicity. For example in H9C2 cardiomyoblasts, Ma et al (2013) observed doxorubicin-
induced changes in p53-acetylation and histone deacetylases HDAC inhibition that were not 
affected by NAC treatment, despite reduction in DNA fragmentation and caspase 3 activation 
(Ma et al, 2013) in response to ROS-scavenging by NAC. p53-acetylation has been observed to 
promote apoptosis in previous reports (Zhang et al, 2011b; Yuan et al, 2011) This indicates that 
Dox could activate different cell-death pathways that maybe dependent and independent of 
ROS, and these may co-exist. This is important, since a number of in vivo models of Dox toxicity 
have utilised large bolus doses to induce cardiotoxicity (e.g., Zhang et al, 2012; Wang et al, 
2012). As mentioned in an earlier section, necrotic or apoptotic pathways of cell-death may 
predominate depending on the concentration of Dox used, and it ought to be highlighted that 
apoptosis itself may lead to ROS generation (Montaigne et al, 2012). Further highlighting the 
ambiguity of the role of ROS-species, in in vivo rodent models, chronic dosing regimens of Dox 
has previously been reported to increase the myocardial antioxidant activity measured by total 
antioxidant performance (Ferreira et al, 2007), indicating that ROS generation due to 
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anthracycline treatment may be more complex than a causal effect of drug administration. 
Small scale observational studies in humans had previously reported acute decrease in cardiac 
lipid peroxidation in response to Dox infusion, as estimated by the levels of lipid conjugate di-
enes (Minotti et al, 1996). Moreover, in clinical practice, the use of ROS-scavengers, e.g. NAC 
and alpha-Tocopherol, have failed to protect against the cardiotoxicity of anthracyclines (van 
Dalen et al, 2011). This highlights that the role for ROS-species as a critical mediator in Dox 
mediated cardiotoxicity is still unclear. In this context, the data described in this report indicates 
that ROS-independent death pathway may have a role in the model of Dox-toxicity we 
characterised. Reports investigating the cardiotoxicity of Dox may describe the presence of 
ROS-species in cardiomyocytes after Dox treatment as reflective of- or a marker- of a 
pathological process (Zhang et al, 2012). The results we observed suggest a requirement for 
caution in interpreting such data and in correlating the presence of ROS to cell-death levels.  
  
5.3.2. Doxorubicin does not to alter resting mitochondrial transmembrane potential in 
cardiomyocytes in vitro. 
Having established that ROS-scavenging did not rescue cardiomyocytes from doxorubicin-
induced cell-death, we explored the role of other potential pathways in the cardiomyocyte-
death due to Dox in the model of cell-death. Anthracyclines treatment in rodent models have 
been shown to alter the mitochondrial bioenergetic pathway, for example by reduced activity 
of the mitochondrial genome-encoded components of respiratory chain (Lebrecht et al, 2010), 
and by inhibition of the proteins that drive the proton-motive force and ATP generation, e.g., 
mitochondrial NADH and Succinate dehydrogenase protein, as well as the function of the Mg2+-
dependent F1F0-ATPase (Berthiaume et al, 2007). Dox therefore has been postulated to lead to 
loss of the proton-motive force that drives ATP generation. Rapid decline in the mitochondrial 
transmembrane potential (ΔΨm) has been reported in ex vivo models, e.g., within in 1 hour in 
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Langendorff-perfused rat hearts as observed by Montaigne et al (2010) in response to 1 µM 
Dox, or in murine cardiomyocytes within 72 hours after administering a bolus 25 mg/kg of dose 
of Dox in vivo (Zhang et al, 2012). ΔΨm collapse may occur in response to a number of 
pathological mechanisms, including in particular Ca2+ overload and ROS-species generation. 
Collapse of ΔΨm is a mechanism of induction of cell-death, e.g. by release of Cytochrome C. We 
therefore considered the hypothesis that fall in ΔΨm may have a role in the toxicity we observed 
in response to Dox in this in vitro model of doxorubicin-toxicity.  
In the experiments described, we used TMRM as an agent to report ΔΨm. A number of dyes 
have been used to investigate the transmembrane potential, which are as a class lipophilic and 
accumulate in the mitochondria according to the Nernst potential (Perry et al, 2011). This 
includes the compounds Rhod123, JC-1, Dioc6, TMRM and TMRE, each with its advantages and 
weaknesses. Rhod123 was considered unsuitable for our experimental aims, since dye 
aggregation and consequent quenching of fluorescence at higher probe concentrations holds 
the possibility of aberrant depolarization of ΔΨm. Further, Rhod123 has been previously shown 
to inhibit mitochondrial respiration more than TMRM (Scaduto and Grotyohann, 1999). 
Similarly, JC-1 reports ΔΨm as a dual-colour, ratiometric assessment of the monomeric to the 
aggregate forms, but is highly sensitive to probe loading concentrations. Moreover, it is highly 
photosensitive, and in the aggregate form is slowly permeant, requiring time typically in the 
order of 90 minutes to reach equilibration in cardiomyocytes (Mathur et al, 2000), which we 
considered unsuitable for experimental purposes. DiOC6 was considered unsuitable since 
beyond extremely low concentrations in the order of 1 nM, the dye may be toxic to 
mitochondrial respiration and, moreover, may erroneously estimate transplasmalemmal 
potential rather than transmitochondrial potential (Rottenberg and Wu, 1998). The ethyl and 
methyl esters of tetramethylrhodamine (TMRE and TMRM respectively), for comparison, 
equilibrate rapidly across the cardiomyocyte in the order of 15 minutes, and was therefore 
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considered the most suitable probes. TMRM was used in preference to TMRE since it offered 
the lowest potential for inhibiting mitochondrial respiration when used at a concentration 
below 0.5 µM (Scaduto and Grotyohann, 1999). At nanomolar concentrations (1-30 nM), 
TMRM aggregates within the mitochondria, and consequent fluorescence provides an accurate 
assessment of the pre-existing ΔΨm (Perry et al, 2011). We therefore used a low concentration 
(30 nM) TMRM and estimated the optical fluorescence using 10% intensity incident He-Ne laser 
to report the transmembrane potential.  
As an initial characterisation experiment, we confirmed that 30 nM TMRM fluorescence 
decreased in both control and Dox treated cells in response to 200 nM FCCP. FCCP is a 
mitochondrial uncoupler and leads to loss of ΔΨm, with consequent decrease of the 
fluorescence of TMRM in the nanomolar concentrations we used (Joshi and Bakowska, 2011). 
This loss of fluorescence upon treatment with an uncoupler was used as a confirmation that 
TMRM fluorescence was dependent on mitochondrial accumulation, and therefore dependent 
on ΔΨm in this model. Further, the fluorescence post-depolarisation was similar across all three 
treatment times in both Dox-treated cells and control, which allowed us to conclude that 
TMRM loading and optical fluorescence was not influenced by the presence of Dox itself. It 
ought to be highlighted that in cells treated with Dox for 4 hours (Dox 4 and corresponding 
control Cont 4), the initial mean 30 nM TMRM fluorescence was noted to be markedly lower in 
both Dox 4 h as well as control, compared to the cardiomyocytes treated for 30 minutes (Dox 
0 and Cont 0), as well as 18 hours (Dox 18 and Cont 18). A wide variation was also noted in the 
baseline fluorescence, which persisted in the first 20 seconds beginning with introduction of 
200nM FCCP (Fig. 5.3, panel B). The reason for this is unclear, but may reflect the low number 
of repeat experiments from which the data is collected (n=2), particularly given that this 
variation was not noted in the two other groups; the variation appeared to settle in the 
subsequent 60 seconds; and that fluorescence values later in the decaying trend approached 
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and reflected the values observed in the other two time groups. A larger sample size would 
have increased the robustness of this experiment, and ought to be considered in similar future 
experiments. 
In subsequent experiments, we pre-treated cardiomyocytes with Dox for 30 minutes (Dox 0), 4 
hours (Dox 4) and 18 hours (Dox 18) and analysed the differences in optical fluorescence of 
TMRM compared to control groups. However, these experiments did not detect any significant 
differences in the ΔΨm amongst the different treatment groups. The results are collated from 
six repeat experiments (n=6) which, although not pre-calculated, was guided by acceptable 
sizes and commonly reported numbers in literature. Further, possible wash-off of dead cells 
from laminin attachments during the process of buffer exchanges during probe loading may 
yield artefactual false results. We had previously analysed differences in total cell-count after 
Dox treatment and PI introduction during the development and characterisation of the model 
of Dox toxicity (fig. 4.5.), and found no significant differences in cell count relative to control 
groups. This allowed us to conclude with confidence that Dox treatment did not influence ΔΨm 
in this in vitro ARVM model. 
ΔΨm has been previously reported to fall in response to Dox by other authors. For example, 
Fisher et al reported a fall in ΔΨm in cultured adult mouse ventricular myocytes using the JC-1 
dye following 18 hours incubation with 1 μM Dox (Fisher et al 2005). Similarly, Dox-treatment 
in ex-vivo models in isolated, Langendorff-perfused, rat hearts (Montaigne et al, 2010) as well 
as cardiomyocytes isolated from mice following in vivo treatment with Dox (Zhang et al, 2012) 
showed a decline in resting ΔΨm. One explanation for these differences in observations may be 
the differences in experimental set ups. Montaigne et al used an ex vivo model, perfusing intact 
hearts in a Langendorff model. They used a lower concentration (1 μM doxorubicin) for a 
shorter time-period (1 hour), and measured the epicardial fluorescence of JC-1 dye aggregates 
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to estimate mitochondrial transmembrane potential semi-quantitatively. It is worth noting that 
at a similar dose-range in this isolated cardiomyocyte model, we do not observe any discernible 
differences in cell-death which led us to conclude that 1 μM Dox did not inflict any substantial 
injury. Similarly, Zhang et al (2012) isolated murine cardiomyocytes 72 hours after a large bolus 
dose of 25 mg/Kg intraperitoneally. They too used JC-1 dye, and observed a decrease in ΔΨm 
(Zhang et al 2012). It is worth highlighting that the dose used by Zhang et al is several folds 
higher than what may be used physiologically in humans. Further, we used TMRM rather than 
JC-1 to measure ΔΨm. As explained above, aggregate (i.e., red) JC-1 equilibrates slowly across 
the cardiomyocyte and further the fluorescence is highly sensitive to probe loading 
concentrations and loading times. Furthermore, the fluorescence may change independently 
of ΔΨm under some circumstances, e.g. by surface to volume ratio (Perry et al, 2011). These 
factors ought to be considered when analysing the differences of our findings compared to 
other groups. The results however indicate alterations of the mitochondrial transmembrane 
potential is not a mediating factor in induction of cell-death. It ought to be emphasised in this 
section however, that the data described do not allow any conclusions to be drawn regarding 
the mitochondrial energetic state, since ΔΨm is influenced by the net gradient of ionic species 
across the mitochondrial membranes, but the proton gradient may be maintained or even 
increased without any changes in the ΔΨm, for example due to accumulation of cationic-species 
within the cytoplasm (Perry et al, 2011). 
5.3.3. Influence of doxorubicin treatment on mPTP transition in vitro. 
Our results described above indicated that dissipation of ΔΨm was not involved in the cell-death 
we observed in this model, leading us to explore the role of other possible mechanisms of cell-
death to explain cardiomyocyte toxicity observed. Opening of the mitochondrial permeability 
transition pore (mPTP) is considered a final event in induction of cellular death pathway, or the 
“point of no return” in cell-death. The mPTP had previously been reported to be involved in the 
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induction of cardiomyocyte death in heart failure in murine models of pressure overload (Elrod 
et al, 2010). Further, known pore-induction stimuli include Ca2+-overload within the 
mitochondria, and doxorubicin-treatment has been shown to alter Ca2+ regulating proteins 
including SERCA2A and RyR. Furthermore, an increased sensitivity to induction of mPTP 
opening is noted in rats treated with Dox (Ascensão et al, 2010). We therefore hypothesised 
that an increased sensitivity to induction of mPTP could be a mechanism of cell-death in this 
model, which we explored in the subsequent experiment. 
For reasons discussed above, TMRM was used as a reporting agent in this experiment exploring 
mPTP transition. We used a higher concentration of 3 µM of TMRM in these protocols. At these 
high concentrations TMRM is used in a dequenching mode, whereby accumulated dye within 
the mitochondria in the polarised state is released into the cytosol upon depolarisation, leading 
to unquenching of fluorescence. The collapse of the transmembrane potential which occurs on 
mPTP depolarisation is reflected by a non-linear increase in the fluorescence intensity of the 
probe. In the final state of the pore reaching a freely-permeant state, fluorescence intensity of 
TMRM plateaus as the probe is released into the cytosol. The added advantage of TMRM in 
experimental design was that at micromolar concentrations, TMRM further functions as a 
photosensitiser of ROS generation when subjected to high intensity laser, and therefore 
provides a source of oxidative stress that may induce the mPTP to reach the freely permeant 
“open” state. Measuring the fluorescent intensity versus time therefore provides a reflection 
of the rate of depolarisation, and therefore allows identification of increased vulnerability of 
the pore to reach the permanently open state by comparison of time taken to mPTP transition 
between different treatment groups. This experimental setup has been reported in our lab 
before (Hausenloy et al, 2003a; Davidson et al, 2006).  
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 We used a higher intensity of 40% He-Ne laser to elicit TMRM fluorescence and generate 
oxidative stress. We used Ciclosporine A (CsA) as a positive control to inhibit the mPTP 
transition. CsA has been shown previously to bind to the Peptidyl Prolyl cis-trans isomerase 
Cyclophilin D (Cyp D) with high affinity, and is to date the most specific inhibitor of Cyp D known 
(Rao et al, 2014). CsA acts as a “desensitiser” of the pore transition, rather than blocking pore 
induction altogether (Bernardi et al, 2006; Halestrap and Richardson 2015), and mPTP 
transition in the presence of CsA requires higher levels of induction stimuli, e.g. Ca2+. We used 
CsA at a 1 µM concentration, which has been reported previously to offer robust protection 
against pharmacological induction of mPTP in isolated ARVM models investigating heart failure 
(Xu et al, 2016). 
5.3.3.1. Doxorubicin treatment does not increase increase time taken to mitochondrial 
permeability pore transition. 
We identified no differences in the time to mPTP transition between Dox-treated 
cardiomyocytes and control. Surprisingly, CsA increased the time to pore induction in control 
cells only, but not in Dox-treated cardiomyocytes. The experiments were repeated to a total 
sample size of seven (n=7), which in the context of an in vitro experimental set up is a sample 
size large enough to draw very confident conclusions. The results are therefore interesting, 
since these observations are different from those reported by other groups in in vitro 
experiments (Gharanei et al, 2013a and 2013b), in ex vivo models (Montaigne et al, 2010), as 
well as in in vivo models (Marechal et al, 2011). For example, Marechal et al observed an 
increase in Ca2+-induced mPTP transition in vivo with doxorubicin, administered both as a large-
dose bolus as well as in an interrupted dosing models. The authors noted this response of mPTP 
induction to be abrogated by co-administration of 1mg/kg CsA. Similarly, Gharanei et al 
observed a protection from mPTP transition reported by 3 µM TMRM fluorescence 
dequenching when 0.2 µM CsA was used in conjunction with doxorubicin-treatment (Gharanei 
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et al, 2013a). Several explanations may be considered to account for these differences. The 
experimental set up we used differed in a number of ways from those used by other groups. 
For example, Gharanei et al (2013a) estimated mPTP induction using 3 µM TMRM, but they 
subjected primary adult rat cardiomyocytes to 10 mins of 1 μM Dox treatment after incubating 
cells overnight prior to transferring to laminin coated surface. The differences in timing of 
seeding to laminin plate and the consequent differences in cytoskeletal feedback signalling 
(Ross and Borg, 2001; Langenbach and Rando, 2002) maybe one explanation for the differences 
between the results we observed and those of Gharanei et al. Similarly, Montaigne et al (2010) 
measured the epicardial fluorescence of mitochondrial dye JC-1 following 60 min of 1 µM Dox 
infusion in isolated perfused rat hearts. As explained above, aggregate (i.e., red) JC-1 
fluorescence is sensitive to probe loading concentrations and times, and may change 
independently of ΔΨm under some circumstances. The findings we describe suggest it may be 
informative to re-explore the mPTP induction times with more than one reporting dye, e.g. 
Rhod123 in addition to TMRM, as this may allow greater clarity and more robust data on which 
to draw conclusions and reconcile the differences in these observations. 
A further interesting result stands out from these experiments. The positive control CsA was 
able to desensitise the mPTP to induction stimulus in control cardiomyocytes only, but not in 
Dox treated cells. This is interesting, since this shows that the protective effect of CsA is 
abrogated in Dox-treated cells.  We are not aware of similar observations having been reported 
before. Two hypotheses ought to be considered. We used 1 µM CsA, which has been used to 
evaluate mPTP induction by other groups before in in vitro in ARVM models of chronic drug-
induced toxicity (Xu et al, 2016). This concentration offered robust protection from mPTP-
induction assessed by Ca2+-induced swelling. In our own lab 1 µM CsA has been used in in vitro 
experiments, estimating mPTP induction in murine cardiomyocytes, and identified robust 
protection (Dongworth et al, 2014). However, it ought to be highlighted that in ex vivo models 
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of IR-injury, protection against reperfusion injury is observed with 200 nM but not 1μM CsA 
(Griffiths and Halestrap, 1993). A narrow therapeutic window of 200-400 nM concentration has 
been reported in in vitro models of IR-injury using female SD rat ARVMs in the past (Nazareth 
et al, 1993). Moreover, CsA itself may cause toxicity in cardiomyocytes, which has been 
attributed to elevation of intracellular Ca2+ through the Ca2+ sensitive receptor (CsR), albeit at 
concentrations 3 to 8-times higher than those used in our experiments (Florio et al, 2003; Tang 
et al, 2011). Further, daunorubicin-treated rabbit models show altered intracellular Ca2+-
regulatory proteins, e.g. SERCA2A and 2B, RYR2 and Calsequestrin (Stěrba et al, 2011), which is 
likely to reflect a class-specific effect. Since Ca2+ is a known pore induction stimulus, and 
mitochondrial Ca2+ uptake through the Ca2+-uniporter is dependent on the electrochemical 
gradient of Ca2+, the hypothesis ought to be considered that the time taken to mPTP induction 
in the presence of CsA after Dox pre-treatment is a reflection of a compensation, where 
protection of the mPTP by CsA (as observed in control) is masked by a decrease in pore-
induction time due to Ca2+ overload in the mitochondria. This hypothesis may be investigated 
further using Ca2+ sensitive dyes (eg, Fluo-4) to identify free cytosolic Ca2+, e.g., after Dox 
treatment and after introducing CsA. 
A second hypothesis that may explain the results we observed includes modification of the CsA-
sensitive structure in the mitochondria. The mitochondrial receptor for CsA is Cyp D, which it 
binds with high affinity (KD=13.4nM) (reviewed in Halestrap and Richardson, 2015; Gutiérrez-
Aguila and Baines, 2015; Bernardi and Di Lisa, 2015). It is possible therefore that the attenuation 
of the protective effect of CsA in Dox pre-treated cells is due to alterations of Cyp D. Whether 
this alteration is at the level of gene expression, mRNA translation, protein degradation, or 
post-translational modification is impossible to deduce without further work. Estimation of 
gene expression and estimation of protein content may be carried out using widely used 
techniques, e.g. PCR and Western blotting respectively. However, interestingly, the structure 
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and function of Cyp D ought to be considered briefly when considering post-translational 
modifications that may explain these observations. In the suggested model of the mPTP 
induction, Cyp D has been suggested to interact with inorganic phosphate carrier (PiC) and 
adenine nucleotide translocase (ANT) in the assembled mPTP complex (Halestrap and 
Richardson, 2015), and interact with the lateral stalk of the F1F0-ATP synthase in the mPTP 
(Javadov and Kuznetsov, 2013) and inhibits the enzymatic activity of the complex. CsA binding 
to Cyp D leads to dissociation of Cyp D from ANT and PiC (Halestrap and Richardson, 2015), and 
further restores the enzymatic activity of the F1F0 complex (Giorgio et al, 2009). In the context 
of post-translational control of Cyp D function, it is worth highlighting that CsA binding site in 
Cyp D is a highly conserved α-helix, termed the CsA binding domain (CSBD). Analysis of Cyp D 
molecular structure reveals a lysine residue (K166) which lies stereochemically adjacent to the 
CSBD and is highly conserved from yeast to humans. K166 is deacetylated by the mitochondrial 
HDAC Sirtuin-3 (Sirt-3), and has been postulated to be a potential mechanism for regulating the 
mPTP protective function of Cyp D. Sirt-3 null mice show an increased vulnerability to Ca2+ 
induced swelling at 16 months, but not 3 or 6 months age (Haffner et al, 2010). For comparison, 
we used SD rat as a source of cardiomyocytes within a 150-450g weight range, which falls in a 
typical maximum age of 3 months (Brower et al, 2015). Interestingly, in cell-line models, Dox 
treatment has been observed to attenuate Sirt-3 expression in H9C2 cardiomyoblasts, which 
has been linked to dysfunction of the mitochondrial bioenergetic pathway (Cheung et al, 2015). 
Further, a role for Sirt-3 mediated deacetylation has been suggested for regulating a number 
of proteins of the mitochondrial ATP generating pathway including Acetyl CoA synthetase 
isoforms (ACeS2), Succinate dehydrogenase, Isocitrate dehydrogenase, NDUFAA9 (Pillai et al, 
2010), many of which have been found to be attenuated at gene expression or protein 
expression levels in animal models of Dox toxicity (Khiati et al, 2014). Importantly, Dox 
treatment has further been described to directly deplete Sirt-3 both in in vitro as well as in vivo 
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models of Dox cardiomyopathy (Pillai et al, 2016). Therefore, a hypothesis ought to be 
considered that the results we observed may be explained by altered post-translational 
modification of cell-survival or of bioenergetic pathways as a consequence of Sirt-3 inhibition 
in this ARVM model.  It may therefore be hypothesised that similar post-translational 
modification—specifically, acetylation of Cyp D— may be responsible for the abrogation of CsA-
dependent mPTP protection that we observe in this ARVM model. This hypothesis maybe 
investigated by exploring the acetylation status of Cyp D, and indeed of other targets of Sirt-3-
mediated deacetylation, after subjecting cardiomyocytes to Dox treatment as described in the 
model. Antibodies against acetylated-Lysine are commercially available, and this may be 
considered a potential future course of experiments.  
5.3.3.2. Co-incubation with Ciclosporine A does not protect cardiomyocytes from doxorubicin-
toxicity. 
In light of the results discussed in the preceding section, we re-explored the cell-death in the 
model in the presence of both Dox and 1 µM CsA.  In our previous experiment, the positive 
control CsA was introduced concomitantly with probe loading, after pre-treating 
cardiomyocytes with Dox for 18 hours. We considered the hypothesis that post-translational 
alterations to Cyp D leads to altered CsA binding, and explains the abrogation of CsA-mediated 
mPTP-protection in Dox pre-treated cells. Previous reports show post translational 
modifications of Cyp D, e.g. in sirt-3 knockout mice, renders the mPTP more prone to induction 
stimuli in aged rats, and the presence of CsA rescues the mPTP from this vulnerability (Haffner 
et al, 2010). Therefore we explored if the presence of CsA throughout the doxorubicin-exposure 
period reduced cell-death, which may indicate vulnerability of the pore as a factor in cell-death, 
and allow clarification of the data described above which suggested no excess vulnerability 
towards mPTP induction after doxorubicin-treatment. Conversely, to explain the abrogation of 
CsA-induced mPTP protection in Dox pre-treated cells, we further considered a hypothesis that 
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CsA may induce cytosolic and consequently mitochondrial Ca2+ overload in doxorubicin-
stressed cells. Therefore, this experiment also allowed us to explore if 1 µM CsA was 
independently toxic in this model, and whether presence of CsA exacerbated cardiomyocyte 
injury secondary to doxorubicin.  
As shown in fig. 5.6, we failed to identify any significant differences in cardiomyocyte death due 
to Dox alone, and cell-death due to co-treatment of Dox and CsA. We concluded from this 
experiment that presence of CsA offered no benefit against doxorubicin-induced injury, and 
therefore the mechanism of cell-death is likely to be independent of any increase in the 
vulnerability to mPTP transition. Further, the presence of CsA did not exacerbate Dox injury and 
CsA alone did not show any significant toxicity. We therefore concluded that the abrogation of 
CsA-responsive pore protection that we observed in Dox pre-treated cells is unlikely to be due 
to balances in ion fluxes, e.g. Ca2+. The results discussed above are collated from seven repeat 
experiments (n=7), which allows considerable confidence in the results we observed. Our 
results differ from those noted by other groups. For example, Marechal et al (2011) noted a 
protection against the toxicity of Dox in vivo both after acute bolus injection (10mg/kg 
doxorubicin), as well as in an interrupted dosing model when CsA was administered (1mg/kg) 
in mice. The authors observed protection from Dox-induced ventricular dysfunction, as well as 
preservation of mitochondrial bioenegregtics, preserved transmitochondrial potential, and 
protection from Ca2+ induced mPTP transition. Similarly, Gharanei et al (2013a) demonstrated 
an exacerbation of the injury due to ischaemia-reperfusion in the presence of 1µM Dox in 
isolated rat Langendorff-perfused hearts, as well as in ex vivo papillary muscle contraction 
models. The presence oft of CsA (0.2 µM) abrogated this excess injury. Conversely in an in vitro 
model using H9C2 cardiomyobloasts, Merten et al (2006) were able to inhibit of Dox-induced 
calcineurin signalling with 100nM CsA, but were unable to prevent Dox-induced hypertrophy, 
which the authors demonstrated to be due to activation of the PI3K/Akt pathway. This 
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highlights that multiple protein-signalling cascades may be activated by anthracycline-
treatment, and the pathological effect of the respective cascades ought to be correlated to the 
model under investigation. It ought to be highlighted that we did not include a separate positive 
control, with cell-death due to 1 µM CsA serving as an internal positive control. It may be argued 
that a dose-response study of cardiomyocyte-death due to CsA, and use of a toxic dose of CsA 
(if any) as a positive control may make the experiment more robust, and would allow better 
understanding and characterisation of the independent effect of CsA in the in vitro isolated cell-
model we have used, and therefore allow a better interpretation of the effect of CsA on Dox-
toxicity in our model. This may be explored in future work. Furthermore, to explore if Ca2+ 
signalling or overload is a factor in the toxicity of doxorubicin, in this in vitro approach, directly 
imaging free Ca2+ with Ca2+ probes may offer more clarity. These maybe considered limitations 
of this experiment, and future experiments particularly investigating the role of Ca2+ in this 
model of Dox-toxicity needs to include direct visualisations of ionic Ca2+ and explore the 
activation status of known Ca2+ signalling cascades induced by doxorubicin. 
It is necessary to highlight that CsA interacts with other Cyclophilin molecules e.g. Cyp A, and 
inhibits Calcineurin signalling, which is a potential compounding factor (Bernardi and Di Lisa, 
2015). Re-exploring cell-death and mPTP induction due to Dox in the presence of a different 
pore-protecting agent, Bongkrekic acid or Sanglifehrin A (SfA), may therefore offer more insight 
into the role of the mPTP in Dox cardiotoxicity. We did not use Bongkrekic acid due to its 
potential for inhibition of oxidative phosphorylation (Malekova et al, 2007). SfA and CsA both 
bind Cyp D with similar affinity, but SfA offers an advantage in avoiding activation of potential 
confounding factors, e.g. Calcineurin inhibition (Hausenloy et al, 2012) and maybe considered 
a suitable mPTP protective agent if the role of mPTP induction is re-explored in this model of 
Dox cardiotoxicity.    
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5.3.4. Hypoxic preconditioning protects against doxorubicin-induced cardiomyocyte death. 
As mentioned earlier in introduction, Dox has been observed to modulate the signalling 
cascades PI3K/Akt and the MAPK ERK 1/2 cascades which are induced by HP. The exact role of 
these cascades in the toxicity of anthracyclines is far from clear, with some evidence, e.g., from 
in vitro cardiomyoblast cell-lines (Merten et al, 2006), ex vivo models (Deres et al, 2005, 
Gharanei et al, 2013) and in vivo approaches (Ichihara et al, 2007)  noting an induction 
response. Conversely, other groups have noted attenuation responses to PI3K/Akt consequent 
to Dox-treatment, e.g., in in vivo rodent models, which has been correlated with symptomatic 
heart failure (Lou et al, 2005). Similarly, MAPK ERK 1/2 has been described in some experiments 
to play an injurious role, with data from, e.g., in vitro experiments using cardiomyopblast cell 
lines indicating a role in induction of apoptosis through the p53-mediated death pathway (Liu 
et al, 2008). Data from ex vivo models support the evidence of phosphorylation induction of 
MAPK ERK 1/2 as a consequence of Dox treatment, although the role this activation plays is 
unclear (Ghanaranei et al, 2013b). Contrasted with these repots, in vitro, neonatal rat 
cardiomyocytes display an induction of apoptosis on Dox treatment when ERK 1/2 is selectively 
inhibited (Zhu et al, 1999), while the potentiation of both MAPK ERK 1/2 (Su et al, 2006) as well 
as PI3K/Akt (Kitamura et al, 2014) has been observed to offer protection against doxorubicin-
induced cardiac injury. Since both the PI3K/Akt and MAPK ERK 1/2 cascades are known to be 
activated by HP and exert a cardioprotective effect in IR-injury, we explored if HP could protect 
against the cardiotoxicity induced by doxorubicin. In the model of toxicity described, we had 
identified the second window of preconditioning (SWOP) as the most suitable pathway which 
may be capable of protecting against doxorubicin-induced toxicity. Importantly, although the 
key mediators and pathway in SWOP are still unclear, a key role is described for both PI3K as 
well as MAPK ERK 1/2. For example, inhibiting PI3K with the irreversible inhibitor Wortmannin 
abrogated SWOP in in vivo rabbit models of IR-injury (Kis et al, 2003; Raphael and Gozal, 2005).  
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Similarly, the delayed preconditioning effects of opioids have been linked to the activity of MAP 
Kinases p38 as well as ERK 1/2 (Fryer et al, 2001), while inhibiting PI3K and ERK 1/2 has been 
observed to abrogate pharmacologically induced SWOP in ex vivo murine models of IR-injury 
(Bell et al, 2005). The timescale of protection indicates this is likely to be mediated by alteration 
of protein synthesis. Therefore, we hypothesised that an early induction of the RISK proteins 
immediately prior to introducing Dox would offer a protection against cardiotoxicity of Dox in 
the timescale of cell-death that we observed in this model.  
Consistent with this hypothesis, we found that HP protected cardiomyocytes against toxic 
concentrations of Dox. Cell-death in unprotected control cells showed a dose-dependent rise 
with increasing concentrations of doxorubicin, as was observed in previous characterising 
experiments, and was therefore internally consistent with previous data. The results were 
obtained from 5 repeat experiments (n=5). It ought to be re-iterated that in preceding 
experiments, we had not observed any role of oxidative stress or of mPTP induction in 
mediating cell-death due to doxorubicin. It may therefore be concluded that the protection 
offered by HP and indeed by SWOP is independent of any putative role HP may have against 
pathological oxidative stress, or of a role in protecting against mPTP induction (Hausenloy, 
2013a). In this report, we have not investigated the redox state or the function of the 
mitochondrial respiratory chain. Further, we have not investigated the balance of pro-apoptotic 
and anti-apoptotic proteins of the BCL family or the status of p53 enzyme. These are potential 
pathways which may be influenced by both PI3K/Akt and by MAPK ERK 1/2. 
Although direct myocardial preconditioning may be impractical in mitigating anthracycline-
cardiotoxicity, the findings from the above experiments are interesting since various modes of 
preconditioning are possible without direct injury or access to the myocardium. Of particular 
note in this regard, remote ischaemic preconditioning (RIPC), where an ischaemic stimulus is 
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applied to a distal muscular organ, e.g., peripheral muscles or limb, have been observed to 
activate the RISK cascade and offer similar protective influence and, indeed, was observed to 
lower peak delayed troponin rise in myocardial infarction treated with thrombolysis (Yellon et 
al, 2015). Further, exercise, which may induce similar recurrent transient hypoxia in peripheral 
musculature as well as promote anaerobic adaptation in the myocardium, has been suggested 
to hold a preconditioning potential similar to remote ischaemic preconditioning in protecting 
against IR-injury (Powers et al, 1998).  Interestingly, previous reports exploring cardioprotective 
strategies against anthracyclines note a role for aerobic-exercise induced preconditioning in 
cardioprotection against anthracycline-injury (Chicco et al, 2006a and 2006b, Hydock et al, 
2008). For example, Hydock et al (2008) reported a protective effect of aerobic-exercise 
preconditioning against doxorubicin-induced left ventricular function deterioration in vivo as 
well as in isolated-perfused hearts in rats subjected to a bolus-regimen of toxicity of Dox. 
Subsequent work indicates this may in part be due to reduced cardiomyocyte-accumulation of 
Dox (Jensen et al, 2013). Exercise-induced preconditioning has also been suggested to 
upreguate myocardial levels of manganese superoxide dismutase (MnSOD) (Yamashita et al, 
1999; Marini et al, 2007). This is interesting, since levels of MnSOD has previously been 
observed to further correlate with delayed ischaemic protection, or the second window of 
protection (SWOP) (Hoshida et al, 2002). This highlights that the protection against 
anthracycline-injury in cardiomyocytes activated by HP, RIPC and other cardioprotective 
interventions including exercise may be translated into clinical applications with a better 
understanding, particularly, of the molecular pathways activated in SWOP. 
5.3.4.1. Investigating hypoxic preconditioning induced RISK pathway against doxorubicin 
toxicity. 
SWOP is postulated to be mediated by a number of putative and confirmed signalling cascades 
including the components of RISK (PI3K/Akt and MAPK ERK 1/2), as well as other parallel and 
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interdependent pathways e.g. nitric oxide signalling, tyrosine kinases, and protein kinase C 
(PKC) (Hausenloy, 2013a). We therefore explored the relevance of PI3K/Akt and MAPK ERK 1/2 
in protecting against Dox-cardiotoxicity by inhibiting the respective signalling cascades. We 
used the molecule LY294002 to inhibit PI3K/Akt, and PD98059 to inhibit MAPK ERK 1/2. A 
number of inhibitors of PI3K/Akt have been studied, including Wortmannin, LY294002, 
Quercetin, as well as derivatives of these compounds (McNamara and Degterev, 2011). Both 
Wortmannin and LY294002 has been used in our lab and are well studied (Bell and Yellon, 
2003). However, Wortmannin is relatively nonspecific with broader cross-reactivity, and further 
it is more unstable and toxic in animals, limiting the potential for any future in vivo work. We 
therefore used LY294002 as an inhibitor of PI3K/Akt, at a working concentration of 10 µM, 
which has been reported in literature to offer potent attenuation of Akt phosphorylation 
(Aikawa et al, 2000). Similarly, we used the MEK1 inhibitor PD98059 as an inhibitor of MAPK 
ERK 1/2 phosphorylation since, of multiple kinase inhibitors, it is the most specific kinase 
inhibitor (Davies et al, 2000).  
In these experiments using cell-death as a measure of Dox-toxicity, we observe that inhibition 
of PI3K/Akt pathway with LY294002 abrogated the protective effect of HP, but inhibition of the 
MAPK ERK 1/2 appeared to exert no discernible effect on HP-induced protection. This 
suggested that the protective effect of HP against Dox-toxicity required the  activation of the 
PI3K/Akt signalling cascade. It ought to be highlighted that we did not use a separate positive 
control, e.g., insulin which may have served the role of a known inducer of PI3K/Akt and of 
MAPK ERK 1/2. In this context, the lack of any effect on HP-induced protection that is observed 
despite the presence of PD98059 is difficult to interpret. The suggestion may be raised that 
activation of MAPK ERK 1/2 had no role in the conferring the protection that was observed with 
HP, but require confirmation of phosphorylation induction of the ERK 1/2 pathway, which was 
not possible due to the lack of a positive control. The results we noted reflect the observations 
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of five repeat experiments (n=5). Of note, our results reflect the suggested protective role of 
activation of PI3K/Akt pathway against Dox-toxicity noted in wider literature. For example, 
Taniyama and Walsh (2002) had previously observed a protective effect using adenovirus-
mediated consitutively active Akt in a rodent model of Dox-toxicity, whereby potentiating Akt 
pathway protected against deterioration of fractional shortening, decline in left ventricular 
dysfunction, and decline in cardiac mass. Similarly, Fu et al (2007) had previously reported a 
role for PI3K/Akt induced by Erythropoietin (Epo) in protecting neonatal rat ventricular 
myocytes (NRVMs) against the toxicity of Dox in vitro, but not MAPK ERK 1/2. In their report, 
Fu et al were able to abrogate the protection of Epo using 50 µM LY294002. By comparison, we 
used a lower concentration of LY294002 (10µM) to inhibit PI3K/Akt in the experiments, which 
is towards the lower end of a working concentration 1-100 µM. The  protective role for HP-
induced PI3K/Akt suggested by the cell-death data we observed, further, is consistent with the 
previously reported effect of potentiating PI3K pathways in vivo. For example, Kitamura et al 
(2014) observed that deleting ARIA (apoptosis regulator through modulating IAP expression), a 
plasma-membrane recruiter for the PI3K-phosphatase phosphatase and tensin homologue 
(pTEN) protein, protected against Dox-induced cardiac dysfunction and death in a murine 
model. However, these reports ought to be contrasted with the reported observations and role 
of PI3K/Akt phosphorylation-induction noted by other groups in Dox-toxicity. For example, as 
explained earlier, Merten et al (2006) had noted a phosphorylation response for protein kinase 
B (PKB), a downstream mediator of Akt. The authors noted an Akt-dependent hypertrophic 
response in cultured H9C2 cardiomyoblast derived cell lines, which they deemed to be 
reflective of a pathological response. In their experiments, Merten et al exposed the 
cardiomyoblasts to 1 µM Dox for upto 2 hours, and noted that the hypertrophic response could 
be abrogated by 20 µM LY294002. For comparison, we used an isolated adult rat ventricular 
myocyte model, and exposed these cells to 7.5µM Dox for 18 hours. Moreover, as discussed in 
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the next section, upon Western blotting we observed no evident Akt phosphorylation response 
in the after-sequence of Dox-treatment at time points of 15 minutes, 4 hours and 18 hours in 
this ARVM model. This differs from the sustained Akt phosphorylation that Merten et al 
observed for upto 360 minutes following exposure to Dox in their cardiomyoblast cell-model. 
The differences in the experimental set up, particularly the differences between a proliferating 
cardiomyoblast model and a terminally differentiated ARVM model may be a possible 
explanation, but this requires further experimental work and direct comparison under 
controlled conditions. This was beyond the scope of our current report. In a different 
experimental set up, Deres et al (2005) reported Akt phosphorylation-induction when isolated 
Langendorff-perfused rat hearts were subjected to 100 µM Dox for 60 minutes. The authors 
hypothesised this phosphorylation to be a possible response to activation of the kinase via 
nitration of tyrosine residues of receptor tyrosine kinases, secondary to reactive oxygen and 
nitrative species generation. Supporting this hypothesis, Akt phosphorylation in these 
experiments could be abrogated by concomitant perfusion with 200 µM dihydrolipoamide, an 
antioxidant. Similarly, Ichihara et al (2007) had noted increased phosphorylation of Akt in an in 
vivo model of toxicity, which could be inhibited by the administration of superoxide dismutase. 
It ought to be highlighted that in the model we characterised, we used a concentration of 7.5 
µM Dox, significantly lower than that used by Deres et al. Moreover, the experiment we 
conducted exploring the role of N-acetyl cycsteine against doxorubicin-toxicity failed to show 
any protective effect, raising the suggestion that in the model we analyse, reactive oxygen 
specied may have a limited role in pathogenesis and induction of cell-death (discussed above). 
It is important to highlight that PI3K/Akt induction may be a stress response, and may serve to 
stabilise against mitochondrial fission. For example, in their 2013 report Gharanei et al (2013b) 
demonstrated activation of PI3K/Akt phosphorylation in response to Dox-treatment in a 
Langendorff-perfused rodent heart model, which increased when mitochondrial division 
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inhibitor mdivi-1 was coperfused with Dox. In a different report (Gharanei et al, 2013a) the 
group noted an increase in phosphorylated Akt content in rat heart when Dox was introduced 
in the reperfusion phase of an ischaemia-reperfusion protocol in a Langendorff-appratus. This 
upregulation could be inhibited by administration of 0.2 µM CsA. This may indicate that 
activation of PI3K/Akt noted in the after-sequence of Dox-treatment may be a stress-adaptation 
that aims to stabilise against the induction of mitochondrial apoptotic pathways (Ushio-Fukai 
et al, 1999). It is therefore worth considering a hypothesis that preactivation of PI3K/Akt may 
have a protective role against Dox-toxicity, which differs from the activation of PI3K/Akt 
observed in cells subjected to Dox-insult. This latter activation, as hypothesised by Deres et al, 
may be a consequence of nitration or amino acid Tyrosine residues as a consequence of 
reactive species accumulation. This hypothesis requires further exploratory work in the isolated 
ARVM model that we have used in our experiments, e.g., by sequential activation or inhibition 
of PI3K/Akt at different time points of Dox-treatment. However, this was again beyond the 
scope of the work reported here. 
Concomitant with investigations into the role of PI3K/Akt pathway, we also explored the effect 
of inhibiting MAPK ERK 1/2 on HP-induced protection against Dox-induced cell-death. Hypoxic 
preconditioning is known to induce MAPK ERK 1/2 via the RISK-pathway. However, as explained 
in earlier sections the role of MAPK ERK 1/2 in Dox-induced cardiotoxicity is conflicting. Reports 
by different groups offer evidence in support of a deleterious role for pathway. For example, 
Liu et al (2008) reported an increase in ERK 1/2 phosphoprotein levels and nuclear translocation 
in H9C2 cardiomyoblasts in response to Dox treatment at a concentration of 1 µM, which the 
authors noted to be accompanied by nuclear translocation of phosphorylated p53 and 
induction of apoptotic pathway. The MEK1 inhibitor U0126 at 20 µM concentration inhibited 
both ERK 1/2 phosphorylation-induction as well as phosphorylated-p53 translocation to the 
nucleus, suggesting a role for ERK 1/2 induction in the apoptosis mediated by Dox on the cell-
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lines. Similarly, Bien et al (2007) had noted a phosphorylation response of the ERK 1/2 cascade 
in an in vivo murine model of Dox cardiomyopathy. Gharanei et al, in their 2013 report 
(Gharanei et al, 2013a) had observed a phosphorylation induction of MAPK ERK 1/2 in a 
Langendorff-perfused rat heart model in the after-sequence of Dox-treatment, where IR-injury 
is used as an added stress. Other groups however report evidence indicating a protective or 
compensatory adaptation in cardiomyocytes via the induction of MAPK ERK 1/2. For example, 
as noted earlier in introduction, reports, e.g., by Lou et al (2005) noted a transient increase in 
ERK 1/2 phosphoprotein levels over 4 hours in a rodent model of Dox cardiomyopathy, followed 
by a decline over a period of three weeks. This reflected a decline in mRNA expression and 
accompanied clinically correlated heart failure in the experimental animals. Similarly, Wang et 
al (2012) noted a decrease in phosphorylated ERK 1/2 levels within five days of a bolus 20mg/kg 
Dox in a murine model of cardiotoxicity, along with an increased level of phosphorylated p53. 
These could be reversed by overexpression of the ubiquitin ligase chaperone protein C-terminal 
HSP70 interacting protein (CHIP) using a transgenic expression model, and was associated with 
decrease in markers of doxorubicin-induced cardiomyocyte apoptosis as well as ventricular 
dilatation. Since hypoxic preconditioning is known to induce MAPK ERK 1/2 via the RISK-
pathway, we hypothesised this particular signalling pathway may have a role in mediation of 
the protective effect that HP offered against Dox-toxicity in the in vitro model of toxicity we 
characterised. We did not use a positive control agent to induce MAPK ERK 1/2 in our 
experiments exploring cell-death, e.g., insulin. This should be considered a limitation of the 
experimental design, and need addressed in future work. Our experimental data, however, 
reflect observations by other groups. For example, in an H9C2 cardiomyoblast model 
Spallarossa et al (2006) noted an increase matrix metalloproteinases (MMP) MMP-2 and MMP-
9 in response to Dox-treatment, which could be attenuated with the β-blocker Carvedilol, with 
N-acetyl cysteine, and with Dexrazoxane. Dexrazoxane and Carvedilol both resulted in an 
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upregulation of phosphorylated MAPK ERK 1/2 levels, but inhibiting MAPK ERK 1/2 using 
pretreatment with 50 µM PD98059, the authors did not observe any differences in MMP-2 and 
MMP-9 protein expression and activity induced by the exposure to 0.5 µM Dox alone. This 
suggested the activation of MAPK ERK 1/2 was not consequential in the protective effect 
observed due to Carvedilol and NAC. Similarly a report by Fu et al (2007) noted phosphorylation 
induction of MAPK ERK 1/2, but the authors reported that the MEK1 inhibitor U0126 did not 
inhibit the protective effect of Epo. For comparison, we used 30 µM PD98059 as an inhibitor of 
MEK1-induced MAPK induction. It ought to be highlighted that repression of MAPK 
phosphatases by anthracycline compounds have been noted to induce upregulation of 
phosphorylation ERK 1/2, at least in breast epithelial and breast carcinoma cell lines (Small et 
al, 2003). Furthermore, ERK 1/2 may be induced by cellular stress including heat stress and 
substrate deprivation, while extracellular stress induced signalling e.g. as induced through lysis, 
mechanical agitation, and tensile stimuli, may lead to induction response in MAPK ERK 1/2 
(Yamazaki et al, 1996). Moreover, ischaemic stress and reperfusion injury has been reported as 
stimuli capable of phosphorylation induction of ERK 1/2 (Araujo et al, 2001; Takeishi et al, 
2001). Indeed, in subsequent Western blots (discussed further below), although 
phosphorylated ERK 1/2 was detected in response to HP as well as the positive control agent 
insulin, signals were also noted in control sample, and failed to reach statistical significance in 
the differences in p-ERK 1/2 levels between different samples. It ought to be emphasised 
therefore that the role of MAPK ERK 1/2 require further clarification in future work, where 
experimental design ought to include a positive control agent for induction of MAPK ERK 1/2 in 
cell-death experiments. 
5.3.5. Western blots. 
The analysis of the Western blot experiments we conducted were challenging. Although blot 
analysis detected phosphorylated protein content both for PI3K/Akt and MAPK ERK 1/2 
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following HP, crucially the increase in levels of phosphorylated proteins failed to reach 
statistical significance compared to control. Furthermore, in analysis of MAPK ERK 1/2 
induction, p-ERK 1/2 inductions were also noted in control lysates. It ought to be highlighted 
that in our experimental setup, we evaluated phosphoprotein to total protein content as a ratio 
normalised to the loading controls in each sample in the respective blots. This protocol was 
established since, due to the small volume of protein content in the available cell cultures, we 
harvested protein by directly lysing cells with the loading buffer. We used GAPDH as loading 
control for Akt, and α-tubulin as loading control for blots exploring phosphorylation of ERK 1/2. 
The molecular weight of GAPDH (37 kDa) is distinct from that of Akt (56 kDa) and, in well 
resolved SDS-PAGE blots, would be expected to appear as a distinct signal with greater 
migration compared to that of Akt. Similarly, α-tubulin (molecular weight 50kDa) was chosen 
as loading control for ERK 1/2 (molecular weights 42 and 44 kDa) since the signal for α-tubuluin 
would be expected to migrate less compared to the two ERK 1/2 protein bands in a well-
resolved SDS-PAGE membrane. Both GAPDH (Diez and Simm, 1998) and α-tubulin (Belmadani 
et al, 2002) are known to be expressed abundantly in adult rat ventricular myocytes and 
perform housekeeping roles, and has been reported from our lab previously (Hausenloy et al, 
2005, Davidson et al, 2006). We used insulin as a positive control to induce phosphorylation of 
Akt and of ERK 1/2, and observed phosphorylation responses of both p-Akt and p-ERK which 
were consistent with previously reported data (Aikawa et al, 2000).  
In these Western blot experiments, we observed phosphorylation of Akt both after HP and after 
insulin pre-treatment. As highlighted above, although the phosphorylation induction of Akt in 
response to HP and in response to insulin were consistently greater compared to control 
throughout the experiments, this failed to reach statistical significance. The sample size for the 
Western blots was 3 (n=3), which may be a factor in lack of sensitivity on statistical analysis. 
This ought to be considered a limitation of our experiments.  However, we note that insulin 
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provided a very strong phosphorylation response, and 10 µM LY294002 attenuated this Akt 
phosphorylation, both of which was consistent with previous reports in Akt phosphorylation 
observed in in vitro neonatal rat cardiomyocyte models (Aikawa et al, 2000). Further, LY294002 
has a broad specificity against PI3K, and has also been observed to inhibit additional pathways, 
e.g. lipid-kinases (Arrowsmith et al, 2015). More selective and sub-group specific inhibitors are 
available, and further work may include inhibition of respective components within the PI3K-
induced cascades.  
In subsequent Western blots, we explored the modulation of the respective phosphoprotein 
isoforms of Akt and ERK 1/2 due to Dox alone at various time points of treatment. However, 
our analyses were limited by poor quality blots despite optimising blot conditions. The results 
of our experiments revealed no discernible response for phosphorylation of PI3K/Akt 15 
minutes, 4 hours, and 18 hours after introduction of Dox alone. This differs from data observed 
by other groups (Gharanei et al, 2013a). In this regard, it is necessary to highlight that the 
sample size with which we explored Dox-induced modulation of PI3K/Akt was small (n=2). 
Moreover, as our initial characterising experiments established, the volume of total and 
phosphoprotein content were low, and therefore strict adherence to protocol to limit sample 
volume and to optimise blotting conditions are necessary. Although the possibility exists that 
Dox-treatment alone does not induce PI3K/Akt phosphorylation in this model, particularly in 
light of divergence from a number of previously reported findings (Ichihara et al, 2007), more 
robust data with larger number of repeat experiments is necessary before confident 
conclusions can be drawn.   
The Western blot analyses for MAPK ERK 1/2 that we carried out to analyse phosphorylation 
induction in response to HP were similarly challenging, owing to repeated poor signals in two 
out of three blots for non-phosphorylated (total or t) isoforms of ERK 1/2. This was despite 
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optimising experimental and blotting conditions. Similar to the blots for HP-induced Akt 
phosphorylation, statistical analysis failed to identify significance within the limits of the sample 
size we obtained (n=3). Although the levels of phospho-protein content for MAPK ERK 1/2 upon 
western blotting was most prominent (normalised to loading control α-tubulin levels) for HP, 
weaker signals were also noted with the positive control insulin and a weak signal was identified 
in control cells. All three signals were inhibited by PD98059. Since ERK 1/2 may be induced by 
extracellular stimuli including lysis, mechanical agitation, as well as by tensile stimuli, the stress 
during cell lysis itself may be a possible explanation for the p-ERK inductions we observed in 
control cardiomyocytes. Experimental conditions were optimised by incubating cells in ice 
during protein collection, and lysed in an environment with minimal agitation. However, it is 
recognised that a certain level of phosphorylation response may be inevitable.  Repeat Western 
blot experiments for phosphoprotein expression for both phosphorylated and total ERK 1/2 
may therefore confirm or refute the significance in HP-induced activation of the respective 
kinase cascades. 
As with PI3K/Akt, we explored the phosphorylation status of MAPK ERK 1/2 at 15 minutes, 4 
hours and 18 hours after subjecting cardiomyocytes to Dox-treatment. However, although we 
observed no clear signal to indicate p-ERK induction, caution ought to be exercised in particular 
light of the fact that the sample size in both experiments were two (n=2). As for the PI3K/Akt, 
it is not possible from this limited data to support or refute wether Dox-treatment alone in this 
model activates p-ERK, at least in the timescales we explored. This, therefore, requires more 
rigorous exploration with larger sample size and optimisation of Western blotting protocol to 
obtain standardised protein content in sample lysate, and to obtain clear signals for both 
proteins of interest and loading controls. This may be explored in more detail in future work. 
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Chapter 6. Conclusions, limitations, future directions and 
significance. 
 
6.1. Summary, limitations, and future directions. 
6.1.1. Summary. 
In this thesis, we describe the development and characterisation of an in vitro primary adult rat 
cardiomyocyte model that allows us to investigate the cardiotoxicity of doxorubicin. Using this 
model, we identified hypoxic preconditioning (HP) as an intervention capable of protecting 
cardiomyocytes against Dox toxicity. We were further able to shed some light into the potential 
mechanisms through which this protection is mediated, identifying PI3K/Akt pathway as the 
protein-cascade of interest. Our results offer some support for the observations by other 
groups which show manipulation and potentiation of the PI3K/Akt pathway as having a role in 
the protection against anthracycline-cardiotoxicity. We were not, however, able to clarify the 
role of MAPK ERK 1/2 cascade in Dox-cardiotoxicity or in protection against this. Future work is 
required to explore further role and activation of status of MAPK ERK 1/2 induction in response 
to HP in this model, and to explore the respective role in mitigating Dox-toxicity against 
cardiomyocytes. Further future work is also necessary to clarify the phosphorylation induction 
of both PI3K/Akt and of MAPK ERK 1/2 after Dox treatment to explore the phosphorylation 
status of the respective kinases. The phosphorylation responses of both PI3K/Akt and of MAPK 
ERK 1/2 over longer timescales following HP ought to be explored. Further, future work ought 
to be carried out using more specific inhibitors of PI3K/Akt, and will be of immense interest. 
Of the described mechanisms of toxicity of Dox that we explored, the experiments we carried 
out failed to identify a pathological role for oxidative stress, of alterations to the ΔΨm, or a role 
for increased vulnerability of the mPTP to transition as an explanation of doxorubicin-induced 
cardiomyocyte death in the model we developed and characterised. However, over the course 
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of our investigations, we found that Dox-treatment altered the capacity of CsA to protect the 
mPTP against induction from sensitising agents, possibly indicating a change to the levels or 
function of Cyp D.  Whether such a change is reflective of a more widespread underlying 
mechanism, e.g. post-translational modification, is unclear. Investigation of the potential 
mechanisms including post-translational modifications of the proteins constituting the pore 
would be exciting, but is beyond the scope of this current work. Other putative death 
mechanisms, including the role of BCL group of death regulators and of p53-induced death 
pathways were not explored in this current work, but would also be a logical progression in 
planning of future experiments.  
6.1.2. Limitations 
A key general limitation in the work undertaken in preparing this report includes variations in 
the number of repeat experiments and unequal sample distribution. In some experiments, 
including in establishing initial cell-model of doxorubicin-toxicity, and in evaluating the effect 
of IR-injury in doxorubicin-stressed cardiomyocytes, the sample sizes (n value) were unequal 
and small, to the order of n=2. This reduces statistical power of the experiments (Kim, 2014). 
In our experimental set up, we attempted to address this potential problem by establishing all 
experiments in duplicate, and utilised Students t-test in statistical analysis where the n value in 
the experiments were very low. However, consistent observations in subsequent repeat 
experiments with similar treatment groups over the course of the experiments described above 
allowed us a measure of confidence in the results we observed. Future work ought to consider 
predefining acceptable significance levels (α-value) and precalculation of sample size in order 
to optimise experimental planning and robustness of the results. 
A second limitation that ought to be highlighted is the lack of delineation between the canonical 
cell-death pathways, particularly between necrosis, apoptosis, and necroptosis. Further, 
contribution of altered autophagic flux in the injury due to Dox was not probed nor delineated 
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in this report. Emerging evidence suggest that anthracycline cardiotoxicity on the myocardium 
is the culmination of a complex interplay of these canonical death pathways, but characterising 
and investigating the individual contributions of these was beyond the scope of our work, in 
the model we characterised. Particularly, the lack of information on the extent of necrosis and 
apoptosis in this model necessitated a broad approach in exploring the known toxicity 
mechanisms. However, future work ought to consider the identification of necrotic or apoptotic 
death pathways as a key part of experimental setup, since this is directly relevant in light of our 
data which showed deviation from “classic” ANTC-toxicity descriptors, including a question 
over the role for ROS-scavenging and on the role of the mPTP in induction of cardiomyocyte-
death in this model.  Approaches currently in use in molecular biology, e.g., Cytochrome C 
levels, LDH assays or estimation of early markers of necrosis e.g., HMGB1 levels may be used 
to assess necrotic cell-death, while approaches e.g., annexin staining, TUNEL assay for DNA 
laddering, or Caspase 3 assay may provide insight into apoptotic death pathway in the model 
we have developed and characterised. Moreover, since Dox also induces early degradation of 
intracellular proteins, the role of autophagy maybe explored through e.g. myosin light chain 
isoform (LCII to I) ratios. These are potential topics that ought to be reflected on in future work. 
In the work described above, we established an in vitro model of doxorubicin-toxicity on 
isolated cardiomyocytes. Anthracycline cardiotoxicity, as discussed earlier, is characterised by 
early asymptomatic sub-clinical changes which may reflect the physiological compensatory 
capacity of the intact heart. We used a pure culture of terminally differentiated adult 
mammalian ventricular cardiomyocyte as our model to investigate the cell-type predominantly 
at risk of injury, and known to concentrate anthracyclines the most within the intact 
myocardium. However, this necessarily limits the physiological translation of the results of our 
experiments. The adult mammalian heart is a composite not only of mature cardiomyocytes, 
but also of a support network of endothelial cells, fibroblasts, immune-cells including resident 
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and recruited macrophages, as well as a potential reservoir of smaller population of immature 
or senescent progenitor cells. It is therefore necessary to reconcile the results we observe in 
both other in vitro models, e.g., neonatal rat ventricular myocytes, as well as in higher 
physiological models, e.g. ex vivo models, for example Langendorff-apparatus perfursed heart 
systems. Exploring the work we describe in different cell model is particularly relevant since 
ARVMs display a high basal cell-death, although this phenomenon is particularly relevant in cell-
culture established to time scales exceeding 24 hours (Louch et al, 2011). In our experiments, 
we attempted to address this by establishing minimum acceptability criteriae, and excluding 
experiments from analyses where basal cell-death exceeded 20% after 24 hours. It may be 
argued that an additional approach possible would have been to evaluate cell-death at 
beginning of the experiment and normalising this to basal-cell death at the end of experimental 
procedure. Moreover, in some experiments, e.g., evaluation of the role and induction of the 
RISK kinases in relation to doxorubicin-toxicity, our findings diverge from those described by 
other groups, some of which have been carried out in different models, e.g., ex vivo  models 
used by Gharanei et al and Montaigne et al. Therefore, repeating our experiments in both 
immature cell-lines, e.g., NRVMs, as well as in ex vivo and in vivo models will alow examination 
of the robustness of the data we gathered, as well as reconciliation of the results and 
differences with those described by other groups in differing models. Further, in exploring the 
protective potential of HP against Dox-induced cell-death in vitro, we did not implement a 
positive control. In future experimental work, therefore, a known inducer of the RISK kinases, 
e.g., insulin, ought to be considered when evaluating the role of the respective protein cascades 
PI3K/Akt and MAPK ERK 1/2. The results should be of interest not only to the molecular biologist 
exploring mechanism of ANTC-cardiac injury, but also hold direct relevance to the clinical 
practice in oncology and cardiology today. 
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6.1.3. Clinical significance.  
Approaches to potentiating PI3k cascade, such as genetic manipulation, e.g. as reported by 
Kitamura et al (2014), are impractical in humans as a cardioprotective intervention, and further 
unlikely to be cost-effective. However, these findings are exciting since it is well established 
that RISK pathway activation and cardioprotection is also elicited by the application of a 
preconditioning stimulus to an organ or limb remote from the heart (Hausenloy and Yellon, 
2016). This intervention, called remote ischaemic preconditioning (RIPC), reduces ischaemia-
reperfusion (IR) injury, and decreases peak troponin levels in patients undergoing thrombolysis 
for ST-elevation myocardial infarction (Yellon et al, 2015). The role of RIPC in protection against 
anthracycline-cardiotoxicity are indeed under investigation (Chung et al, 2015), and the results 
will be of immense interest. Moreover, lifestyle interventions, for example exercise 
preconditioning are postulated to share common biomolecular pathways to activation of what 
is considered the second window of preconditioning, and therefore will be of immense interest 
to both the clinican and the molecular biologist in translating into practical intervention against 




































Angshuman Maulik   Page | 175 
 
Appendix a. Buffers for adult rat ventricular myocytes isolation. 
 
a. Perfusion buffer. 
   
Salts Molarity (mM) g/500ml g/L g/2L 




3.79 7.59 15.18 
KCl 5.4 0.2 0.4 0.8 
MgCl2 1.4 0.066 0.133 0.266 
Na2HPO4 
(anhydrous) 
0.4 0.028 0.057 0.114 
HEPES 
(not HEPES sodium) 
4.2 0.5 1 2 
pH to 7.3 at 37ºC 
Glucose † 10 0.9 1.8 3.6 
Taurine † 20 1.25 2.5 5 
Creatine † 10 0.655 1.31 2.62 
 
Table 1. Composition of perfusion buffer solution used to isolate cardiac myocytes. 
 
 
b. Isolation buffers. 
 
Solution Final concentration Addition 
   
1 (to clear heart of blood) 750µM CaCl2 37.5µl of 1M CaCl2 
2 (to arrest heart) 100µM EGTA 2mg of EGTA 
3 (to digest heart) 100µM CaCl2 and 0.5mg/ml 
Collagenase 
40µl of 100mM CaCl2 
15-20mg of collagenase 
18mg is good 
4 (to re-introduce CaCl2) 0.5mM CaCl2 12.5µl of 1M CaCl2 
5 (to re-introduce CaCl2) 1m CaCl2 25µl of 1M CaCl2 
Table 2. Solutions used and the purposes  during isolation process for adult rat ventricular 
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Appendix b. Representative photographs of cardiomyocytes 
following different treatment protocols. 
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Fig. III. Ischaemia reperfusion induced cell-death following 4 h pretreatment 
with 2 µM Doxorubicin. 
 
 
Fig. IV.  Ischaemia reperfusion induced cell-death following 18 h pretreatment 
with 2 µM Doxorubicin. 
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Fig. V. Ischaemia-reperfusion induced cell-death in preconditioned 
cardiomyocytes (HP protocol 1). 
 
 
Fig. VI. Ischaemia-reperfusion induced cell-death in the second window in 
preconditioned cardiomyocytes (HP protocol 2). 
 
Angshuman Maulik   Page | 180 
 
 
Fig. VII. Ischaemia-reperfusion induced cell-death in the first window in 
preconditioned cardiomyocytes (HP protocol 2). 
 
 
Fig. VIII. Cell-death in cardiomyocytes subjected to 7.5 µM Doxorubicin and to 
1µMH2O2, with and without 250nM N-acetl cysteine (NAC) for 18 h. 
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Fig. IX. Cell-death in cardiomyocytes subjected to 18 h of 7.5 µM Doxorubicin 
(Dox) with and without 1µM Ciclosporine A (CsA). 
 
Angshuman Maulik   Page | 182 
 
 
Fig. X. Cell-death after 18 h with various concentrations of Dox in preconditioned 
(HP) and non-preconditioned cells.  
 




Fig. XI. Influence of 10 µM LY294002 (LY) and 30 µM PD98059 (PD) on 
preconditioned (HP) and non-preconditioned cells subjected to 18 h of 7.5 µM 
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